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 ABSTRACT 
 
Viruses are infectious agents that must infect the cells of living organisms in order 
to reproduce. They have relatively simple genomes which encode few proteins but can 
compensate for their simplicity by hijacking components of their cellular hosts. 
Arenaviruses, a family of zoonotic viruses carried by rodents, encode only 4 proteins. 
One of these proteins, Z, is responsible for several functions during the virus life cycle 
including driving the formation and release of new virus particles at the plasma 
membrane of infected cells. Relatively little is known about how this viral protein is 
regulated or the complement of host proteins it engages in order to produce new virus 
particles or augment Z’s other functions. To address this gap in knowledge, mass 
spectrometry was used to identify phosphorylation sites in the Old World arenavirus, 
lymphocytic choriomeningitis virus (LCMV) Z protein. Phosphorylation sites were 
identified at serine 41 (S41) and tyrosine 88 (Y88). Functional studies using recombinant 
(r)LCMV containing mutations at these phosphorylation sites revealed that both were 
important for the production of defective interfering (DI) particles. DI particles are 
replication-incompetent virus particles that interfere with the production of infectious 
virus and mitigate its cytopathic effect. While a mutation that mimics phosphorylation at 
S41 reduced LCMV’s ability to produce both infectious and DI particles, this mutation 
had a much stronger impact on DI particles. Production of DI particles in Y88-mutant 
rLCMV was drastically reduced while the impact on infectious virus was minimal. Y88 
lies within a type of viral late domain (PPXY) also found in matrix proteins of several 
disparate virus families where it has been shown to drive infectious virus release by 
recruiting the membrane scission machinery of the cellular endosomal sorting complex 
required for transport (ESCRT). Inhibition of the ESCRT pathway drastically reduced 
LCMV DI particle but not infectious virus release indicating that Z’s PPXY late domain 
and the cellular ESCRT complex are required specifically for the production of DI 
particles. Mass spectrometry was also used to identify host protein partners of Z as well 
as the host proteins recruited into virus particles for the New World arenavirus, Junín 
(JUNV). ESCRT complex proteins were enriched in JUNV virus-like particles (VLPs) 
and bona fide virions. In contrast to LCMV, inhibition of the ESCRT complex resulted 
in significantly less infectious JUNV release. This indicates that the ultimate role of 
ESCRT engagement by the Old World arenavirus, LCMV, differs from that of New 
World, JUNV. This work represents the first demonstration that a viral protein motif and 
the host machinery it engages selectively drive DI particle production independently of 
infectious virus. It also suggests that host cell kinases can dynamically regulate the 
production of DI particles through phosphorylation of Z. Finally, the late domain-mutant 
rLCMV generated in these studies represents the first LCMV strain known to produce 
undetectable levels of DI particles which provides the opportunity to assess the impact 
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 CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
1.1. Introduction 
Arenaviruses are a family of viruses that include several species which can cause 
a range of diseases in humans including severe hemorrhagic fever. Currently there are no 
FDA-approved drugs or vaccines available to specifically treat arenavirus infection in 
humans which highlights the need for an increased understanding of the basic biology of 
these viruses. Arenaviruses are extremely simple organisms encoding only 4 proteins. 
Accordingly, these 4 proteins must each be capable of engaging various machinery from 
their cellular host in order for the virus to replicate. One of these arenavirus proteins, Z, 
carries out several functions during the virus life cycle including driving the formation and 
release of virus particles at the plasma membrane of infected cells. The current model of 
Z-mediated virus release posits that Z must recruit the cellular endosomal sorting complex 
required for transport (ESCRT) pathway by way of its C-terminal late domain. However, 
a detailed understanding of Z/ESCRT-mediated arenavirus release is lacking. Additionally, 
little is known about the specific host proteins that the Z protein interacts with during the 
virus life cycle in order to accomplish release as well as its various other functions.  
In this work, we sought to address deficiencies in the understanding of virus-host 
interactions for the arenavirus Z protein. Mass spectrometry was used to identify 
phosphorylation sites on the arenavirus Z protein mediated by host cell kinases as well as 
to uncover novel protein-protein interactions between the Z protein and its cellular host. 
Through subsequent functional studies, we discovered that the prototypic arenavirus, 
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lymphocytic meningitis virus (LCMV), uses the late domain contained within its Z protein 
and the cellular ESCRT pathway to specifically drive the production of defective 
interfering (DI) particles. A second phosphorylation site in Z was also shown to be 
important for both infectious virus and DI particle production. Finally we have uncovered 
Z-host protein-protein interactions for another arenavirus, Junín, which led to the discovery 
that unlike LCMV, Junín virus requires the ESCRT pathway to drive infectious virus 
release. These proteomics discovery studies and subsequent functional analyses have 
advanced the understanding of how late domains in the arenavirus Z protein and the cellular 





Arenaviruses are enveloped, negative-sense RNA viruses found in different 
regions of the world. Phylogeny of the Arenaviridae family has been recently restructured 
to include two genera, mammarenaviruses and reptarenaviruses (Radoshitzky et al., 2015). 
Both genera are zoonotic viruses which are carried in either rodents for the 
mammarenaviruses or snakes for the reptarenaviruses (Buchmeier et al., 2007; Hetzel et 
al., 2013; McCormick et al., 1986; Stenglein et al., 2012). The mammarenavirus, Tacaribe 
virus, is unique in the Arenaviridae family as it is carried in Artibeus bats (Downs et al., 
1963). For sake of simplicity, from this point forward the mammarenaviruses will be 
referred to as arenaviruses and no further discussion of the reptarenaviruses will be 
included. 
Arenaviruses typically establish a persistent, lifelong infection in their rodent 
hosts that is initiated through vertical transmission of the virus from infected mother to 
offspring (Downs et al., 1963). Horizontal transmission through exposure of naïve rodents 
to urine, feces, or saliva from infected rodents also occurs, but mice infected as adults are 
less likely to become chronically infected (Childs and Peters, 1993). The rodent carrier of 
each arenavirus is species-specific and thus the distribution of each arenavirus is limited to 
the geographic distribution of its rodent host. Thus, most arenaviruses have a relatively 
limited geographic range with the exception of lymphocytic choriomeningits virus 
(LCMV), which is carried in the common house mouse (Mus musculus) and has a 
worldwide distribution (Childs and Peters, 1993). The arenavirus family is divided into two 
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major groups, the Old World and New World arenaviruses, which represent viruses found 
primarily in Africa or the Americas, respectively (Emonet et al., 2009a).   
Several of the arenaviruses cause disease in humans. Human infection with 
arenaviruses can occur through direct contact with infected rodents or through exposure to 
virus aerosolized from infected rodent excreta (Keenlyside et al., 1983). Several 
arenaviruses from both the Old World and New World groups cause severe hemorrhagic 
fever in humans with high fatality rates. The Old World arenavirus, Lassa virus (LASV), 
causes the greatest number of infections of all the arenaviruses with an estimated 100,000-
300,000 cases per year resulting in an estimated annual toll of 5,000 deaths (McCormick 
et al., 1987). Additionally, ~30% of survivors of LASV infection become deaf and the 
mortality rate associated with infection during pregnancy is high for both the mother and 
fetus (Cummins et al., 1990; Price et al., 1988). Six New World arenaviruses are known to 
cause hemorrhagic fever in humans. Junín, Machupo, Sabiá, and Guanarito viruses are the 
causative agents of Argentine, Bolivian, Brazilian, and Venezuelan Hemorrhagic Fever, 
respectively (Charrel and Lamballerie, 2003). The North American arenavirus, White 
Water Arroyo virus as well as Chapere virus, found in Bolivia, also cause hemorrhagic 
fever in humans (Byrd et al., 2000; Delgado et al., 2008b). Finally, the first arenavirus 
discovered, LCMV, was identified as the causative agent in an outbreak of encephalitis in 
St. Louis in 1933 (Armstrong and Lillie, 1934). LCMV infections in healthy humans ranges 
from a sub-clinical infection to aseptic meningitis (Bonthius, 2012). LCMV is a significant 
concern during pregnancy, as it can result in severe birth defects or spontaneous abortion 
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(Barton et al., 2002; Strausbaugh et al., 2001). LCMV has also caused several deaths in 
cases of solid organ transplants where the donor was infected with LCMV and the 
immunosuppressive therapy the recipients received following organ transplantation 
allowed the LCMV infection to proceed virtually unchecked (Fischer et al., 2006).  
There are very limited options for prevention or treatment of human infection with 
any of the arenaviruses. There are no U.S. Food and Drug Administration (FDA)-approved 
vaccines available for the prevention of any of the arenaviruses. A live, attenuated vaccine 
strain of the South American arenavirus, Junín virus (JUNV), called Candid 1 (C#1) has 
been shown to reduce cases of Argentine hemorrhagic fever in the endemic region, but it 
has not been approved by the U.S. FDA (Enria et al., 2008b). Off-label use of the 
nucleoside analog, ribavirin, has been shown to significantly reduce the case fatality rate 
of Lassa fever particularly when treatment was started within 6 days following fever onset 
(McCormick et al., 1986). A small clinical trial with ribavirin for Argentine hemorrhagic 
fever failed to demonstrate any efficacy in reducing mortality (Enria et al., 2008b). The use 
of immune plasma from convalescent survivors of arenavirus infection has been tried for 
Lassa fever and Argentine hemorrhagic fever, but was only effective for Argentine 
hemorrhagic fever (Maiztegui et al., 1979; McCormick et al., 1986). 
Arenaviruses are enveloped viruses ranging in size from 50-300nM and contain 
protrusions on the outer surface comprised of the viral transmembrane glycoprotein (Burns 
and Buchmeier, 1993). Arenavirus virions have electron dense granules visible by electron 
microscopy that are presumed to be ribosomes from which they derive their namesake, for 
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the Latin word, arenosus, meaning sandy (Rowe et al., 1970). Arenaviruses have a 
segmented, negative-sense RNA genome comprised of two single-stranded segments with 
an ambisense coding strategy. Each genome segment encodes two proteins. The 
nucleoprotein (NP) and glycoprotein (GP) are encoded by the small (S) segment while the 
large (L) segment encodes the RNA-dependent RNA polymerase (L) and the matrix protein 
Z (Auperin et al., 1986; Clegg et al., 1991; Djavani et al., 1997; Lukashevich et al., 1997; 
Riviere et al., 1985; Salvato and Shimomaye, 1989; Singh et al., 1987). All four proteins 
are structural components of the virion. GP is a transmembrane protein that forms spikes 
on the exterior of the virion, NP and L together with the genome segments form 
ribonucleoprotein (RNP) complexes which are packaged into virions, and Z forms a matrix 
layer on the interior side of the viral membrane (Lee and de la Torre, 2002; Neuman et al., 
2005; Salvato et al., 1992a; Strecker et al., 2003).  
Arenaviruses enter cells through receptor-mediated endocytosis, undergo 
replication and assembly in the cytoplasm, and are released from the cell via budding from 
the plasma membrane (Urata and Yasuda, 2012). GP mediates cell entry by binding cell 
surface receptors including the transferrin receptor for Clade B New World arenaviruses, 
including JUNV, and α-dystroglycan for Old World arenaviruses (including LCMV and 
LASV) and clade C New World arenaviruses (Cao et al., 1998; Radoshitzky et al., 2007; 
Spiropoulou et al., 2002). LCMV and LASV can also use alternate cell surface receptors 
including DC-SIGN, LSECtin, Axl and Tyro3 (Shimojima and Kawaoka, 2012; Shimojima 
et al., 2012). Upon receptor binding to the cell surface receptor, the virus is endocytosed 
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and the bound virus enters the endocytic pathway (Borrow and Oldstone, 1994; Kunz, 
2009; Martinez et al., 2007; Quirin et al., 2008). In endosomes, GP triggers fusion of the 
viral envelope with the endosomal membrane releasing viral ribonucleoproteins into the 
cytoplasm (Klewitz et al., 2007). Viral replication occurs in the cytoplasm where the 
genome is transcribed and replicated by the L polymerase but also requires NP (Lee et al., 
2000; Lopez et al., 2001). Virus assembly occurs at the plasma membrane where the Z 
matrix protein coordinates the recruitment of the glycoprotein and the ribonucleoprotein 
(RNP) complex, which consists of the viral genome, NP and the L polymerase, into 
budding virions (Fehling et al., 2012). Finally, the budding and release of progeny virions 
is mediated by the Z protein (Perez et al., 2003; Strecker et al., 2003). 
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1.3. The Z Matrix Protein 
The arenavirus Z matrix protein is a small protein ranging in size from 90-103 
amino acids which is largely comprised of a central zinc-binding really interesting new 
gene (RING) domain (Salvato et al., 1992b; Salvato and Shimomaye, 1989). Z also has 
functionally important C-terminal tetrapeptide motifs called late domains as well as an N-
terminal myristoylation site (Perez et al., 2003; Perez et al., 2004a; Strecker et al., 2003; 
Strecker et al., 2006). The RING domain is required for mediating certain protein-protein 
interactions including interaction with the viral L polymerase and certain host proteins 
including eIF4E, PML, PRH and the ribosomal P proteins (Borden et al., 1998a; Borden et 
al., 1998b; Djavani et al., 2005; Kentsis et al., 2001). The RING domain’s interaction with 
the L polymerase and eIF4E are necessary for Z’s role in the regulation of viral polymerase 
activity and host cell cap-dependent translation, respectively (Campbell Dwyer et al., 2000; 
Cornu and de la Torre, 2002; Jacamo et al., 2003a; Kentsis et al., 2001; Kranzusch and 
Whelan, 2011). The Z protein of every arenavirus (except Tacaribe virus) contains one or 
two tetrapeptide late domains, either P(S/T)AP or PPXY, within the C-terminal tail region 
(Fehling et al., 2012). These viral late domains are thought to be required for efficient 
arenavirus release and the loss of these domains has been shown to result in decreased 
arenavirus virus-like particle (VLP) release (Djavani et al., 1997; Fehling et al., 2012). The 
majority of arenavirus Z proteins, except the Old World arenaviruses LCMV, Mobala, 
Dandenong, Ippy, Luna and Merino Walk virus, also contain a YXXL motif within the 
RING domain that is involved in Z’s interaction with viral NP for at least Tacaribe (TACV) 
and Mopeia (MOPV) virus (Fehling et al., 2012; Groseth et al., 2010; Shtanko et al., 2011; 
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Urata et al., 2009). Finally, the Z protein is myristoylated within its N-terminal region on 
the glycine residue at the second position (Perez et al., 2004a; Strecker et al., 2006). This 
modification mediates Z’s interaction with the plasma membrane and is essential for its 
budding activity as well as Z’s interaction with plasma membrane-localized viral GP which 
is necessary for proper virus assembly (Capul et al., 2007; Perez et al., 2004a; Strecker et 
al., 2006).  
Z is responsible for a number of critical functions in the viral life cycle including 
regulating viral genome replication and transcription, repressing translation of viral and 
cellular mRNAs, antagonizing the innate immune response, coordinating virus assembly, 
and driving virus budding and release. The Z protein directly binds the L polymerase and 
results in dose-dependent inhibition of polymerase activity (Cornu and de la Torre, 2001; 
Jacamo et al., 2003b; Kranzusch and Whelan, 2011). Z locks the L polymerase in a 
promoter bound state which may serve as a mechanism to ensure recruitment of both the 
polymerase and the viral genome into arenavirus particles (Kranzusch and Whelan, 2011). 
Z can also repress the translation of capped mRNAs by directly binding to and inhibiting 
the translation initiation factor eIF4E through its RING domain (Campbell Dwyer et al., 
2000; Kentsis et al., 2001; Kranzusch and Whelan, 2011; Volpon et al., 2010). Several host 
factors involved in the innate immune response depend on eIF4E for their expression, thus, 
Z protein inhibition of eIF4E may serve as one mechanism by which arenaviruses can 
suppress the host immune response (Fehling et al., 2012). Z has also been shown to 
antagonize the host immune response through interferon antagonism. The initial finding 
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indicated that Z proteins of several New World arenaviruses, but not the Old World 
arenaviruses LCMV or LASV, directly bind to retinoic acid-inducible gene I (RIG-I) and 
thus inhibit type I interferon production (Fan et al., 2010). However, a more recent study 
contradicted that finding in part by demonstrating that LCMV and LASV Z as well as the 
Z protein of other pathogenic arenaviruses, but not non-pathogenic arenaviruses, can bind 
to and inhibit RIG-I (Xing et al., 2015). Z from pathogenic arenaviruses can also inhibit 
interferon production by antagonizing melanoma differentiation-associated protein 5 
(MDA5) (Xing et al., 2015). The Z protein’s interaction with both RIG-I and MDA5 is 
mediated through Z’s N-terminal domain (Xing et al., 2015). 
The most prominent role of Z is to drive assembly, budding, and release of virions 
at the plasma membrane. The sites of virus particle assembly must contain all of the 
arenavirus proteins as well as the viral genome in order to produce infectious virus 
particles. Z functions as the central coordinator for the assembly of virus particles at sites 
of budding by interacting with glycoprotein (GP) and the viral ribonucleoprotein (RNP) 
complex (Capul et al., 2007; Schlie et al., 2010). Accordingly, Z is the only arenavirus 
protein to interact directly with each of the other three arenavirus proteins. The viral GP is 
a transmembrane protein that traffics to the cell’s plasma membrane where it can be 
packaged into nascent virions. Z interacts with plasma membrane-localized GP by way of 
its N-terminal myristoylation modification (Capul et al., 2007; Perez et al., 2004a; Strecker 
et al., 2006). The RNP complex consists of NP, the L polymerase, and the viral genome 
segments. Thus, interaction of Z with any of the individual RNP components may facilitate 
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the recruitment of the RNP complex into nascent virions. Z’s interaction with NP is well-
established and appears to be conserved across the arenavirus family (Casabona et al., 
2009; Eichler et al., 2004; Groseth et al., 2010; Levingston Macleod et al., 2011; Ortiz-
Riano et al., 2011; Shtanko et al., 2010). Finally, Z has been shown to bind directly to the 
L polymerase through its RING domain (Jacamo et al., 2003b; Kranzusch and Whelan, 
2011). As the  Z-L interaction results in viral genome promotor-bound, inactive 
polymerase, the recruitment of viral genome into nascent virions may be ensured 
(Kranzusch and Whelan, 2011). 
The release of arenavirus virions has traditionally been thought to be mediated by 
Z’s recruitment of the cellular endosomal sorting complex required for transport (ESCRT) 
through its C-terminal late domains, either P(S/T)AP and/or PPXY (Perez et al., 2003; 
Strecker et al., 2003; Urata et al., 2006). Accordingly, Z, in the absence of other viral 
proteins, can induce the formation of virus-like particles (VLPs) and thus is both necessary 
and sufficient for driving the budding process (Eichler et al., 2004; Perez et al., 2003; 
Strecker et al., 2003). Mutation of the PPXY late domain, present in Old World arenavirus 
Z proteins, results in decreased VLP production for LCMV and LASV (Perez et al., 2003; 
Strecker et al., 2003). Mutation of the P(S/T)AP late domain, present in most New World 
and some Old World arenaviruses, similarly results in  reduced VLP production for LASV 
and Lujo virus (LUJV), but other arenaviruses have not yet been tested (Perez et al., 2003; 
Strecker et al., 2003; Urata et al., 2016). Disruption of certain ESCRT proteins has also 
been shown to reduce arenavirus VLP production. Silencing (si)-RNA-mediated 
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knockdown of the ESCRT protein, TSG101, resulted in decreased LCMV and LASV Z 
VLP production but did not reduce LUJV VLP production (Perez et al., 2003; Urata et al., 
2006; Urata et al., 2016). Supporting the role of TSG101 in VLP release, LASV Z and 
TSG101 have also been shown to interact in a manner that appears to require both the 
PPXY and P(S/T)AP late domains (Fehling et al., 2012). Knockdown or overexpression of 
a dominant-negative form of the ESCRT accessory protein, VPS4A/B, also decreased 
LASV Z, but not Lujo Z, VLP release (Urata et al., 2006; Urata et al., 2016). Finally, 
treatment with small molecules that inhibit the interaction between PPXY late domains and 
Nedd4 family ubiquitin ligases, which have been shown to be a critical link between viral 
matrix proteins and the ESCRT complex, reduced LASV VLP production (Han et al., 2014; 
Votteler and Sundquist, 2013). While these various studies have provided strong support 
for the role of late domains and the ESCRT pathway for the release of some arenaviruses, 
these experiments have relied on the use of VLP assays which do not always faithfully 
recapitulate all the facets of the whole virus. The only studies to date that have assessed 
the role of either late domains or ESCRT factors with complete, infectious virus are with 
Pichinde virus (PICV). In that study, recombinant PICV with mutations to its PSAP late 
domain was viable but the release of infectious virus particles was attenuated (Wang et al., 
2012). Additionally, the New World arenavirus Tacaribe (TACV) lacks a functional late 
domain in its Z protein indicating that arenavirus budding and release may, at least in some 
cases, be independent of known late domains or require additional, unidentified factors 
(Urata et al., 2009).  
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While the PPXY and P(S/T)AP late domains found in most arenavirus Z proteins 
are bona fide late domains, the majority of arenavirus Z proteins, with the exceptions of 
the Old World arenaviruses LCMV, Mobala, Dandenong, Ippy, Luna and Merino Walk 
virus, also contain an additional motif in the central region of the protein (Fehling et al., 
2012). This motif, YLCL, resembles another type of late domain found in the budding 
proteins of other viruses (Fehling et al., 2012). While this motif has been shown to be 
required for Z-NP interaction for TACV and MOPV, it has not been shown to function as 
a viral late domain driving arenavirus release as has been shown for the YPXL motif found 
in equine infectious anemia virus and other retroviruses (Groseth et al., 2010; Puffer et al., 
1997; Votteler and Sundquist, 2013). LUJV represents a unique case in that it has two 
separate motifs that resemble the YPXL motif in equine infectious anemia virus (Urata et 
al., 2016). LUJV Z has a YLCL motif that does not contribute to VLP production but also 
has a YREL motif that does impact VLP production (Urata et al., 2016). However, 
knockdown of the YPXL-binding, ESCRT accessory protein, ALIX (also known as AIP1 
or PDCD6IP), did not impact LUJV VLP release leaving in question whether YREL 
functions as a viral late domain in LUJV (Urata et al., 2016; Votteler and Sundquist, 2013). 
While the arenavirus Z protein is clearly the driving force of arenavirus release, substantial 
diversity exists among the different arenavirus Z proteins and it appears that different Z 
proteins may utilize host cell machinery in distinct ways to drive virus release. Substantial 
work is needed to understand the host cell machinery employed by the different arenavirus 
Z proteins to accomplish this essential function.  
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1.4. Defective Interfering Particles 
Defective interfering (DI) particles are a class of virus particles produced by a 
wide range of viruses that cannot self-replicate and specifically interfere with the 
production of homologous infectious virus (also known as standard virus) (Huang, 1973; 
Huang and Baltimore, 1970). These particles were first discovered by von Magnus in the 
1950’s for influenza virus and in the decades that followed, many viruses were shown to 
produce DI particles including vesicular stomatitis virus (VSV), Sendai virus, arenaviruses, 
Rift Valley fever virus and others (Bellett and Cooper, 1959; Huang, 1973; Kingsbury et 
al., 1970; Mims, 1956; von, 1951). DI particles contain a normal viral structural protein 
content and at least part of the viral genome (Huang, 1973; Huang and Baltimore, 1970). 
For many viruses, deletions in the viral genome have been identified and associated with 
the defective phenotype. Large deletions in the open reading frame for the viral polymerase 
have been found in some DI particles for both VSV and influenza virus (Davis et al., 1980; 
Epstein et al., 1980; Moss and Brownlee, 1981), but there exists significant heterogeneity 
in the types, locations and sizes of deletions in DI genomes, as has been extensively 
demonstrated with VSV (Lazzarini et al., 1981). This heterogeneity fits with the model that 
DI genomes are produced by rare aberrant replication events in which the viral polymerase 
jumps to a distal site on the template strand without releasing the daughter strand yielding 
an incomplete genome (Lazzarini et al., 1981). DI genomes, while missing large coding 
regions, must have functional replication initiation and termination sites in the untranslated 
regions as the interfering ability of DI particles require that the DI genome can be replicated 
by the viral polymerase (Lazzarini et al., 1981). Accordingly, the model of DI interference 
15 
 
posits that the truncated genomes are replicated by the viral polymerase at higher 
frequencies than that of longer, intact genomes and thus replication of DI genomes will 
predominate (Huang, 1973; Huang and Baltimore, 1970).  
DI particle-mediated interference is a distinct and highly specific mechanism that 
reduces the production of infectious virus. Studies with several different viruses have 
shown that interference occurs at an intracellular site. If DI particles are added to cultured 
cells well after standard virus, interference still occurs, indicating that DI particles do not 
simply block cell entry of standard virus by binding cell surface receptors (Cole and 
Baltimore, 1973; Dutko and Pfau, 1978; Huang and Wagner, 1966). DI particle 
interference occurs only in cells dually infected with both a DI particle and infectious virus 
(Kingsbury and Portner, 1970; Stampfer et al., 1971). Consequently, infections at low 
multiplicities result in greater standard virus production as more cells are not infected with 
both standard virus and DI particles (Huang and Baltimore, 1970). One of the most 
fascinating and not well understood aspects of DI particle interference is that DI particles 
will only interfere with homologous standard virus (Huang, 1973). VSV DI particles do 
not interfere with unrelated encephalomyocarditis virus ruling out a general cell-mediated 
antiviral response, such as the interferon response, induced by DI particles as the 
mechanism of interference (Huang and Wagner, 1966). The specificity of interference also 
extends to closely related viruses. For example, DI particles from the Indiana serotype of 
VSV were 100 times more effective at inhibiting standard virus production of the Indiana 
serotype than of the New Jersey serotype (Huang and Wagner, 1966). A similar observation 
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has been made for arenaviruses, where treatment with DI particles of the New World 
arenavirus, Parana, confers complete interference with Parana standard virus production 
but only partial interference against the related Old World arenavirus, LCMV, and vice 
versa (Staneck and Pfau, 1974; Welsh et al., 1972). Neither LCMV nor Parana DI particles 
interfere with the rhabdovirus VSV (Staneck and Pfau, 1974; Welsh et al., 1972).  
Arenavirus DI particles share many of the same features as the DI particles from 
other virus families with a few key exceptions. They interfere with homologous but not 
heterologous standard virus production (Staneck and Pfau, 1974), contain a full 
complement of the viral structural proteins (Welsh and Buchmeier, 1979), can be 
neutralized by immune-specific sera (Welsh et al., 1972), and they cannot reproduce or 
even synthesize viral proteins without co-infection of a cell with standard helper virus 
(Welsh and Oldstone, 1977). DI particle-mediated interference is maintained even when 
arenavirus DI particles are added to cells well after infection with standard virus indicating 
that interference occurs intracellularly (Dutko and Pfau, 1978). However, unlike many 
other virus families, no large genomic deletions have been identified and associated with 
arenavirus DI particles. The only genomic deletions that have been identified for 
arenaviruses are short truncations within the untranslated regions of the genome segments 
(Meyer and Southern, 1997). These truncated genomes are present at both acute and 
persistent stages of infection but are more abundant during persistence during which DI 
particles predominant relative to standard virus (Lehmann-Grube et al., 1969; Meyer and 
Southern, 1997; Staneck et al., 1972; Welsh and Oldstone, 1977; Welsh and Pfau, 1972). 
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Thus, it is assumed that these terminally truncated genomes comprise the genetic material 
of arenavirus DI particles, but the evidence to assert this assumption is limited. This 
suggestion that arenavirus DI particle genomes differ by very few nucleotides from their 
standard virus counterpart does fit with the size and weight of arenavirus DI particles, for 
which little or no difference from standard virus particles exists (Gschwender and Popescu, 
1976; Welsh et al., 1972; Welsh and Oldstone, 1977). In contrast, VSV DI particles, which 
contain larger genomic deletions, can be readily separated by gradient centrifugation as 
their buoyant density differs significantly from standard virus due to significant loss in total 
packaged nucleotides (Huang et al., 1966).  
The sensitivity of arenavirus DI particles to ultra-violet (UV) light treatment is 
drastically reduced relative to standard virus unlike the DI particles of other well-studied 
viruses including VSV and Sendai virus (Huang et al., 1966; Kingsbury et al., 1970; Welsh 
et al., 1972). Arenavirus DI particles can sustain UV treatments that readily eliminate any 
standard virus activity (Damonte et al., 1983; Staneck and Pfau, 1974; Welsh et al., 1972). 
UV light exposure generates lesions in nucleic acids which ultimately blocks genome 
transcription and the amount of UV light exposure positively correlates with the frequency 
of damaged sites within the genome (Abraham and Banerjee, 1976; Michalke and Bremer, 
1969). The decreased susceptibility to UV light of arenavirus DI particles suggests that 
their interfering activity may be less dependent on the genomic material than the DI 
particles of other viruses (Welsh et al., 1972). Intriguingly, the arenavirus Z protein can 
render cells refractory to infection with homotypic virus and is a strong inhibitor of the 
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viral polymerase (Cornu and de la Torre, 2001; Cornu et al., 2004; Jacamo et al., 2003a; 
Kranzusch and Whelan, 2011). As prevention of the viral polymerase from replicating the 
standard virus genome is thought to be the primary mechanism of DI particle-mediated 
interference, a role for the arenavirus Z protein in interference is logical (Lazzarini et al., 
1981). Alternatively, the kinetics of UV inactivation for arenaviruses suggest that the size 
of the functional region for interfering activity is small. Accordingly, UV-mediated damage 
kinetics can be used to assess the size of the region responsible for interfering activity 
(Abraham and Banerjee, 1976; Bay and Reichmann, 1979). VSV DI particles are readily 
inactivated by UV light indicating a large functional region required for DI particle-
mediated interference (Bay and Reichmann, 1979). Alternatively, certain strains of Sinbis 
virus DI particles retain interfering activity following much longer UV exposures, like 
arenaviruses, indicating that only a small region of the DI genome is required for 
interference (Kowal and Stollar, 1980). Finally, the relative resistance of arenavirus DI 
particles to UV light has been used to obtain functionally pure DI particle preparations so 
that they can be studied in the absence of standard virus (Welsh et al., 1972). 
RNA viruses, other than retroviruses, lack the ability to establish latent infections 
through viral genome integration into a host cell’s DNA, like retroviruses can, or to be 
maintained in episomes like that of DNA viruses (Boldogh et al., 1996; Perrault, 1981). 
Nevertheless, many RNA viruses possess the ability to maintain persistent infections. The 
mechanisms that permit this persistence are multifaceted, but a role for DI particles in 
persistent infection of some RNA viruses has been demonstrated in vitro (Ahmed and 
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Graham, 1977; Andzhaparidze et al., 1982; Carthy et al., 1981; Holland and Villarreal, 
1974; Holland et al., 1976; Kawai et al., 1975; Popescu and Lehmann-Grube, 1977; Roux 
and Holland, 1979; Schmaljohn and Blair, 1977; Weiss et al., 1980). Cultures of 
persistently infected cells with viruses from different families typically have a high 
percentage of cells infected and express cytoplasmic viral antigen but reduced cell surface 
viral antigen compared to acutely infected cells (Holland et al., 1980; Roux and Waldvogel, 
1983; Welsh and Oldstone, 1977). The persistently infected cultures are resistant to 
superinfection by homologous virus but permissive to heterologous virus and produce little 
standard virus (Holland et al., 1980). The reduction in cell surface antigen combined with 
decreased release of standard virus caused by DI particles are thought to be major factors 
permitting persistent infection whereby active viral replication and protein expression is 
permitted and balanced by the contribution of DI particles in reducing immune response to 
infection and protecting infected cells (Roux and Waldvogel, 1983; Welsh and Oldstone, 
1977).  
While the role of DI particles during persistent infections for numerous viruses in 
vitro is fairly well-established, their significance in vivo is less clear. DI particles have been 
detected in experimental persistent infections in vivo for some viruses including LCMV, 
VSV and reovirus but the lack of sensitive assays for detecting DI particles for many virus 
families has limited the ability to detect low levels of DI particles in animals (Barrett and 
Dimmock, 1986; Cave et al., 1984; Popescu and Lehmann-Grube, 1977; Spandidos and 
Graham, 1976). There is substantial evidence, however, demonstrating that DI particles 
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can protect against pathology or delay or prevent death related to viral infection in vivo 
(Barrett and Dimmock, 1986; Dimmock and Kennedy, 1978; Doyle and Holland, 1973; 
Help and Coto, 1980; Holland and Doyle, 1973; Spandidos and Graham, 1976; Welsh et 
al., 1977). This protection in vivo has been shown, at least in some cases, to be specific to 
the interfering genomes in DI particles and not to a non-specific host immune response 
(Barrett and Dimmock, 1986). In particular, antibody-mediated protection was ruled out 
by demonstrating that biologically active VSV DI particles, but not UV-inactivated DI or 
standard virus particles protected mice against lethal VSV challenge despite the 
maintenance of protein antigenicity following UV treatment (Jones and Holland, 1980). 
Furthermore, studies with Semliki Forest virus (SFV) have shown that the DI particle-
mediated protection does not extend to heterologous viruses and that infected mice 
protected by DI SFV lack immune infiltrates, both providing evidence against immune 
involvement in protection (Crouch et al., 1982; Dimmock and Kennedy, 1978). In the case 
of arenaviruses, DI particles have been detected at acute and persistent stages during in 
vivo infections, and have been shown to elicit protection against standard virus challenge 
in vivo (Help and Coto, 1980; Popescu and Lehmann-Grube, 1977; Staneck and Pfau, 1974; 
Welsh et al., 1977). While these studies help to support the idea that DI particles are 
involved in the establishment and maintenance of natural persistent infections of RNA 
viruses, as has long been hypothesized for arenaviruses, the evidence falls substantially 
short of confirming this hypothesis.  
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1.5. The ESCRT Pathway and Late Domains 
The endosomal sorting complex required for transport (ESCRT) pathway, also 
known as the vacuolar protein sorting (VPS) pathway in yeast, is a highly conserved system 
that mediates specific forms of membrane biogenesis in cells. The ESCRT pathway drives 
reverse topology membrane biogenesis events in which the membrane forms vesicles in a 
direction away from the cytoplasm where the membrane must be constricted towards the 
cytoplasm and is the only pathway known to mediate such events (Schoneberg et al., 2017; 
Votteler and Sundquist, 2013). The ESCRT pathway was originally discovered in yeast 
where disruption of certain VPS/ESCRT proteins resulted in an aberrant endosome-like 
structure, called a class E compartment, and the failure to deliver endocytosed integral 
plasma membrane proteins to the vacuole (Raymond et al., 1992; Rieder et al., 1996). The 
class E compartment results from the inability of intralumenal vesicles to bud into late 
endosomes and form multivesicular bodies (MVB) (Hurley, 2008; Katzmann et al., 2002). 
In addition to functioning in MVB formation, the ESCRT pathway is also critical for 
several other functions in host cells including cytokinesis (Carlton and Martin-Serrano, 
2007; Morita et al., 2007), shedding of microvesicles at the plasma membrane (Nabhan et 
al., 2012), formation of exosomes (Hurley, 2015; Raposo and Stoorvogel, 2013), and 
micro- and macro-autophagy (Lee et al., 2007; Rusten et al., 2007; Sahu et al., 2011), as 
well as a growing list of other endogenous functions (Hurley, 2015). In 2001 it was 
demonstrated that the ESCRT pathway is required for HIV-1 virus release at the plasma 
membrane (Martin-Serrano et al., 2001). Since then, a wide range of enveloped viruses 
have been shown to exploit the ESCRT pathway to drive virus release at the plasma 
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membrane as well as for some viruses that bud into internal compartments (Tabata et al., 
2016; Votteler and Sundquist, 2013). The function of the ESCRT pathway in these various 
processes is to cleave the thin membrane stalk formed during vesicle formation to permit 
separation of the newly formed vesicle from its parent membrane (Schoneberg et al., 2017). 
ESCRT proteins also contribute to the initial membrane curvature for MVB formation 
(Hanson et al., 2008). In other ESCRT-driven processes, however, adaptor proteins such 
as HIV-1 Gag for virus budding or non-ESCRT host proteins are thought to drive 
membrane curvature without help from ESCRT proteins (Campbell and Rein, 1999; 
Votteler and Sundquist, 2013). 
The ESCRT pathway is composed of four protein complexes called ESCRT-0, -
I, -II, and –III and the accessory proteins ALIX and VPS4 which are recruited in a 
sequential fashion to drive membrane scission. ESCRT-0, -I and –II function to assemble 
a stable scaffold at target membrane sites and to recruit the membrane-cleaving ESCRT-
III complex (Schoneberg et al., 2017). ESCRT proteins are initially recruited to membrane 
sites by adaptor proteins. The ESCRT-0 proteins, Hrs and Stam, serve as adaptors for MVB 
formation where they bind to ubiquitinated endosomal cargos through their ubiquitin 
binding domains (Bache et al., 2003a; Bache et al., 2003b; Hanson and Cashikar, 2012). 
Other adaptor proteins include viral matrix proteins such as HIV-1 Gag or arenavirus Z 
protein for virus budding (Garrus et al., 2001; Perez et al., 2003), ARRDC1 for 
microvesicle shedding (Nabhan et al., 2012), CEP55 for cellular abscission (Carlton and 
Martin-Serrano, 2007), and Syntenin/Syndecan for exosome formation (Baietti et al., 
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2012). These adaptor proteins can then recruit early acting ESCRT factors from the 
ESCRT-I complex or the accessory protein ALIX through short peptide motifs called late 
domains that were originally discovered in different viruses (discussed in detail below). 
These include the TSG101-binding P(S/T)AP found in Hrs and ARRDC1 and the ALIX-
binding YPXL found in Syntenin (Bache et al., 2003a; Baietti et al., 2012; Nabhan et al., 
2012). A unique ALIX-binding motif in CEP55 can also bridge the target membrane and 
cargo to early acting ESCRT factors (Carlton and Martin-Serrano, 2007). Each ESCRT-I 
complex contains a single copy of TSG101 that provides a direct link to some of the 
ESCRT adaptor proteins, as well as VPS28, which links ESCRT-I to the ESCRT-II protein, 
VPS36, through its C-terminal domain (Gill et al., 2007; Kostelansky et al., 2006). Once 
the ESCRT-II complex is recruited to membrane scission sites, another ESCRT-II protein, 
VPS25, initiates ESCRT-III complex formation through binding to CHMP6 (Carlson and 
Hurley, 2012; Im et al., 2009). CHMP6 can subsequently recruit another ESCRT-III 
protein CHMP4 which together with CHMP3 drives membrane scission (Carlson and 
Hurley, 2012; Im et al., 2009; Wollert et al., 2009). ESCRT adaptor proteins that recruit 
ALIX can bypass the ESCRT-I/II complex as ALIX interacts directly with the ESCRT-III 
protein CHMP4 (Kim et al., 2005; McCullough et al., 2008). Following membrane 
scission, the ESCRT-III protein, CHMP2, recruits the AAA ATPase VPS4, an ESCRT 
accessory protein, which disassembles and recycles the ESCRT complex (Obita et al., 
2007; Stuchell-Brereton et al., 2007; Wollert et al., 2009).  
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Not all ESCRT adaptors appear to engage all ESCRT complexes starting with 
ESCRT-0 as with the sorting of ubiquitinated integral membrane proteins in MVB 
formation. ARRDC1 has a PSAP motif which directly binds Tsg101 allowing microvesicle 
shedding to bypass ESCRT-0 (Kuo and Freed, 2012; Nabhan et al., 2012). Syntenin and 
CEP55 can both directly bind ALIX, albeit through different types of motifs, permitting 
direct recruitment of ESCRT-III (Baietti et al., 2012; Lee et al., 2008). The ESCRT 
pathway has also evolved layers of redundancy to ensure recruitment of the ESCRT-III 
scission machinery for cellular processes. CEP55, in addition to directly binding ALIX, 
also directly interacts with Tsg101 thus employing a pathway that utilizes ESCRT-I (Lee 
et al., 2008). ALIX can also directly interact with TSG101 via the PSAP motif in ALIX 
raising the possibility that ALIX may provide a direct link to both ESCRT-I and ESCRT-
III (Martin-Serrano et al., 2003; von Schwedler et al., 2003). Finally, ubiquitin-conjugated 
proteins may also play a role in recruitment of the ESCRT pathway as many ESCRT-I/II 
components contain ubiquitin binding domains (Shields and Piper, 2011). This could 
provide a means of bypassing earlier ESCRT complexes or acting as a redundant pathway 
for which to recruit the ESCRT-III membrane scission machinery.  
Viruses hijack the ESCRT pathway by encoding motifs that mimic those found in 
various ESCRT pathway components. These motifs are called late domains because their 
disruption results in arrest of virus production at late steps in the virus life cycle, 
specifically virus release. The first late domain was discovered in HIV-1 where mutations 
to its PSAP motif in the Gag protein resulted in budded virions that were still attached to 
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the cell’s plasma membrane by a thin membrane stalk (Göttlinger et al., 1991; Huang et 
al., 1995). Since that initial discovery, a diverse range of viruses have been shown to 
encode functional P(S/T)AP late domains including many other retroviruses, some 
arenaviruses, filoviruses, and the non-enveloped Bluetongue virus (Martin-Serrano et al., 
2001; Perez et al., 2003; Strecker et al., 2003; Urata et al., 2007; Votteler and Sundquist, 
2013; Wirblich et al., 2006). These viral motifs mimic the same motif found in the ESCRT-
0 protein Hrs and allow the virus to directly recruit Tsg101 (Bache et al., 2003a). Three 
other types of late domains were subsequently discovered: PPXY which was first 
discovered in Rous sarcoma virus (RSV), FPIV in paramyxoviruses, and YPXL, first 
discovered in EIAV (Li et al., 2009a; Parent et al., 1995; Pei et al., 2010; Puffer et al., 
1997; Schmitt et al., 2005). While the YPXL late domain was later shown to directly bind 
the ESCRT accessory protein ALIX, like the cellular protein Syntenin, the mechanism by 
which the PPXY and FPIV late domains link to the ESCRT machinery is unclear (Li et al., 
2009a; Pei et al., 2010; Schmitt et al., 2005; Votteler and Sundquist, 2013). 
The PPXY late domain has been found to function in the release of a diverse range 
of viruses including several retroviruses, filoviruses, Old World arenaviruses, hepatitis B 
virus and Bluetongue virus (see Table 1.1 for specific references) (reviewed in (Votteler 
and Sundquist, 2013)). While the mechanism by which this motif recruits the ESCRT 
pathway is unclear, the PPXY motif has been shown to directly interact with WW domains 
found in Nedd4 family E3 ubiquitin ligases (Chen and Sudol, 1995; Ingham et al., 2005; 
Ingham et al., 2004; Staub et al., 1996). Many PPXY-containing viruses, including 
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filoviruses (Han et al., 2016; Harty et al., 2000; Timmins et al., 2003; Urata and Yasuda, 
2010; Yasuda et al., 2003), rhabdoviruses (Harty et al., 1999), and some retroviruses (Blot 
et al., 2004; Bouamr et al., 2003; Kikonyogo et al., 2001; Medina et al., 2008; Sakurai et 
al., 2004; Yasuda et al., 2002) have been shown to directly interact with Nedd4-like 
ubiquitin ligases. Furthermore, the enzymatic activity of these ligases must be intact in 
order to facilitate virus egress and has been demonstrated specifically for filoviruses and 
the retroviruses human T-cell leukemia virus (HTLV-1) and RSV (Blot et al., 2004; Han 
et al., 2016; Martin-Serrano et al., 2005; Sakurai et al., 2004; Segura-Morales et al., 2005; 
Urata and Yasuda, 2010; Vana et al., 2004; Yasuda et al., 2003). This suggests that these 
ligases are recruited to sites of viral budding where they ligate ubiquitin onto proteins at 
that site. Some viral proteins, including Marburg and Ebola virus VP40 (Han et al., 2016; 
Harty et al., 2000), RSV and HTLV-1 Gag (Blot et al., 2004; Strack et al., 2000; Vana et 
al., 2004), and VSV M (Harty et al., 2001), are ubiquitinated by these ligases. However, 
the target of Nedd4 family-mediated ubiquitination in other PPXY-containing viruses is 
unclear. Additionally, the mechanism by which Nedd4-mediated ubiquitination results in 
recruitment of the ESCRT-III scission machinery is unknown. Two major hypotheses exist. 
One posits that a ubiquitin binding domain found in some of the ESCRT-0, -I, or –II 
components directly binds to the ubiquitinated protein which can in turn recruit the 
ESCRT-III scission machinery. An alternate possibility is that the arrestin-related 
trafficking proteins, which also contain a PPXY motif, provide a linkage to the ESCRT-III 
scission machinery (Rauch and Martin-Serrano, 2011).   
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Arenaviruses, like any other virus, must replicate and release progeny virions 
from infected cells. Knowledge of the molecular mechanisms that drive this process for 
arenaviruses has grown over the last 15 years, but the exact composition of the cellular 
components exploited by the virus to facilitate release and the modifications that regulate 
this process are largely unknown. Several studies have revealed that the viral late domains 
present in most arenavirus Z proteins are functionally important for Z-mediated release and 
that some of the ESCRT proteins are also required for release. However, these studies have 
largely relied on VLP release assays, which do not always faithfully recapitulate all the 
facets of the virus life cycle. Importantly, arenaviruses produce at least two classes of virus 
particles: standard, infectious particles and DI particles. In this work, use of a complete 
virus system to assess the importance of Z protein motifs and the role of the ESCRT 
pathway was critical for advancing our understanding of arenavirus release. 
In the first study, mass spectrometry analysis identified a phosphorylation site on 
the LCMV Z protein at Y88. This site was of particular interest as it was part of the PPXY 
late domain in LCMV Z which has been shown to regulate VLP release (Perez et al., 2003). 
To build on this earlier finding on the late domain and assess the function of this 
phosphorylation site specifically, we generated recombinant viruses with mutations at Y88 
that either mimicked the charge of a phosphate group or blocked phosphorylation. This 
work led to the discovery that the PPXY late domain and the cellular ESCRT pathway that 
it recruits are both required for the production of DI particles but are dispensable for 
standard virus. This is the first example of a virus using separate release pathways for 
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standard and DI particles. This also indicates that there must be other motifs in LCMV Z 
and additional cellular components responsible for standard virus production that are yet 
to be discovered. Finally, this work suggests that host cells may be able to dynamically 
regulate DI particle production by host kinase-mediated phosphorylation at Y88. 
In the second study, a phosphorylation site at S41 in LCMV Z was discovered 
using mass spectrometry. This site lies outside of any motif known to function in Z protein-
mediated release. Recombinant viruses harboring mutations to the S41 phosphorylation 
site were used to assess the overall significance of this site. While the production of 
standard virus and DI particles was not impacted by a non-phosphorylatable alanine 
substitution (S41A), a phosphomimetic substitution at this site (S41D) decreased the 
release of both. The impact on DI particle release was more substantial, however. This 
revealed that S41 is a novel regulatory motif for Z-mediated virus release and provided 
further evidence that host cells employ kinases to regulate this process. 
In the third study, the host protein interaction network of the JUNV Z protein was 
mapped and the host protein content of JUNV C#1 virions was uncovered using mass 
spectrometry. A variety of functional host protein groups were enriched in these conditions 
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Arenaviruses cause severe diseases in humans but establish asymptomatic, 
lifelong infections in rodent reservoirs. Persistently-infected rodents harbor high levels 
of defective interfering (DI) particles, which are thought to be important for establishing 
persistence and mitigating virus-induced cytopathic effect. Little is known about what 
drives the production of DI particles. We show that neither the PPXY late domain 
encoded within the lymphocytic choriomeningitis virus (LCMV) matrix protein nor a 
functional endosomal sorting complex transport (ESCRT) pathway is absolutely required 
for the generation of standard infectious virus particles. In contrast, DI particle release 
critically requires the PPXY late domain and is ESCRT-dependent. Additionally, the 
terminal tyrosine in the PPXY motif is reversibly phosphorylated and our findings 
indicate that this posttranslational modification may regulate DI particle formation. Thus 





Arenaviruses cause severe and often fatal diseases in humans yet typically 
establish lifelong, asymptomatic infections in their rodent reservoirs. Several families of 
enveloped RNA viruses, including the arenaviruses, encode short amino acid motifs, 
called late domains, to hijack host proteins in the endosomal sorting complex required 
for transport (ESCRT) to drive the release of virus particles from the host cell’s outer 
membrane. Many late domain-containing viruses produce defective interfering (DI) 
particles in addition to standard, infectious virus. DI particles cannot self-replicate but 
interfere with the production of infectious virus and mitigate virus-induced cytopathic 
effect. Arenaviruses such as lymphocytic choriomeningitis virus (LCMV) generate high 
levels of DI particles, yet, the mechanism that drives their formation is not known. We 
show that LCMV’s only encoded late domain, PPXY, and a functional ESCRT pathway 
are critical for DI particle production, but in contrast, are not absolutely required for 
infectious virus production. We also demonstrate that the LCMV PPXY late domain is 
phosphorylated and that this modification may regulate DI particle production. In 
summary, we have discovered a new and unexpected role for a viral late domain in 





Arenaviruses are a family of rodent-borne viruses with a worldwide distribution. These 
viruses typically establish persistent, asymptomatic infections in rodent reservoir species 
(Salazar-Bravo et al., 2002b). In contrast, arenaviruses cause severe and often fatal diseases 
in humans. Several arenaviruses, including Lassa virus and Junín virus, cause hemorrhagic 
fever syndromes whereas infection with the prototypic arenavirus, lymphocytic 
choriomeningitis virus (LCMV), can lead to aseptic meningitis in immunocompetent 
individuals, high lethality in immunocompromised individuals, or severe birth defects in 
the developing fetus (Buchmeier et al., 2007; Fischer et al., 2006). U.S. Food and Drug 
Administration-approved vaccines do not exist for the prevention of arenavirus infection 
and effective antiviral therapies have been limited to the use of ribavirin for Lassa virus 
(McCormick et al., 1986) or immune plasma for Junín virus (Enria et al., 2008a).  
Arenaviruses are enveloped viruses with a single-stranded, bi-segmented RNA 
genome that encodes four proteins in an ambisense manner. The small (S) segment encodes 
the nucleoprotein (NP) and glycoprotein (GP) while the large (L) segment encodes the 
RNA-dependent RNA polymerase (L) and the matrix protein (Z) (Meyer et al., 2002). 
Arenaviruses enter cells via receptor-mediated endocytosis (Rojek and Kunz, 2008), 
undergo genomic replication and transcription in the cytoplasm (Meyer et al., 2002), and 
assemble and bud new particles at the plasma membrane (Urata and Yasuda, 2012). The Z 
protein, which lines the luminal side of the viral membrane, is responsible for a number of 
critical functions in the virus life cycle, including driving the process of viral particle 
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assembly and budding (Fehling et al., 2012). Accordingly, Z can form virus-like particles 
(VLPs) in the absence of other viral proteins and is thought to be both necessary and 
sufficient for driving the budding process (Perez et al., 2003; Strecker et al., 2003).  
Several VLP-based studies indicate that Z drives viral particle release by virtue of 
one or more encoded viral late domain(s) (P(S/T)AP, YXXL, and/or PPXY), which can 
recruit proteins from the cellular endosomal sorting complex required for transport 
(ESCRT) pathway (Perez et al., 2003; Strecker et al., 2003; Urata et al., 2006). ESCRT 
machinery is required for most cellular membrane scission events that result in separation 
away from the cytosol including multivesicular body formation and cellular abscission 
(Carlton and Martin-Serrano, 2007; Hurley, 2008; Morita et al., 2007). Many enveloped 
viruses are known to hijack cellular ESCRT machinery via their late domains to complete 
the final membrane scission step required for virions to bud from host membranes (for 
review see (Votteler and Sundquist, 2013)).  
Viruses from diverse families, including arenaviruses, produce defective interfering 
(DI) particles in addition to standard, infectious virus during the normal course of infection 
(Huang and Baltimore, 1970). DI particles are largely similar to standard virus particles in 
their appearance and viral protein content but cannot self-replicate, and interfere with the 
production of homologous standard virus (Huang and Baltimore, 1970). In many cases, the 
primary difference between DI particles and standard virus is thought to be the presence of 
deletions in the viral genome (Huang, 1973). With regard to LCMV, small deletions in the 
terminal untranslated regions of genomic and antigenomic RNAs have been observed, but 
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it is not known whether these RNAs have interfering properties or are selectively 
incorporated in DI particles (Meyer and Southern, 1997). The interfering activity of 
arenavirus DI particles can be blocked by neutralizing antibodies but is maintained even 
after treatment with ultra-violet (UV) radiation, unlike standard particles, which are highly 
susceptible to both treatments (Jacobson and Pfau, 1980). Arenaviruses generate high 
levels of DI particles both in cell culture (Welsh and Pfau, 1972) and in host rodents 
(Popescu and Lehmann-Grube, 1977). It has long been postulated that arenavirus DIs are 
an important factor in the establishment of persistent infection (Burns and Buchmeier, 
1993; Huang and Baltimore, 1970; Oldstone, 1998) but a causal link between arenavirus 
DI particles and persistence has yet to be firmly established. 
There are several outstanding questions regarding the arenavirus matrix protein, 
including how its functionality is regulated and how, in the context of a fully replicating 
virus, encoded late domains contribute to the production of standard and DI particles. 
Herein we demonstrate that LCMV’s sole late domain, PPXY, is not required for standard 
virus budding but instead is the driving force of DI particle release. Further, standard virus 
appears to bud independently of ESCRT machinery while DI particle release is ESCRT-
dependent. Finally, we show that the LCMV PPXY motif is tyrosine phosphorylated and 




The LCMV matrix protein is reversibly phosphorylated 
 
Figure 2.1. The LCMV matrix protein PPXY late domain is reversibly phosphorylated. (A) Protein 
lysates from sucrose-banded LCMV strain Armstrong 53b particles were separated on polyacrylamide gels 
and stained with Coomassie brilliant blue. A gel slice containing the Z protein (indicated by the red box) was 
excised, subjected to in-gel tryptic and/or chymotryptic digestion, and extracted peptides were analyzed by 
mass spectrometry for the presence of phosphorylated peptides as described in the Materials and Methods. 
(B) Representative low energy collision-induced dissociation tandem mass spectra of a chymotryptic peptide 
harboring the indicated phosphotyrosine residue or the same peptide unphosphorylated. Both peptides were 
identified from virion-derived LCMV Z protein. The tandem mass spectra were collected in an Orbitrap 
(MS1)-linear ion trap (MS2) mass spectrometer. Y# denotes phosphotyrosine. The SEQUEST XCorr values, 
the precursor observed mass and the associated PPM are indicated. Fig S1 shows the corresponding 
calculated and measured b- and y-type ions indicating identified fragment ion masses. (C) Depiction of the 
LCMV Z protein. G, glycine at position 2 that is myristoylated; RING, the central zinc-binding really 
interesting new gene (RING) domain; PPPY, LCMV’s only known late domain that contains the Y88 site of 
phosphorylation. (D) Tyrosine 88 in the LCMV matrix protein is phosphorylated. HEK293T cells were 
transfected with an empty vector or a plasmid encoding LCMV Z (either WT or Y88F) with a C-terminal 
streptavidin binding peptide (SBP) tag. Following a 15 minute exposure to either water or the tyrosine 
phosphatase inhibitor, H2O2, Z was affinity purified from cell lysates using magnetic streptavidin beads and 
screened via western blot using antibodies specific for phosphotyrosine or the SBP tag. Results are 
representative of 3 independent experiments. (E) LCMV is phosphorylated in rodent cells. L929 cells were 
infected or not with a rLCMV that encodes a streptavidin binding peptide (SBP) fusion tag at the C terminus 
of Z. Two days later, cells were exposed to either water or the tyrosine phosphatase inhibitor, H2O2, for 15 
minutes. SBP-tagged Z was then affinity purified from cell lysates using magnetic streptavidin beads and 
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screened via western blot using antibodies specific for phosphotyrosine or the SBP tag. Results are 
representative of 3 independent experiments. 
 
The matrix protein plays a multifactorial role in the arenavirus life cycle yet little is known 
regarding how its various functions are regulated. Given the importance of phosphorylation 
for regulating the functionality of matrix proteins of other virus families (Bajorek et al., 
2014; García et al., 2012; Hemonnot et al., 2004; Kolesnikova et al., 2012; Pei et al., 2011), 
we were interested in whether LCMV’s matrix protein might also be phosphorylated. 
LCMV strain Armstrong 53b particles grown in Vero E6 cells were purified via sucrose-
banding (Figure 2.1A) and subjected to mass spectrometry. This analysis revealed a 
tyrosine phosphorylation site near the C-terminus of the LCMV Z protein at position 88 
(Y88) (Figures 2.1B and 2.S1), which lies within LCMV Z’s PPPY late domain (Figure 
2.1C). Both phosphorylated and unphosphorylated peptides containing this residue were 
observed at a ratio of 1 to 11, respectively, which suggests that ~10% of the total Z protein 
in this virion preparation is phosphorylated (Figures 2.1B and 2.S1C). Because the virion 
preparation contained a mixture of both standard infectious virus and DI particles, we were 
not able to determine whether the phosphorylated Z was derived from standard particles, 
DI particles, and/or both types of particles. To confirm the phosphorylation site, plasmids 
encoding either WT Z or a phenylalanine mutant (Y88F) that cannot be phosphorylated 
were transfected into HEK293T cells and 2 days later the cells were treated with either 
water or the tyrosine phosphatase inhibitor, hydrogen peroxide. WT Z and Y88F Z were 
affinity purified and probed with a phosphotyrosine-specific antibody. The 
phosphotyrosine signal detected from WT Z was greatly enhanced following inhibition of 
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tyrosine phosphatases (Figure 2.1D). Substitution of tyrosine 88 with phenylalanine, to 
prevent phosphorylation, resulted in a complete loss of detectable phosphotyrosine signal 
in both settings indicating that Y88 may be the only tyrosine of the 3 encoded in LCMV Z 
that is phosphorylated (Figure 2.1D) by endogenous kinases in these cells. To determine 
whether LCMV Z is tyrosine phosphorylated in the context of a relevant rodent cell line, 
we infected murine L929 cells with a rLCMV that encodes Z with a C-terminal streptavidin 
binding peptide (SBP) tag. Two days later, cells were either treated with hydrogen peroxide 
or not and Z was affinity purified from cell lysates for western blot analysis. As shown in 
Figure 2.1E, a phosphotyrosine signal was clearly detectable from Z and was enhanced 




The LCMV matrix protein PPXY late domain is dispensable for the production of 
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Figure 2.2. The LCMV Z PPXY late domain is dispensable for the production of infectious LCMV 
particles. (A) Sequence alignment of arenavirus Z proteins reveals conservation of Y88 among most Old 
World, but not New World, arenaviruses. (B) Recombinant (r)LCMV containing substitutions at Z Y88 that 
either mimic constitutive phosphorylation (Y88E) or cannot be phosphorylated (Y88F and Y88A) were 
generated using reverse genetics as described in the Materials and Methods. Vero E6 cells were infected at 
an MOI of 0.01 and the quantity of infectious virus released at each of the indicated time points was 
determined via plaque assay. Data are presented as mean PFU ± standard error of the mean (SEM) of 3 
independent experiments. (C) Summary of two way analysis of variance (ANOVA) with Holm-Sidak’s test 
for multiple comparisons of log-transformed data for virus growth curves in (B). (D) The area of plaques 
from rLCMV WT or Z Y88 mutants was measured using Image J. Data represent the mean ± SEM of plaques 
analyzed from 16 wells from 6-well plates. Mean values were compared using the Kruskal-Wallis non-
parametric test with Dunn’s multiple comparisons test. (E) Mutation of the PPXY domain reduces Z budding 
function in a VLP assay while phosphorylation of this domain at Y88 does not further impact budding. A 
plasmid encoding LCMV Z WT, Z G2A, or the indicated Z Y88 mutants was transfected into HEK293T cells 
and 1 day later cells and VLP-containing supernatants were collected and screened via quantitative western 
blot for Z. The percent VLP release was calculated as the amount of Z protein found in the cell culture media 
relative to the amount in cells. Data are presented as mean release ± SEM relative to WT Z from 3 independent 
experiments. A one way ANOVA with Holm-Sidak’s test for multiple comparisons was used to compare the 
mean values. (C-E), n.s. (not significant), *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, as determined 
by the indicated statistical tests. 
 
The finding that LCMV Z is phosphorylated at Y88 was intriguing as this residue is part 
of LCMV’s only late domain, PPPY. This motif is well conserved among most Old World 
arenavirus Z proteins (Figure 2.2A) and its importance for the budding activity of LCMV 
and Lassa virus Z in the context of VLP-budding assays has been well described (Perez et 
al., 2003; Strecker et al., 2003). To investigate the role of this late domain in the context of 
authentic virus and to determine whether tyrosine phosphorylation may regulate its 
function, we generated recombinant (r)LCMV encoding either phenylalanine or alanine at 
position 88 to prevent phosphorylation at this site or glutamic acid to mimic constitutive 
phosphorylation. The alanine mutant was included as a reference to previous studies on the 
function of this late domain for LCMV and Lassa virus Z, which used alanine substitutions 
at Y88 to assess the contribution of this late domain to Z’s budding efficiency in VLP 
assays (Perez et al., 2003; Strecker et al., 2003). Viruses containing all three mutations 
63 
 
were recoverable despite the well-described defect in Z’s budding efficiency caused by 
mutation of this residue (Figure 2.2B) (Perez et al., 2003; Strecker et al., 2003). The growth 
kinetics of rLCMV Z-Y88F and Z-Y88A during the first 36 hours (hr) post-infection (pi) 
were nearly identical, but impaired ~15-fold compared to rLCMV WT (P ≤ 0.0001; Figures 
2.2B and 2.2C). The growth rate of the rLCMV Z-Y88E phosphomimetic was also 
attenuated compared to WT virus over this same time frame (~4-fold less PFU at 36 hr pi, 
P ≤ 0.05, Figures 2.2B and 2.2C). However, the phosphomimetic virus grew to ~4–fold 
higher titers than the alanine or phenylalanine mutants (P ≤ 0.01; Figures 2.2B and 2.2C). 
Additionally, the mean plaque size for rLCMV Z-Y88E was significantly increased 
compared to the Z-Y88F and Z-Y88A viruses (0.67 vs 0.53 or 0.52 mm2; P ≤ 0.01; Figure 
2.2D), indicating that virus spread was partially restored in the phosphomimetic virus. 
Notably, each mutant virus eventually reached peak WT titers. Given the delayed kinetics 
observed in the mutant viruses, we tested for reversion mutations at 72 hr pi and confirmed 
that each virus retained its respective mutated residue at position 88 and its small plaque 
phenotype (Figure 2.2D). Collectively, these results demonstrate that the PPXY late 
domain is not absolutely required for the formation and release of standard infectious 





Phosphorylation of the PPXY late domain does not enhance Z’s ability to form 
VLPs.  
Point mutations made at Y88 suggested that dynamic phosphorylation of this residue was 
important for the function of the matrix protein. Given the important role of the LCMV 
matrix protein and its late domain motif in regulating viral budding (Perez et al., 2003; 
Strecker et al., 2003), we next investigated the specific effect these point mutations had on 
Z’s budding efficiency in a VLP release assay. Because the LCMV Z protein is sufficient 
for the production of VLPs in the absence of any other viral proteins (Perez et al., 2003; 
Strecker et al., 2003), we were able to assess the budding activity of plasmid-derived WT 
or Y88-mutant Z proteins. As a control, we also included the LCMV Z G2A mutant, which 
exhibits a pronounced defect in VLP formation due to its inability to be myristoylated at 
this glycine residue (Perez et al., 2004b). HEK293T cells were transfected with plasmids 
encoding WT or Y88 mutants and 1 day later the VLP-containing supernatant and cells 
were collected and analyzed by quantitative western blotting. The budding activity of all 
three Z Y88 mutants was significantly reduced compared to WT Z, indicating that 
mutations in this region reduce the efficiency of VLP release (Figure 2.2E). In particular, 
the impaired VLP release exhibited by the Z Y88A mutant confirmed earlier findings by 
Perez et al. (Perez et al., 2003). We did not observe a significant difference between the 
budding of the Z-Y88E phosphomimetic compared to Y88F and Y88A (Figure 2.2E). This 
suggests that the partial gain of fitness observed with the phosphomimetic rLCMV-Z-Y88E 
virus in Figure 2.2B is not due to an increase in budding activity and as such Y88 
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phosphorylation does not appear to directly regulate the budding function of this late 
domain. However, because the VLP budding assay measures only the release of matrix 
protein, in the absence of other viral proteins, it is possible that this assay does not 
recapitulate all the facets of infectious virion production. 
 
PPXY late domain mutant viruses release substantially less viral structural proteins 
and genomes without a corresponding loss of infectious units 
 
Figure 2.3. PPXY late domain mutant viruses release substantially less viral structural proteins and 
genomes without a corresponding loss of infectious units. (A-E) An equal quantity of PFUs of rLCMV 
WT, Z Y88F, Z Y88E, or Z Y88A were concentrated via ultracentrifugation through sucrose and screened 
for viral NP (B), GP2 (C), or Z (D) via quantitative western blot or L segment vRNA (E) or S segment vRNA 
(F) via qRT-PCR. Representative western blots for NP, GP2, and Z are shown in (A). Data in (B-F) are 
representative of the mean ± SEM relative to rLCMV WT from at least 3 independent experiments. (B-E) *p 
< 0.05; **p < 0.01; ****p < 0.0001, determined using the one-way ANOVA with Holm-Sidak’s test for 
66 
 
multiple comparisons. Note that in panels B-F, the Y88 mutant viruses were not statistically different from 
one another.  
 
To investigate the protein and genome composition of virions containing mutated late 
domains, an equivalent quantity of cell-free infectious virus particles from each rLCMV 
strain was concentrated for screening. Quantitative western blotting revealed substantial 
reductions in the total amount of NP, GP, and Z in the Y88 mutant particles relative to WT 
virus (Figures 2.3A-2.3D). However, no difference was observed in the levels of these 
proteins among the three Y88 mutant viruses (Figures 2.3A-2.3D). The quantity of Z 
protein detected in the Y88 mutant virus preparations was <3% of WT virus (Figure 2.3D) 
whereas NP and GP quantities were ~25% of WT virus (Figures 2.3B and 2.3C). Viral 
genome content in particles was assessed by qRT-PCR. On a per PFU basis, the quantity 
of either L or S segment genomic RNA in the non-phosphorylatable mutants, Y88F and 
Y88A, was significantly reduced versus WT (P ≤ 0.05, Figures 2.3E and 2.3F). However, 
genome levels in the phosphomimetic virus, Y88E, were not significantly different than 
WT (Figures 2.3E and 2.3F), which may explain a component of its partially restored 
growth kinetics (Figure 2.2B). The observation of reduced viral proteins and/or genomes 
released from cells infected with the Y88 mutant viruses combined with the fact that WT 
LCMV is known to produce relatively large quantities of DI particles (Welsh and Pfau, 
1972) led us to hypothesize that the PPXY mutants may have defects in their ability to 
generate DI particles, which could explain their greatly reduced levels of viral protein and 




The PPXY late domain drives the production of DI particles. 
 
Figure 2.4. LCMV DI particle production is impaired in the absence of a functional PPXY domain. (A-
B) Equivalent PFUs of WT, Z Y88F, Z Y88E, or Z Y88A rLCMV (range 25 to 2.5 x 104 PFUs) were 
inoculated onto monolayers of Vero E6 cells and a standard plaque assay was performed. Representative 
images of crystal violet-stained wells are shown in (A). Inhibition of standard infectious virus-induced 
cytopathic effect by DI particles at each dose was determined by measurement of the mean pixel intensity of 
each well using Image J software (B). The data in (B) are representative of the mean ± SEM relative to 
rLCMV WT (at 250 PFU per well) from 3 independent experiments and were tested for statistical 
significance with a two way ANOVA and Holm-Sidak’s test for multiple comparisons. (B) *p < 0.05; ***p 




A substantial fraction of virus particles produced by LCMV are DI particles (Staneck et 
al., 1972). Accordingly, inoculation of LCMV at low multiplicities of infection (MOI) 
results in efficient production of standard virus and spread, while high MOIs do not. This 
seemingly contradictory phenomenon is caused by DI particles, which inhibit the 
propagation of standard virus and its ability to cause cytopathic effect with one hit kinetics 
(Popescu et al., 1976; Welsh and Pfau, 1972). Monolayers inoculated with high 
concentrations of standard infectious LCMV exhibit no cytopathic effect due to DI particle 
inhibition, but as the inoculum is diluted, standard virus particles that infect cells in the 
absence of a co-infecting DI particle will subsequently form plaques. We exploited this 
phenomenon to initially evaluate the relative amounts of DI particles generated by the 
PPXY mutant viruses. Equal infectious doses of WT virus and each Y88 mutant, spanning 
a range of 25 to 25,000 PFU, were applied to Vero E6 cell monolayers in a standard plaque 
assay (Figures 2.4A and 2.4B). Evidence of possible DI particle interference is clearly seen 
in WT virus, where the most concentrated viral sample (25,000 PFU) resulted in no cell 
death while in successive 10-fold dilutions (2,500 and 250 PFU) the number of DI particles 
per cell is lowered allowing standard virus to enter cells in the absence of DI particles and 
form plaques (Figure 2.4A). In contrast, the PPXY-mutant viruses exhibited a considerable 
increase in cytopathology (Figure 2.4A, 25,000 and 2,500 PFU). Quantification of the 
observed cytopathology confirmed the striking phenotype and revealed significant 
differences between the mutant and WT viruses (Figure 2.4B). Intriguingly, the 
cytopathology of the rLCMV Z-Y88E phosphomimetic at 25,000 PFU was significantly 
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less than both Y88F or Y88A viruses and therefore more closely resembled WT virus 
(Figure 2.4B).  
 
Figure 2.5. The PPXY late domain drives the production of DI particles. (A-B) Development and 
validation of a plaque interference assay for the measurement of LCMV DI particle activity. In (A), a stock 
of rLCMV WT containing both standard infectious virus particles and DI particles was subjected to UV 
irradiation for 2 min to inactivate standard LCMV particles but spare DI particles. Serial 5-fold dilutions of 
this UV-treated virus preparation (UV-LCMV) were added to Vero E6 cells followed by a fixed amount of 
50 PFU of the indicated challenge virus (rLCMV WT; Junín virus Candid 1, (JUNV C#1), or vesicular 
stomatitis virus (VSV)). Additional controls were wells that received i) media only, ii) serial 5-fold dilutions 
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of the stock LCMV virus preparation before UV treatment (no UV LCMV), iii) serial 5-fold dilutions of the 
stock LCMV virus preparation following UV treatment (UV-LCMV), or iv) 50 PFU per well of standard 
LCMV, JUNV C#1, or VSV, as indicated. Following a 1 hr incubation at 37oC to permit viral particle 
absorption, cells were overlaid with agarose and subsequently fixed and stained with crystal violet to 
visualize whether the UV-LCMV preparation impacted the ability of each virus to form plaques. The LCMV 
DI titer is expressed as plaque interfering units50 (PIU50) per mL of a given sample and was calculated as 
described in the Materials and Methods. In (B), rLCMV WT containing both standard and DI particles was 
subjected to the indicated filtration or not and then subjected to UV irradiation as described in (A). Serial 5-
fold dilutions of each UV-LCMV preparation (filtered or not) were added to Vero E6 cells followed by a 
fixed amount of 50 PFU of rLCMV WT. As described in (A), the ability of these UV-LCMV preparations to 
interfere with the ability of standard LCMV to from plaques was measured via plaque assay and LCMV DI 
titers are reported as PIU50/mL. In (A-B), the graphical results represent the mean LCMV DI titer ± SEM 
for 3 independent experiments and representative wells for each condition are shown directly below each 
graph. (C) LCMV DI particle production requires a functional PPXY domain. The rLCMV WT or Y88 
mutants examined in Figure 4 were subjected to the assay described in (A-B) to directly measure the DI 
particle titer present in each virus preparation. Briefly, each indicated rLCMV preparation was subjected to 
UV-irradiation to inactivate standard infectious LCMV particles while preserving DI particle activity. Serial 
5-fold dilutions of each UV-treated sample were inoculated onto Vero E6 cells, followed by the addition of 
50 PFU of standard LCMV. Following a 1 hr incubation at 37oC to permit viral particle absorption, cells 
were overlaid with agarose and subsequently fixed and stained with crystal violet to visualize whether the 
various UV-treated rLCMV preparations impacted the ability of standard LCMV particles to form plaques. 
For each rLCMV, DI titer is reported as mean PIU50/mL ± SEM for 3 independent experiments. (A-C) n.s. 
(not significant), *p < 0.05; ***p < 0.001; ****p < 0.0001, determined by first substituting values of 19 
PIU50/mL (just below the limit of detection value of 20 PIU50/mL) for samples that were below the limit of 
detection  and then performing a one way ANOVA.  
 
 To confirm that the interfering activity observed in Figure 2.4 was indeed due to 
LCMV DI particles, we next established an assay to directly and quantitatively measure 
LCMV DI particle activity. At present, no consistent biochemical or genetic signature 
exists to distinguish LCMV DI particles from standard infectious particles (Stocker et al., 
1994; Welsh and Buchmeier, 1979). In an attempt to uncover such a signature, we 
separated preparations of rLCMV WT or Y88 mutants via density ultracentrifugation. 
Similar to previous studies (Gschwender and Popescu, 1976; Pedersen, 1979; Peralta et al., 
1981; Stocker et al., 1994; Welsh and Buchmeier, 1979), we were unable to isolate 
fractions containing pure DI particles as abundant levels of standard virus were detectable 
across all 15 fractions (Figure 2.S2). Therefore, it was not possible to identify a DI particle-
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specific signature for screening purposes. Despite this limitation, several assays, including 
a yield reduction assay (Welsh and Pfau, 1972), a plaque reduction assay (Welsh et al., 
1972), and a focus interfering assay (Popescu et al., 1976) have historically been used for 
accurate measurement of LCMV DI particle abundance and activity levels. Indeed, these 
assays were originally used to define LCMV DI particles. We utilized the plaque 
interference assay (also known as the plaque reduction assay) analogous to that used in 
(Welsh and Pfau, 1972) but also capitalized on the strong UV-resistance exhibited by 
LCMV DI particles, but not standard virus particles (Welsh et al., 1972). Briefly, cell-free 
virus preparations containing both standard and DI particles were treated with UV to 
neutralize standard virus particles while leaving the interfering properties of DI particles 
intact (Figure 2.5A). It should be noted that standard virus particles treated with UV do not 
acquire detectable interfering properties (Figure 2.5A) (Dutko and Pfau, 1978). Limiting 
dilutions of this UV-treated sample were applied to Vero E6 cells, followed by the addition 
of a fixed quantity of LCMV PFUs. As shown in Figure 2.5A, this allows for the 
determination of LCMV DI particle activity and is expressed as plaque interfering units50 
(PIU50) per mL of a given sample. Importantly, we recapitulated several key controls from 
previous studies to demonstrate the specificity of this assay for LCMV DI particles. In 
particular, UV-treated LCMV DI particle preparations only interfered, in a dose-dependent 
manner, with the growth of homologous LCMV, but not heterologous viruses such as 
vesicular stomatitis virus (VSV) or the New World arenavirus Junín virus Candid 1 (JUNV 
C#1), which rules out a nonspecific antiviral factor as a mediator of interference (e.g. 
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interferon) (Figure 2.5A). Further, passing LCMV DI particle-containing supernatant 
through a series of filters (0.45 µm, 0.2 µm, 30 kDa, 10 kDa) showed that interference is 
not due to soluble factors that are smaller than 30 kDa (e.g. cytokines) or larger (>0.2 µm) 
membrane bound entities such as bacteria (Figure 2.5B). When this assay was applied to 
the rLCMV WT and Y88 mutant samples examined in Figure 2.4, it confirmed that the 
rLCMV WT samples exhibited substantial DI particle interfering activity (mean 926 
PIU50/mL ± 68 SEM), but that the mutant Y88 viruses had much less (Figure 2.5C). There 
was no detectable DI activity for either the Y88F or Y88A viruses while the Y88E virus 
contained intermediate levels of interfering activity (mean 131 PIU50/mL ± 64 SEM). 
Collectively, the findings in Figures 2.4 and 2.5 support the hypothesis that the LCMV 
PPXY late domain is required for the efficient formation of DI particles and that 
phosphorylation of Y88 may play a regulatory role in DI particle production and the 




Efficient DI particle formation requires a functional ESCRT pathway 
 
Figure 2.6. Efficient DI particle formation requires a functional ESCRT pathway. (A) VSV requires a 
functional ESCRT pathway for infectious virus release. T-Rex HEK293 cells stably transduced with vectors 
for tetracycline-based induction of WT vacuolar protein sorting 4B (VPS4B) or the DN VPS4B mutant, EQ, 
were treated with tetracycline to induce the expression of WT or DN VPS4B. Both the WT and DN VPS4B 
proteins have GFP fusion tags. One hr following VPS4B induction, the media was removed and cells were 
infected with VSV in media containing tetracycline. One hr later, the viral inoculum was removed and 
replaced with fresh media containing tetracycline. Six hr later (8 hr post-VPS4B induction; 7 hr post-
infection), supernatants were collected to determine VSV PFU titers via plaque assay. Cell protein lysates 
were also generated at this time to verify the induction of VPS4B WT or EQ expression using an anti-GFP 
antibody. Protein lysates were also screened for actin as a loading control. Viral titers represent the mean 
VSV PFU ± SEM from 3 independent experiments and were tested for statistical significance with an 
unpaired t test with Welch’s correction. (B-E) LCMV requires a functional ESCRT pathway for the release 
of DI particles, but not standard infectious particles. T-Rex HEK293 cells stably transduced with vectors for 
tetracycline-based induction of WT VPS4B or the DN VPS4B EQ were infected with rLCMV WT and 2 d 
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later treated with tetracycline to induce the expression of WT or DN VPS4B. Six hr after VPS4B induction 
(54 hr pi), the cells were washed and given fresh media containing tetracycline. Supernatants were collected 
18 hr later (72 hr pi) and titered via plaque assay. Similar to (A), protein lysates were collected at 72 hr pi 
and screened for VPS4B WT or DN using an anti-GFP antibody or for actin as a loading control. Extra wells 
containing cells grown on cover slips were also fixed at 72 hr pi to examine, via immunofluorescent confocal 
microscopy, the expression and localization of WT or DN VPS4B (green) or LCMV NP (red). A 143 µm 
square is shown for each panel. The results shown in (B) represent the mean LCMV PFU ± SEM from 4 
independent experiments and were tested for statistical significance with an unpaired t test with Welch’s 
correction. (C) Equivalent PFUs of virus (range 2 x 102 to 2 x 104) produced from WT or DN VPS4B cells 
were inoculated onto monolayers of Vero E6 cells and a standard plaque assay was performed. Representative 
images of crystal violet-stained wells are shown in (C). Inhibition of standard infectious virus-induced 
cytopathic effect by DI particles at each dose was determined in (D) by measurement of the mean pixel 
intensity of each well using Image J software. The data in (D) are representative of the mean ± SEM relative 
to WT VSP4B (at 2,000 PFU per well) from 4 independent experiments and were tested for statistical 
significance with a two way ANOVA and Holm-Sidak’s test for multiple comparisons. (E) The assay 
described in Fig 5 was used to directly measure the LCMV DI titer present in the supernatants collected from 
the VSP4B WT or DN cells at 72 hr pi. Briefly, each virus-containing preparation was subjected to UV-
irradiation to inactivate standard infectious LCMV particles while preserving DI particle activity. Serial 5-
fold dilutions of each UV-treated sample were inoculated onto Vero E6 cells, followed by the addition of 50 
PFU of standard LCMV. Following a 1 hr incubation at 37oC to permit viral particle absorption, cells were 
overlaid with agarose and subsequently fixed and stained with crystal violet to visualize whether the various 
UV-treated rLCMV preparations impacted the ability of standard LCMV particles to form plaques. The 
LCMV DI titers are reported as mean PIU50/mL ± SEM for 4 independent experiments and were tested for 
statistical significance with an unpaired t test with Welch’s correction. (A-B, D-E) n.s. (not significant), *p 
< 0.05, **p < 0.01, as determined by the indicated statistical tests. 
 
Viral late domains can drive virus budding by recruiting components of the 
cellular ESCRT pathway to complete the final membrane scission step. Given the 
important role that the LCMV PPXY late domain played in the production of DI particles 
(Figures 2.4A, 2.4B, and 2.5C), we hypothesized that this late domain might be recruiting 
the ESCRT pathway machinery to drive DI particle formation. To test this hypothesis, we 
utilized cell lines that lack a functional ESCRT pathway due to inducible expression of a 
dominant negative (DN), E235Q point mutant, of VPS4, an ATPase involved in the final 
stages of ESCRT pathway function (Dalal et al., 2004; Lin et al., 2005; Taylor et al., 2007). 
Because the ESCRT pathway can also affect LCMV entry (Pasqual et al., 2011), we first 
infected cells with LCMV for 48 hr to allow the entire monolayer to become infected before 
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inducing expression of WT or DN VPS4. The cells were washed and fresh media 
containing the induction agent was added to the cells 6 hr after initial induction (54 hr pi) 
and the virus-containing media was collected 18 hr later (72 hr pi) to determine levels of 
standard infectious particles and DI particles (Figure 2.6). Western blot analysis of protein 
lysates at 72 hr pi confirmed the strong induction of WT and DN VPS4B expression and 
examination of fixed coverslips showed that all cells were expressing both the induced 
VSP4B as well as LCMV NP (Figure 2.6B). This infection protocol was chosen to ensure 
that we were examining virus that was produced in cells expressing the induced VPS4B 
proteins, while minimizing the effect that these proteins could exert on viral entry. 
Expression of DN VPS4B had no impact on the release of standard infectious LCMV (P = 
0.27; Figure 2.6B). In contrast, expression of DN VPS4B led to a marked reduction in the 
release of infectious VSV particles (Figure 2.6A), which is consistent with previous studies 
(Taylor et al., 2007) and confirms the specificity of our findings for LCMV. Measuring 
LCMV DI particle activity as described in Figure 2.4 revealed that WT LCMV produced 
considerably fewer DI particles per standard infectious virus particle in the DN VPS4B 
background when compared to cells expressing WT VPS4B (Figures 2.6C and 2.6D). A 
similar trend for both LCMV infectious virus and DI particle activity was seen in cells 
expressing WT or DN VPS4A (Figure 2.S3). We next used the assay described in Figure 
2.5 to directly quantitate the LCMV DI particle activity in these samples. Consistent with 
the findings in Figures 2.6C and 2.6D, this demonstrated that significantly fewer DI 
particles are made in the context of the DN VPS4B background when compared to WT 
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VPS4B (mean 41 ± 6 SEM vs 1,491 ± 70 PIU50/mL, respectively; P = 0.0022). Thus it 
appears that LCMV DI particle formation requires a functional ESCRT pathway (Figures 
2.6C-2.6E) in addition to a canonical late domain (Figures 2.4 and 2.5C) while standard 







Figure 2.7. Proposed model of PPXY-driven DI particle production. WT virus containing an intact PPXY 
late domain produces high levels of infectious and DI particles. Disruption of the PPXY motif (PPXF or 
PPXA) or disruption of the ESCRT pathway causes decreased overall DI particle production compared to 
standard infectious particles. The phosphomimetic PPXE virus has an intermediate phenotype. 
 
The ability of most arenavirus matrix proteins to drive viral budding is thought to 
be highly dependent upon one or more encoded late domains (Perez et al., 2003; Strecker 
et al., 2003). The arenavirus LCMV encodes a single late domain, PPPY. The PPXY motif 
is found in the matrix proteins of several families of enveloped RNA viruses and for many 
of these viruses is required for the release of infectious virions in an ESCRT-dependent 
fashion (for review see (Votteler and Sundquist, 2013)). We demonstrate here that the 
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PPXY late domain encoded by LCMV is not absolutely required for infectious virus 
release. Further, our data suggest that infectious particle release can occur in the absence 
of a functional ESCRT pathway. Strikingly, we show that the formation of LCMV DI 
particles critically requires a functional PPXY late domain and that this process is ESCRT-
dependent (see Figure 2.7 for our proposed model). Last, our data demonstrate that the 
terminal tyrosine in the LCMV PPXY motif is phosphorylated and that this 
posttranslational modification may exert a regulatory effect on Z’s ability to drive DI 
particle release. Therefore, we have uncovered an unexpected role for the PPXY late 
domain and a possible mechanism for its regulation of DI particle production. 
Our findings raise the intriguing possibility that LCMV utilizes divergent 
pathways for the production of infectious and DI particles. Neither a functional PPXY 
motif nor ESCRT pathway were absolutely required for the release of standard infectious 
particles. These findings, combined with the fact that LCMV Z does not encode additional 
canonical late domains, strongly suggest that infectious LCMV release occurs through a 
novel, unknown mechanism. While the rLCMV PPXY mutants studied here initially 
displayed a slight lag in infectious virus release, each ultimately matched WT levels. 
Consistent with an earlier study by Perez et al. (Perez et al., 2003), we observed that 
mutation of the PPXY domain impairs the ability of LCMV Z to form VLPs (Figure 2.2E). 
This finding in the VLP system may accurately reflect the initial lag in infectious virus 
release seen for rLCMVs bearing the same PPXY mutations (Figures 2.2B and 2.2C) 
and/or their decreased ability to form DI particles (Figures 2.4 and 2.5). With regard to the 
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importance of the ESCRT pathway for infectious virus production, expression of DN 
VPS4B had no impact on the ability of WT rLCMV to form standard infectious virus 
(Figure 2.6B). Similarly, expression of DN VPS4B did not impair the ability of LCMV Z 
to form VLPs when compared to cells expressing WT VPS4B (see Figure 2.S5). This VLP-
based result does not agree with an earlier finding by Perez et al. whereby silencing 
expression of the ESCRT component TSG101 impaired the release of infectious LCMV 
VLPs (Perez et al., 2003). This discrepancy may reflect differences in the particular VLP 
assays employed (VLP release versus infectious VLP release and transduction) or perhaps 
the format of the experiments (siRNA silencing of TSG101 versus inducible expression of 
WT or DN VPS4B). The different VLP systems could also recapitulate different aspects of 
virus particle release, with one VLP assay perhaps mimicking infectious virus production 
while the other more closely resembles DI formation. In similar experiments featuring 
rhabdoviruses (Jayakar et al., 2000; Wirblich et al., 2008b), Ebola virus (Neumann et al., 
2005b), retroviruses (Dilley et al., 2010; Le Blanc et al., 2002a; Yasuda and Hunter, 1998; 
Yuan et al., 2000b), and Hepatitis B virus (Garcia et al., 2013), loss of the PPXY motif 
and/or ESCRT resulted in standard virus growth that remained attenuated compared to WT. 
Interestingly, the New World arenavirus Pichinde remains attenuated following disruption 
of its encoded late domain (PSAP) (Wang et al., 2012), while the matrix protein encoded 
by the New World arenavirus Tacaribe can form VLPs in the absence of its late domain 
(YXXL), but requires VPS4 (Urata et al., 2009). These findings suggest that arenaviruses 
have evolved diverse strategies to drive infectious virus release. One possible explanation 
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for the observed late domain-independent generation of infectious LCMV particles is that 
the LCMV Z protein, either by itself or in combination with other viral structural proteins, 
may be sufficient to drive particle release in the absence of recruited host proteins. 
Alternatively, LCMV may contain additional sequence motifs, either in Z or the other 
structural proteins, that recruit novel host protein machinery to facilitate budding.  
In contrast to standard virus particles, both the PPXY late domain and the ESCRT 
pathway appear critical for the release of DI particles. To our knowledge, this is the first 
example of a virus utilizing a late domain to selectively drive the production of DI particles 
independently of standard virus. That LCMV has evolved such a mechanism likely reflects 
the presumed importance of DI particles for the successful establishment of an 
asymptomatic, persistent infection in reservoir rodents, which ultimately ensures the long 
term maintenance of LCMV in nature (Meyer and Southern, 1997; Popescu and Lehmann-
Grube, 1977). While the existence of arenavirus DI particles has long been realized, 
surprisingly little is known about their exact composition and properties. Our data 
demonstrates that cells infected with the rLCMV PPXY mutants release much less NP, GP, 
and Z per PFU of cell-free virus when compared to WT rLCMV. This is presumably due 
to reduced levels of DI particles being released by the PPXY mutant viruses. Interestingly, 
the degree of reduction was not equivalent among the viral proteins. In particular, Z was 
reduced to the greatest extent (~3% of WT) when compared to NP or GP (~25% of WT), 
which could indicate that Z itself is enriched in DI particles and is critical for the ability of 
DI particles to interfere with the propagation of standard virus particles. Consistent with 
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this idea, Z is able to render cells refractory to superinfection with homologous virus and 
treatment of DI particles with RNA-damaging levels of UV does not reduce their 
interfering ability (Cornu et al., 2004; Welsh et al., 1972). Therefore, it is possible that 
particles containing high quantities of Z, or simply VLPs consisting primarily of Z, may 
represent a class of arenavirus DI particles.  
Arenavirus matrix proteins exhibit significant diversity in the type and number of 
late domains they encode. The PPXY domain is found in several Old World arenavirus 
matrix proteins but not in New World arenaviruses (Figure 2.2A and (Fehling et al., 2012; 
Wolff et al., 2013)). We have observed that the New World arenavirus JUNV C#1, which 
encodes both a PTAP and YXXL late domain, generates considerably fewer DI particles 
per standard infectious particle when compared to the PPXY-containing LCMV (Figure 
2.S4). While it is not known whether the PTAP and/or YXXL motifs contribute to DI 
particle formation in the case of JUNV C#1, this observation may indicate that the PPXY 
domain is particularly strong in driving DI particle assembly and release. It is possible that 
individual arenaviruses require different rates of DI particle formation for optimal fitness 
and have evolved to encode particular late domain combinations to best meet those needs.  
We show that the LCMV Z protein is phosphorylated, which suggests that 
phosphorylation may be important for the regulation of one or more of Z’s functions. The 
fact that this modification occurs at the terminal tyrosine of the PPXY late domain and can 
be detected in virion-derived Z led us to hypothesize that it may influence Z’s budding 
function. To study the impact of this modification we generated rLCMV with mutations at 
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tyrosine 88 that either prevented phosphorylation (Y88F or Y88A) or mimicked it (Y88E). 
Relative to the mutants that cannot be phosphorylated, the Y88E phosphomimetic virus 
generated significantly more DI particles per infectious particle (Figures 2.4 and 2.5C). 
This suggests that reversible phosphorylation of the PPXY motif may act as a rheostat to 
regulate the rate of DI particle production independent of standard virus, possibly through 
the recruitment of ESCRT machinery. Interestingly, the terminal tyrosine of the PPXY late 
domains encoded by Ebola virus and Marburg virus VP40 is also phosphorylated. 
Inhibiting phosphorylation of the Ebola virus VP40 PPXY motif reduced the release of 
infectious virus (García et al., 2012) whereas mutation of the Marburg virus VP40 PPXY 
motif to prevent phosphorylation did not impact infectious VLP release, but instead 
impaired the recruitment and incorporation of nucleocapsids into VLPs (Kolesnikova et 
al., 2012). The role of the PPXY domain and/or its phosphorylation with regard to DI 
particle production in the filovirus model and other PPXY-containing virus families 
remains an open question. In the current model, it will be important to identify the host 
kinase responsible for phosphorylating the LCMV PPXY domain, although this may 
require a comprehensive tyrosine kinase screen as the flanking residues surrounding Y88 
were not recognized by kinase motif prediction tools (Obenauer et al., 2003; Wong et al., 
2007). 
How does the PPXY late domain of LCMV promote the release of DI particles? 
While it is well known that the PPXY motif can drive viral budding, the exact mechanism 
by which it recruits ESCRT proteins to promote this process is not fully understood. 
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Several PPXY-dependent viruses also require NEDD4 family E3 ubiquitin ligases (e.g., 
NEDD4, ITCH, or WWP1), which can directly bind to the PPXY motif via their WW 
domains (for review see (Votteler and Sundquist, 2013)). Recruitment of ESCRT 
machinery could occur due to ubiquitination of Z by a NEDD4 E3 ubiquitin ligase, which 
in turn could recruit ESCRT components (e.g. TSG101) that can bind ubiquitinated 
proteins (Votteler and Sundquist, 2013). Alternatively, arrestin-related trafficking adaptors 
(ARTs) may provide an ESCRT linkage as these proteins interact with both NEDD4 E3 
ubiquitin ligases as well as ESCRT proteins and have been shown to influence both 
multivesicular body formation and viral budding (Rauch and Martin-Serrano, 2011). Under 
this scenario, phosphorylation of the PPXY motif could regulate DI particle release by 
modifying the accessibility of the PPXY domain to NEDD4 E3 ubiquitin ligases. 
All viruses must strike a balance between pathogenesis and persistence, with the 
ultimate goal of ensuring their own maintenance in nature. It has long been postulated that 
DI particles may be one way in which LCMV is able to tip the scales towards persistence, 
thus lowering its immunological profile and fitness cost to its host. By identifying the 
specific cellular pathway required to form these DI particles, and the apparent importance 
of viral phosphorylation in accessing the pathway, our findings raise the possibility that 
arenaviruses can dynamically adjust DI particle production in response to external 
environmental factors. Further, the PPXY mutant viruses we have developed represent a 
new tool that will allow the field to formally test the importance of DI particles for the 
establishment of persistent LCMV infection in reservoir rodents. The ability of the PPXY 
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late domain to drive the production of DI particles is a novel finding with important 
implications for understanding host-pathogen relationships and the design of vaccines and 
antivirals. In particular, PPXY-containing viruses such as Ebola virus and Lassa virus are 
known to persist for long periods following the resolution of acute human disease (Bausch 
et al., 2007; Emond et al., 1982; Varkey et al., 2015). It is possible that DI particles play a 
significant role in allowing these viruses to persist in humans, similar to their presumed 
importance for infection in reservoir species. Therefore, targeting DI particle formation 
could be a promising approach to clear persistent infection in humans. Finally, the 
possibility that the PPXY late domain and ESCRT machinery could broadly drive DI 
particle production in other virus families represents an exciting area of future research. 
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Materials and Methods 
Cells and viruses 
Human embryonic kidney cells (HEK-293T/17) (CRL-11268, American Type culture 
Collection, Manassas, VA) (referred to as HEK293T cells in the manuscript) were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) (11965-092) supplemented 
with 10% fetal bovine serum (FBS) (16140-071), 1% penicillin-streptomycin (15140-122), 
1% MEM Non-Essential Amino Acids Solution (11140-050), 1% HEPES Buffer Solution 
(15630-130), and 1% GlutaMAX (35050-061) purchased from Invitrogen (Carlsbad, CA). 
L929 mouse fibroblast cells (CCL-1, American Type culture Collection) were maintained 
in Minimum Essential Medium (MEM) (11095-080) supplemented with 10% FBS, 1% 
penicillin-streptomycin, 1% MEM Non-Essential Amino Acids Solution, 1% HEPES 
Buffer Solution, and 1% GlutaMAX. Baby hamster kidney cells (BHK-21) were kindly 
provided by M. J. Buchmeier (University of California, Irvine) and grown in DMEM 
supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% GlutaMAX. African 
green monkey kidney cells (Vero E6) were kindly provided by J. L. Whitton (The Scripps 
Research Institute, La Jolla) and grown in DMEM supplemented with 10% FBS, 1% 
penicillin-streptomycin, and 1% HEPES Buffer Solution. T-Rex HEK293 cells stably 
transduced with a tetracycline-inducible plasmid encoding WT or dominant negative EQ 
mutant vacuolar protein sorting 4A (VPS4A) or VPS4B as described in (Dalal et al., 2004; 
Lin et al., 2005; Taylor et al., 2007) were generously provided by M. Kielian (Albert 
Einstein College of Medicine, Bronx) and were maintained in DMEM supplemented with 
86 
 
10% FBS, 1% penicillin-streptomycin, 1% MEM Non-Essential Amino Acids Solution, 
1% HEPES Buffer Solution, 1% GlutaMAX, and 100 µg/mL Zeocin (R250-01, 
Invitrogen). VPS4 expression was induced by incubating cells in the above growth medium 
containing 1 µg/mL tetracycline as described (Taylor et al., 2007). All cell lines were 
grown at 37 ºC in a humidified incubator containing 5% CO2. Lymphocytic 
choriomeningitis virus (LCMV) strain Armstrong 53b was kindly provided by J. L. 
Whitton. Wild-type vesicular stomatitis virus expressing green fluorescent protein (VSV-
GFP) as described in (Stojdl et al., 2003) was kindly provided by J. Hiscott (Vaccine and 
Gene Therapy Institute of Florida, Port St. Lucie) and M. Shaw (Icahn School of Medicine 
at Mount Sinai, New York). Junín virus (JUNV) C#1, which is an attenuated vaccine strain 
derived from the virulent WT JUNV strain XJ as described in (Chosewood et al., 2009; 
Goñi et al., 2006), was kindly provided by M. Buchmeier (University of California, Irvine) 
and R. Tesh (The University of Texas Medical Branch at Galveston). Working stocks of 
these viruses were amplified and titered (via plaque assay) on Vero E6 cells. See below 
under “Generation of Recombinant LCMV” for a description of the recombinant (r)LCMV 
strain Armstrong 53b that were generated for this study. 
Plasmids 
The LCMV Armstrong 53b Z protein (WT, Y88A, Y88E, or Y88F) was subcloned into a 
modified pCAGGS expression vector (Cornillez-Ty et al., 2009) and different 
combinations of these plasmids were used to screen for the phosphorylation of Z (Figure 
2.1D) or the budding efficiency of Z (Figure 2.2E). The WT and Y88 mutant Z genes were 
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fused to the streptavidin binding peptide (SBP) 
(MDEKTTGWRGGHVVEGLAGELEQLRARLEHHPQGQREP) through an 18 base pair 
linker at the C-terminus of Z to permit affinity purification and western blot detection of 
Z. The nucleotide sequence of the WT Z gene matches NCBI gene identifier number 
AY847351 while the translated amino acid sequence for the WT Z gene matches Protein 
Locus number AAX49343. WT Z was amplified by PCR from the pT7-L(+) plasmid 
generously provided by J. C. de la Torre (The Scripps Research Institute, La Jolla) 
(Sanchez and De la Torre, 2006) using the forward primer LCMVZf (5’-
ACAAGTTTGTACAAAAAAGCAGGCTGATATCGCCACCATGGGTCAAGGCAAG
TCCAGA-3’), which has a 5’ overhang containing Gateway AttB1 and Kozak sequences 
and the reverse primer LCMVZr (5’-ACCTCCACCTCCAGCTGCCTCTTCGTAGGGA 
GGTGGAGA-3’), which has an overhang containing the linker sequence. The SBP tag 
was amplified from the pT7-FLAG-SBP-1 plasmid (P3871, Sigma-Aldrich, St. Louis, MO) 
via PCR using the forward primer SBPf (5’- GCAGCTGGAGGTGGAGGTATGGACGA 
AAAAACCACCGGT-3’), which has a 5’ overhang containing the linker sequence, and 
the reverse primer SBPr (5’-ACCACTTTGTACAAGAAAGCTGGGTCTTACGGTTCA 
CGCTGACCCTGCGG-3’), which contains a 3’ overhang with a stop codon preceding an 
AttB2 sequence. The two products were fused by PCR using the Z forward primer and the 
SBPr primer. The cassette was subcloned into the pCAGGS vector using the Gateway 
cloning system (Invitrogen) following the manufacturer’s instructions as has been 
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previously described (Cornillez-Ty et al., 2009; Klaus et al., 2013). The plasmids pC-NP 
and pC-GP, which express the LCMV Armstrong 53b nucleoprotein (NP) and glycoprotein 
(GP), respectively, and plasmids pol-I S and pol-I L, which express the LCMV L and S 
genome segments, respectively, were used to generate rLCMV. These reagents were 
generously provided by J. C. de la Torre and are described in (Flatz et al., 2006). Each of 
the Y88 mutant Z genes used in these studies were synthesized and subcloned into the 
pCAGGS or pol-I L vectors, respectively, by Biobasic, Inc. (Markham, ON, Canada). A 
pol-I L vector containing an SBP-tag directly fused to the C-terminus of Z was also 
generated by Biobasic, Inc. All plasmid sequences were verified by DNA sequencing.  
Identification of phosphorylated residues by mass spectrometry 
To identify phosphorylation sites on LCMV Z via mass spectrometry, Vero E6 cells were 
infected with LCMV strain Armstrong 53b and 48 hr later cell-free virions were purified 
by sucrose-banding as described previously (Burns and Buchmeier, 1991). Purified virions 
were then lysed in Triton buffer (0.5% NP40, 1% Triton X-100, 140mM NaCl, and 25mM 
Tris-HCl containing a protease inhibitor cocktail (04693159001, Roche Applied Science, 
Indianapolis, IN)) and mixed with Laemmli sample buffer (62.5 mM Tris-HCl, 10% 
glycerol, 2% sodium dodecyl sulfate and 0.01% bromophenol blue (B392, Fisher 
Scientific, Pittsburgh, PA)) containing 5% 2-mercaptoethanol. Virion protein lysates were 
separated on a 4-20% Tris-Glycine polyacrylamide gel (EC60255, Invitrogen). The gel was 
stained with Coomassie (40% methanol, 20% acetic acid, and 0.1% Brilliant Blue R 
(B7920, Sigma-Aldrich)), destained with a solution of 30% methanol and 10% acetic acid, 
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and then imaged using a Canon Canoscan 8800F scanner. For mass spectrometry, the 
protein band corresponding to the Z protein was excised and cut into 1 mm cubes and 
processed with chemicals from Fisher Scientific as follows. The gel pieces were rinsed 
with HPLC grade water and then incubated with destain solution (50 mM ammonium 
bicarbonate and 50% acetonitrile) for 30 minutes at 37 ºC. The destain solution was 
removed and the gel pieces were dehydrated by incubating twice with 100% acetonitrile 
for 5 minutes. The gel pieces were reduced with 25 mM dithiothreitol in 50 mM ammonium 
bicarbonate for 30 minutes at 55 ºC. After cooling for 10 minutes at room temperature, the 
gel pieces were dehydrated by incubating with 100% acetonitrile for 5 minutes and then 
alkylated in the dark with 10 mM iodoacetamide in 50 mM ammonium biocarbonate for 
45 minutes at room temperature. The gel pieces were washed two times in destain solution 
for 5 minutes, dehydrated with 100% acetonitrile, then rehydrated with water for 10 
minutes. The gel pieces were further dehydrated with two 5 minute incubations in 100% 
acetonitrile before removing all liquid and drying the gel pieces at room temperature for 
10 minutes. The gel pieces were rehydrated with a solution of 12.5 ng/µL sequencing grade 
chymotrypsin (V1061, Promega, Madison, WI) or 12.5 ng/µL sequencing grade modified 
trypsin (V5111, Promega) in 50 mM ammonium bicarbonate on ice for 30 minutes, before 
digesting overnight at 37 ºC. Peptides were extracted with a solution of 2.5% formic acid 
in 50% acetonitrile while spinning in a microcentrifuge at 13,000 rpm for 10 minutes. The 
supernatant was removed and saved while the gel pieces were subjected to further 
extraction and rinsing with 100% acetonitrile. The second extraction was combined with 
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the initial extraction. All solvent was removed from the extracts using a vacuum centrifuge 
at 37 ºC. The peptides were resuspended in 2.5% formic acid, 2.5% acetonitrile prior to 
mass spectrometry analysis. Peptides were separated over 12 cm of Magic C18, 5 µM, 200 
Å reversed phase material (PM5/66100/00, Michrom Bioresources, Auburn, CA) in a 
microcapillary column using a MicroAS autosampler (Thermo Scientific, Pittsburgh, PA). 
Following 15 minutes of isocratic loading in 2.5% acetonitrile, 0.15% formic acid, the 
peptides were eluted from the column with a 5-35% gradient of acetonitrile with 0.15% 
formic acid over 40 minutes using a Surveyor Pump Plus HPLC (Thermo Scientific). Mass 
spectra were acquired either in an LTQ-XL linear ion trap, or in a linear ion trap-orbitrap 
mass spectrometer (Thermo Scientific) as described previously (Ballif et al., 2008). Briefly, 
for most analyses 10 data-dependent MS/MS spectra followed each survey scan. However, 
in several cases after obtaining the initial spectra for phosphopeptides we followed up with 
targeted MS/MS spectra in order to increase fragment ion coverage. The IPI human 
forward and reverse concatenated database was used to search the raw data using 
SEQUEST software requiring tryptic peptides and either a 2 Da precursor mass tolerance 
(for precursor data acquired in the LTQ) or 20 PPM (for precursor data acquired in the 
orbitrap). In the searches the following precursor mass differences were allowed: serine, 
threonine, and tyrosine residues (+79.96633 Da); methionine (+15.99492 Da) and 
cysteines (+57.02146 Da or 71.0371). 
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Validation of Z phosphorylation 
To confirm that Z was phosphorylated in human cells as well as cells from rodent cells, in 
Figures 2.1D-E, plasmid-derived Z expressed in HEK293T cells and Z from rLCMV Z-
SBP-infected cells were both probed for phosphotyrosine signal via western blot. For 
plasmid-derived Z, 2 x 105 HEK293T cells were seeded in a 12-well plate and transfected 
the next day with 0.8 µg per well of pLCMV-Z WT, pLCMV-Z Y88F, or an empty vector 
using 0.8 µL of a 1 mg/mL solution of polyethylenimine (23966, Polysciences, Inc., 
Warrington, PA) per well. For Z derived from rLCMV Z-SBP-infected cells, 2.5 x 105 
L929 cells were seeded in 6-well plates and infected the next day at an MOI of 0.01. Two 
days following the transfection or infection, H202 at a final concentration of 8.8 mM or an 
equivalent volume of H20 was spiked into the appropriate wells containing HEK293T or 
L929 growth media. After a 15 minute incubation, the cells were lysed in Triton buffer 
containing a protease inhibitor cocktail and PhosStop phosphatase inhibitor cocktail 
(04906837001, Roche Applied Science) and the SBP-tagged Z proteins were affinity 
purified using magnetic streptavidin beads as previous described (Klaus et al., 2013). The 
purified proteins were separated via SDS-PAGE and screened for Z or tyrosine 
phosphorylated-Z via standard chemiluminescent western blotting and detected with film 




Generation of recombinant (r)LCMV 
rLCMV WT, rLCMV Z-SBP and rLCMV containing Z-Y88 mutations (Y88F, Y88E, 
Y88A) were generated using the previously described reverse genetics system (Flatz et al., 
2006). Briefly, 10 µL of Lipofectamine 2000 (52887, Invitrogen) was mixed with 100 µL 
of OptiMEM (31985, Invitrogen) and then added to a plasmid mixture consisting of 1.6 µg 
pC-NP, 2.0 µg pC-L, 1.6 µg pol-I S, and 2.8 µg pol-I L (WT, Z-SBP or containing the 
described Y88 point mutations) in 100 µL OptiMEM and incubated at room temperature 
for 25 minutes. 200 µL of this transfection mixture and 800 µL of OptiMEM was then 
added to 1 well of a 6-well plate which had been seeded the previous day with 3.5 x 105 
BHK-21 cells and washed prior to transfection with 1 mL of OptiMEM. The cells were 
incubated with the transfection mixture for 4 hr after which the media was replaced with 
BHK-21 growth media diluted 5-fold in DMEM. Three days later the supernatant was 
collected, clarified by centrifugation at 1,200 RPM for 5 minutes at 4 oC, and used to infect 
a fresh monolayer of 1.8 x 106 BHK-21 cells in a T-75 flask. Following a 1 hr absorption, 
the inoculum was removed and fresh BHK-21 growth media diluted 5-fold in DMEM was 
added to the cells. Three days later the supernatant of this flask was collected, clarified by 
centrifugation, and titered by plaque assay. To generate an expanded virus stock, Vero E6 
cells were infected with this material at an MOI of 0.0001 and 48 or 72 hr later, 
supernatants were collected, clarified, and titered by plaque assay. A portion of the L 
segment (most of the Z gene, the intergenic region, and part of the L gene) of each rLCMV 
Y88 mutant was sequenced to ensure that these viruses had not reverted. The material used 
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for this sequencing was derived from the 72 hr pi time point shown in Figure 2.2B. Viral 
RNA from clarified supernatants was isolated using the Qiagen Viral RNA mini kit (52906, 
Qiagen, Valencia, CA) according to the manufacturer’s protocol. Viral RNA was converted 
to cDNA using primer L 845- (5’- GCAGGACTTGAGGGCTATGA-3’), Superscript III 
(18080-044, Invitrogen), RNAse Out (10777-019, Invitrogen), and 5 µL of RNA following 
the manufacturer’s protocol for first strand cDNA synthesis. A portion of the L-segment 
containing Z was amplified with 30-40 cycles of PCR using Platinum Pfx DNA polymerase 
(11708-013, Invitrogen) and  primers L126+ (5’- ATAGTACAAACAGGGCCGAAATC 
C-3’) and L764- (5’- TTTGTTGGGTTCAGAGATAAGTGT-3’) following the 
manufacturer’s protocol. The PCR product was prepared for sequencing using ExoSAP-IT 
(78200, Affymetrix, Santa Clara, CA) following the manufacturer’s protocol and 
sequenced by the University of Vermont Cancer Center DNA Analysis Facility. 
SDS-PAGE and western blotting 
Protein lysates were diluted in Laemmli sample buffer containing 5% 2-mercaptoethanol 
and separated on NuPAGE 4-12% Bis-Tris gels with MES buffer. Protein was transferred 
to nitrocellulose membranes using iBlot gel transfer stacks (IB301001 or IB301002, 
Invitrogen) and the Invitrogen iBlot Device as directed by the manufacturer. Efficient 
protein transfer was confirmed by staining membranes with a solution containing 0.1% 
Ponceau S (P3504, Sigma-Aldrich) and 5% acetic acid which was subsequently removed 
by washing with water. Two methods were used for protein detection: quantitative LI-
COR-based detection or standard chemiluminescent-based detection. For quantitative LI-
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COR analysis, membranes were blocked with a solution of 5% milk in PBS for 1 hr and 
incubated overnight at room temperature with the indicated primary antibodies diluted in 
PBS containing 5% milk and 0.2% Tween 20 (BP337, Fisher Scientific). Following 5 
washes in PBS with 0.5% IGEPAL CA-630 (198596, MP Biomedicals, Solon, OH), the 
membranes were incubated for 1 hr at room temperature with secondary antibodies diluted 
in PBS containing 5% milk, 0.2% Tween 20 and 0.02% sodium dodecyl sulfate, washed 5 
times in PBS with 0.5% IGEPAL CA-630 and 1 time with PBS, then imaged using the LI-
COR Odyssey CLx imaging system. For quantitative LI-COR analysis of VPS4B in 
Figures 2.6A, 2.6B, and 2.S5, membranes were probed using the iBind Flex western device 
(SLF2000, Thermo Scientific) with the iBind Flex fluorescent detection solution kit 
(SLF2019, Thermo Scientific) following the manufacturer’s instructions. For 
chemiluminescent-based detection of phosphorylated proteins, the same general procedure 
was used with the following exceptions: i) membranes were blocked with either PBS 
containing 5% milk and 0.05% IGEPAL CA-630 or protein-free blocking buffer (37572, 
Thermo Scientific), ii) primary and secondary antibodies were diluted in PBS containing 
5% milk, 0.05% IGEPAL CA-630 , and 3% fetal bovine serum or protein-free blocking 
buffer, and iii) the secondary antibodies were incubated with the membrane for 2 hr.  
 The following primary antibodies were used for western blotting (at the indicated 
concentrations): mouse anti-streptavidin binding peptide (MAB10764, Millipore, Billerica, 
MA) (1:10,000), rabbit anti-actin (A2066, Sigma-Aldrich) (1:10,000), mouse anti-actin 
(A5441, Sigma-Aldrich) (1:5,000), rabbit anti-actin (A2066, Sigma-Aldrich) (1:2,500), 
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mouse anti-phosphotyrosine (clone 4G10, Millipore) (0.2 µg/mL), mouse anti-green 
fluorescent protein (632380, Clontech, Mountain View, CA) (1:1,000), rabbit anti-LCMV 
Z (880) (1:500), mouse anti-LCMV GP2 (33.6) (1:2,000), and rabbit anti-LCMV 
nucleoprotein (2165) (1:5,000). Antibodies 880, 2165, and 33.6 were generously provided 
by M. J. Buchmeier (University of California, Irvine). For quantitative western blotting, 
the following secondary antibodies from LI-COR were used: IRDye 800CW goat anti-
mouse (926-32210) for the Z release assay in Figure 2.2E at 1:20,000 and in Figure 2.6A, 
6B, and S5 at 1:3,000 (for probing by iBind) and IRDye 680LT goat anti-mouse (926-
68020) and IRDye 800CW Goat anti-rabbit (926-32210) were used at 1:20,000 to detect 
proteins in Figures 2.3A-2.3D. IRDye 680LT goat anti-mouse was used at 1:3,000 (for 
probing by iBind) in Figure 2.S5 to detect actin. A horseradish peroxidase-conjugated anti-
mouse secondary antibody (71045, EMD Millipore, Billerica, MA) diluted 1:5,000 was 
used for chemiluminescent-based detection in Figures 2.1D and 2.1E.  
Virus growth curve 
To determine the growth kinetics of rLCMV in Figure 2.2B, 6-well plates were seeded 
with 1.9 x 105 Vero E6 cells per well. The following day the cells were infected with each 
respective rLCMV at an MOI of 0.01. Supernatants were collected at 12, 24, 36, 48, and 
72 hr pi, clarified by centrifugation at 1,200 RPM for 5 minutes at 4 ºC, then titered by 




Z-virus-like particle (VLP) release assay 
To determine the release efficiency of the Y88 mutant Z proteins in Figures 2.2E and 2.S5, 
2 x 105 HEK293T cells or T-Rex HEK293 cells stably transduced with a tetracycline-
inducible plasmid encoding WT or dominant negative EQ mutant VPS4B were seeded in 
a 12-well plate. The next day cells were transfected with 0.8 µg per well of pLCMV-Z WT, 
Z-G2A, -Z Y88F, -Z Y88E, or -Z Y88A using 0.8 µL of a 1 mg/mL solution of 
polyethylenimine per well. For the experiments shown in Figure 2.S5, VPS4B expression 
was induced with 1 µg/mL tetracycline at the time of transfection. The following day (24 
hr post-transfection) cells and VLP-containing media (which had been clarified) were 
collected, lysed with Triton lysis buffer, and subjected to quantitative western blotting. For 
detection of Z from VLPs produced in VPS4B WT or DN cell lines, SBP-tagged Z was 
affinity purified from lysed VLP-containing media using magnetic streptavidin beads prior 
to quantitative western blot analysis. To calculate the percent VLP release we first 
normalized each Z protein value (from supernatants or cells) by the sum of all Z protein 
bands on a particular gel as described in (Degasperi et al., 2014). The percent VLP release 
was then calculated as the quotient of the Z protein quantity in VLPs divided by the quantity 
of Z in cells [(ZmutVLP / Zmutcells) / (ZWT VLP/ ZWT cells)]. 
Plaque assay and measurement of plaque size and cytopathic effect  
To measure infectious virus titers, a standard plaque assay was employed as follows. Six-
well plates were seeded with 1 x 105 (LCMV and JUNV) or 1 x 106 (VSV) Vero E6 cells 
per well and the following day inoculated with 10-fold serial dilutions of virus in a total 
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volume of 0.5 mL of Vero E6 growth medium. Following a 90 minute absorption at 37 ºC, 
the cells were overlaid with a solution of 0.7% agarose (20-102, Apex Industrial 
Chemicals, Aberdeen, United Kingdom) in Vero E6 growth media. The plates were fixed 
2 (VSV) or 4 (LCMV and JUNV) days later with a solution of 2.5% formaldehyde (1635-
4L, Sigma) in 3x PBS. Following removal of the agarose plugs, the fixed monolayers were 
stained with 0.1% crystal violet (C581-100, Fisher Scientific) and 2.1% ethanol in water. 
To determine the plaque size of rLCMV in Figure 2.2D or the overall level of cytopathic 
effect induced by these viruses in Figures 2.4A, 2.4B, 2.6C, and 2.6D, the wells were 
imaged with an Alpha Innotech digital camera paired to a Computar H6Z0812M motorized 
zoom lens. The area of each plaque as well as the mean pixel intensity of each well was 
calculated using ImageJ software. 
Plaque interference assay 
To determine the titer of LCMV DI particles, samples were transferred to clear snap cap 
tubes (21-402-904, Thermo Scientific) and irradiated for 2 minutes with UV light in a UVP 
CL-1000 ultraviolet crosslinker in to kill standard infectious virus. The samples were 
serially diluted in 5-fold increments and added to 24-well plates which had been seeded 
the previous day with 20,000 (LCMV and JUNV C#1) or 100,000 (VSV) Vero E6 cells 
per well. Subsequently, 50 PFU per well of rLCMV WT (or 50 PFU per well of JUNV C#1 
or VSV in Figure 2.5A) was added to each well containing UV-irradiated samples. UV-
irradiated samples were also added to a second set of wells to which no standard virus was 
added to ensure that all infectious virus had been eliminated from the samples. After a 90 
98 
 
minute absorption period at 37 ºC, the cells were overlaid with a solution of 0.7% agarose 
in Vero growth media and left at 37 ºC. The plates were fixed and stained 2 (VSV) or 4 
(LCMV and JUNV C#1) days later as above for the plaque assay. The plaques were 
counted in each well and the plaque interfering unit 50 (PIU50) was calculated using the 
plaque reduction statistical web tool (https://exon.niaid.nih.gov/plaquereduction). Because 
a unique biochemical or genetic signature to differentiate standard infectious virus particles 
from DI particles has not been defined, the assay we employed relied on measurement of 
the interfering activity of DI particles as opposed to a direct physical measure of the 
particles themselves. For Figure 2.5B, rLCMV WT was filtered with either 0.45 µM 
(28145-481, VWR, Radnor, PA) or 0.2 µM (09-719C, Fisher Scientific) syringe filters or 
Amicon 30K (UFC903024, Millipore) or 10K (UFC901024, Millipore) centrifugal filters 
prior to treatment with UV light and DI titering as above. 
Virus challenge in inducible VPS4A- and VPS4B-expressing cell lines 
To determine the role of the ESCRT pathway in LCMV release, 2.5 x 105 T-Rex HEK293 
cells stably transduced with a tetracycline-inducible VPS4A or VPS4B (WT or dominant 
negative EQ in each case) were seeded in 6-well plates that were first coated with poly D-
lysine (P6407, Sigma-Aldrich) for 5 minutes then washed 3x with PBS. Cells were infected 
24 hr later with rLCMV WT at an MOI of 0.001. Forty-eight hr later (when all cells were 
productively infected) the cells were induced with growth medium containing 1 µg/mL 
tetracycline or a medium only control. Six hr after induction cells were washed 3x with 
PBS and fresh growth medium containing 1 µg/mL tetracycline or medium alone were 
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added. Eighteen hr later the cells and supernatants were collected. In Figures 2.6A and 
2.6B, the cell lysates were probed for VPS4B DN or WT protein (via the GFP fusion tag 
on these proteins) or actin expression by quantitative western blotting. Supernatants were 
titered by plaque assay for infectious virus and DI particle levels by measuring the 
cytopathic effect in a plaque assay with equal PFUs of virus in each well (as described 
under plaque assay) and/or by plaque interference assay. The role of VPS4B in VSV release 
was also tested. For the VSV challenge studies, 5 x 105 VPS4B WT or EQ cells were seeded 
in poly D-lysine treated wells and 24 hr later treated with either growth medium containing 
1 µg/mL tetracycline or medium alone. One hr later, the cells were infected with VSV at 
an MOI of 10. One hr following infection, the cells were washed 3x with PBS and fresh 
growth medium containing 1 µg/mL tetracycline or medium alone was added. Six hr later 
the cells and supernatants were collected and assessed by quantitative western blotting and 
plaque assays, respectively. 
In order to verify uniform VPS4B expression as well as rLCMV WT infection by 
microscopy, in parallel to the experiment described above, 5 x 104 cells were seeded on 
poly D-lysine-treated 12mm glass coverslips in 24-well plates. At the time of harvest (24 
hr post-infection) the coverslips were rinsed with PBS, fixed with 4% paraformaldehyde 
(15714, Electron Microscopy Sciences, Hatfield, PA) in PBS for 20 minutes, then washed 
2x with PBS for 5 minutes. The cells were permeabilized with 0.1% Triton X-100 in 1% 
bovine serum albumin (BSA) in PBS, blocked with 10% normal goat serum (005-000-121, 
Jackson, West Grove, PA) in 1% BSA in PBS, and immunostained with anti-LCMV 
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nucleoprotein antibody (1.3-3) (1:500) kindly provided by M. Buchmeier (University of 
California, Irvine) and secondary anti-mouse Alexafluor 555 (A28180, Thermo Scientific) 
(1:1,000) each for 1 hr in 1% BSA in PBS. DNA was detected with 4’, 6-diamidino-2-
phenylindole hydrochloride (DAPI) (D9542, Sigma Aldrich) in 1% BSA in PBS. Cells 
were washed with 1% BSA in PBS in between each step. Images were acquired on a Zeiss 
LSM 510 laser scanning confocal microscope using a 63X objective lens. Post-capture 
image processing was carried out in FIJI and Photoshop; the GFP fluorescence, NP 
staining, and DAPI signal are shown at equal exposures in all conditions. 
Virion concentration and fractionation 
To determine the NP, GP, and Z protein content of rLCMV virions in Figures 2.3A-2.3D, 
2 x 106 Vero E6 cells were seeded in a T-150 culture flask and infected the next day at an 
MOI of 0.01, 0.001, or 0.0001. At 48 or 72 hr following inoculation, the supernatant was 
collected, clarified by centrifugation, and screened for infectious virus by plaque assay. An 
equal number of plaque forming units of each virus (range 1 to 3x107 PFU per experiment) 
were layered onto a solution of 20% sucrose in TNE buffer, pH 7.4 (10 mM Tris base, 1 
mM EDTA, 0.2 M NaCl) and centrifuged for 2 hr at 30,000 rpm at 4 ºC in a Thermo-
Scientific Sorval WX Ultra 80 ultra centrifuge equipped with a Sorval Surespin 630 rotor. 
The resulting virus pellet was resuspended in 2X-concentrated Laemmli buffer containing 
5% 2-mercaptoethanol, then analyzed by SDS-PAGE and quantitative western blotting. 
To separate rLCMV by gradient centrifugation in Figure 2.S2, 2 x 106 Vero E6 cells 
were seeded in a T-150 culture flask and infected the next day at an MOI of 0.0001. At 72 
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hr following inoculation, the supernatant was collected and clarified by centrifugation. The 
clarified supernatants were added to 50 mL tubes (430290, Corning) containing 
polyethylene glycol (PEG) 8000 (81268, Sigma-Aldrich) and sodium chloride such that 
the final concentrations were 10% and 1%, respectively. The solutions were incubated at 4 
ºC on a rotating platform for 2 hr then were centrifuged for 30 minutes at 10,000 rpm at 4 
ºC in a Thermo-Scientific Sorval Legend RT+ centrifuge equipped with a Sorval Fiberlite 
F15-8x50cy rotor. The supernatant was removed and the virus-PEG pellet was resuspended 
in TNE buffer and screened for infectious virus by plaque assay. Density gradients were 
prepared by layering solutions of 7%, 10%, 13%, 16%, and 19% optiprep (D1556, Sigma-
Aldrich) diluted in PBS in 36 mL tubes (03141, Thermo Scientific) then leaving overnight 
at 4 ºC to allow a continuous gradient to form. An equal number of plaque forming units 
of each virus (range 4 x 107 to 1 x 108 PFU per experiment) was layered onto the continuous 
gradient and centrifuged for 12 hr at 30,000 rpm at 4 ºC in a Thermo-Scientific Sorval WX 
Ultra 80 ultracentrifuge equipped with a Sorval Surespin 630 rotor. The resulting separated 
virus was collected in 2 mL fractions using a New Era NE-9000G programmable peristaltic 
pump and titered via plaque assay. 
Quantitative RT-PCR 
To enumerate copies of LCMV S and L segment genomic RNA contained in virions for 
Figures 2.3E and 2.3F, viral RNA was extracted from cell-free virions using the Qiagen 
Viral RNA mini kit according to the manufacturer’s instructions and subjected to 
quantitative RT-PCR as previous described (Haist et al., 2015). Briefly, cDNA was 
102 
 
generated in a 50 µL RT reaction containing 5 µL of viral RNA, 0.2 µM of the gene specific 
primer S 2865- (5’-CAGGGTGCAAGTGGTGTGGTAAGA-3’) or L 5906- (5’- 
TGGGACTGAGTTTCGAGCATTACG-3’), which are complementary to the S or L 
segment genomic RNA, 5 µL of 10x PCR Buffer II (#E12874, Applied Biosystems, 
Carlsbad, CA), 5 µL of 10 mM dNTP mix (362275, Applied Biosystems), 1 µL RNase 
inhibitor (N808-0119, Applied Biosystems), and 1.25 µL of Multiscribe reverse 
transcriptase (4308228, Applied Biosystems). RT reaction conditions were 25 ºC for 10 
minutes, 48 ºC for 30 minutes, and 95 ºC for 5 minutes. Quantitative PCR was then 
performed in a 25 µL reaction volume consisting of 5 µL of cDNA, 0.9 µM each of the 
forward primer S 2275+ (5’-CGCTGGCCTGGGTGAAT-3’) or L 5517+ (5’-
GGCCTTGTATGGAGTAGCACCTT-3’) and reverse primer S 2338- (5’-ATGGGAAAA 
CACAACAATTGATCTC-3’) or L 5645- (5’-GGTCTGTGAGATATCAAGTGGTAGA 
ATG-3’), 0.2 µM of the TaqMan probe S 2295+ (5’-6FAM-CTGCAGGTTTCTCGC-
MGBNFQ-3’) or L 5582- (5’-6FAM-CTGAAGAATACCACCTATTATACCA-
MGBNFQ-3’), and 12.5 µL of the TaqMan Universal PCR Master Mix (4326614, Life 
Technologies, Grand Island, NY). Reaction conditions were 95 ºC for 10 minutes followed 
by 40 cycles of 95 ºC for 15 seconds and 60 ºC for 1 minute. Copy numbers of LCMV S 
or L segment genomic RNAs were calculated by comparison with a series of standard 
dilutions of the pT7-S or pT7-L plasmids as described (Haist et al., 2015). Data was 
generated on an Applied Biosystems StepOnePlus Real-Time PCR System and analyzed 
with the provided software. 
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Statistical analysis  
Statistical analysis was performed using GraphPad Prism software. For the virus 
growth curves in Figure 2.2B, the data was first log transformed, then a two-way analysis 
of variance (ANOVA) was performed with a Holm-Sidak’s test for multiple comparisons 
to compare viruses at each time point. A one-way ANOVA with Holm-Sidak’s test for 
multiple comparisons was used to analyze the VLP release assay in Figure 2.2E, the viral 
protein levels in concentrated virions in Figures 2.3B-2.3D, and the S and L segment to 
PFU ratios in Figures 2.3E and 2.3F. To compare plaque area in Figure 2.2D, the data were 
first tested for normality using the D’Agostino and Pearson omnibus normality test, then 
the Kruskal-Wallis non-parametric test was used and multiple comparisons were made with 
Dunn’s multiple comparisons test. To analyze the cytopathic effect induced by rLCMV 
WT or Z-Y88 mutants (Figure 2.4B) or by rLCMV WT generated in VPS4B WT or 
dominant negative cells (Figure 2.6D), a two-way ANOVA was performed with the Holm-
Sidak’s test for multiple comparisons. To compare VSV or LCMV virus titers, LCMV DI 
particle titers, or Z VLP levels produced in VPS4B WT or EQ cells (Figures 2.6A, 2.6B, 
2.6E, and 2.S5) a two-tailed unpaired t test with Welch’s correction was performed. To 
compare DI particle titers in Figures 2.5A-2.5C, a value of 19 PIU50/mL (just below the 
limit of detection value of 20 PIU50/mL) was substituted for samples that were below the 
limit of detection and then a one way ANOVA was performed. For all statistical analyses, 
the data utilized was generated from at least 3 independent experiments as indicated in each 
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Figure 2.S1. Fragment ion tables from mass spectra and spectral counts of phosphorylated and 
unphosphorylated tryptic peptides. (A-B) For the indicated phosphorylated (A) and unphosphorylated (B) 
peptides, corresponding to the spectra shown in Fig 1B, the calculated and measured (colored numbers) m/z 
values of the y- and b-type ions are shown. (C) The phosphorylated and unphosphorylated peptides detected 
from virion-derived LCMV Z in Fig 1A are listed. Each MS/MS spectrum was manually examined and found 
to be correct by a comparison to spectra with the highest Xcorr values and by comparing predicted and 
















Seq # b y +1
K 1 129.020 --- 14
I 2 242.186 1454.609 13
S 3 329.218 1341.525 12
T 4 430.266 1254.493 11
A 5 501.303 1153.445 10
P 6 598.356 1082.408 9
S 7 685.388 985.355 8
S 8 772.420 898.323 7
P 9 869.473 811.291 6
P 10 966.525 714.238 5
P 11 1063.578 617.185 4
Y# 12 1306.608 520.133 3
E 13 1435.650 277.103 2




Seq # b y +1
K 1 129.020 --- 14
I 2 242.186 1374.642 13
S 3 329.218 1261.558 12
T 4 430.266 1174.526 11
A 5 501.303 1073.479 10
P 6 598.356 1002.441 9
S 7 685.388 905.389 8
S 8 772.420 818.357 7
P 9 869.473 731.325 6
P 10 966.525 634.272 5
P 11 1063.578 537.219 4
Y 12 1226.642 440.166 3
E 13 1355.684 277.103 2







Figure 2.S2. Profile of standard infectious rLCMV WT or Y88 particles following separation via 
density ultracentrifugation. Vero E6 cells were infected with rLCMV WT, Y88F, Y88E, or Y88A at an 
MOI of 0.0001 and 72 hr later supernatants were clarified, precipitated with PEG-8000, resuspended in TNE, 
and titered for PFU via plaque assay. An equal number of PFU for each rLCMV was layered onto an optiprep 
gradient (7%, 10%, 13%, 16%, and 19%) and centrifuged for 12 hr at 30,000 RPM at 4 ºC. The entire gradient 
was collected in 15 fractions of 2 mL each. Each fraction was titered for PFU via plaque assay. Shown are 


































Figure 2.S3. Efficient DI particle formation requires a functional ESCRT pathway. (A-C) T-Rex 
HEK293 cells stably transduced with vectors for tetracycline-based induction of WT vacuolar protein sorting 
4A (VPS4A) or the DN VPS4A mutant, EQ, were infected with rLCMV WT and 2 d later treated with 
tetracycline to induce the expression of WT or DN VPS4A. 6 hr after VPS4A induction (54 hr pi), the cells 
were washed and given fresh media containing tetracycline. Supernatants were collected 18 hr later (72 hr 
pi) and titered via plaque assay. The results shown in (A) represent the mean PFU ± SEM from 2 independent 
experiments that contained 3 technical replicates and were tested for statistical significance with an unpaired 
t test with Welch’s correction. Equivalent PFUs of virus (range 2 x 101 to 2 x 103) produced from WT or 
DN VPS4A cells were inoculated onto monolayers of Vero E6 cells and a standard plaque assay was 
performed. Representative images of crystal violet-stained wells are shown in (B). Inhibition of standard 
infectious virus-induced cytopathic effect by DI particles at each dose was determined in (C) by measurement 
of the mean pixel intensity of each well using Image J software. The data in (C) are representative of the 
mean ± SEM relative to WT VSP4A (at 200 PFU per well) from 2 independent experiments that contained 
3 technical replicates and were tested for statistical significance with a two way ANOVA and Holm-Sidak’s 











Figure 2.S4. LCMV generates more DI particles per standard infectious particle than JUNV C#1. 
Serial 10-fold dilutions of stock preparations of LCMV or JUNV C#1 were inoculated onto monolayers of 
Vero E6 cells and a standard plaque assay was performed to visualize DI-mediated interference of standard 









Figure 2.S5. Expression of dominant negative VPS4B does not impact the ability of LCMV Z to form 
VLPs. (A-B) T-Rex HEK293 cells stably transduced with a tetracycline-inducible plasmid encoding WT or 
dominant negative EQ mutant vacuolar protein sorting 4B (VPS4B) were simultaneously transfected with a 
plasmid encoding LCMV Z WT and exposed to tetracycline to drive the expression of WT or DN VPS4B. 
One day later both the cells and VLP-containing supernatants were collected. Z from VLP-containing 
supernatants was affinity purified with magnetic streptavidin beads. The quantity of Z affinity purified from 
VLPs or present in the corresponding whole cell lysates was determined via quantitative western blotting. 
The percent VLP release shown in (A) was calculated as the amount of Z protein found in the cell culture 
media relative to the amount in cells. Data are presented as mean release ± SEM relative to WT Z from 3 
independent experiments. A one way ANOVA with Holm-Sidak’s test for multiple comparisons was used to 
compare the mean values. n.s., not significant). In panel (B), cell lysates were also screened by western 
blotting to verify the induction of VPS4B WT or EQ expression using an anti-GFP antibody and for actin as 
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We report that the lymphocytic choriomeningitis virus (LCMV) matrix protein, 
which drives viral budding, is phosphorylated at serine 41. A recombinant (r)LCMV 
bearing a phosphomimetic mutation (S41D) was impaired in infectious and defective 
interfering (DI) particle release while a nonphosphorylatable mutant (S41A) was not. The 
S41D mutant was disproportionately impaired in its ability to release DI particles relative 
to infectious particles. Thus, DI particle production by LCMV may be dynamically 




Arenaviruses are enveloped RNA viruses that establish lifelong, asymptomatic 
infections in reservoir rodents but can cause severe disease in humans (Buchmeier et al., 
2007). The prototypic arenavirus, lymphocytic choriomeningitis virus (LCMV), produces 
high levels of defective interfering (DI) particles during acute and persistent infection 
(Popescu and Lehmann-Grube, 1977; Staneck et al., 1972; Welsh and Pfau, 1972). DI 
particles, which are replication-deficient virus particles that can interfere with the 
propagation of standard infectious virus (Huang and Baltimore, 1970; Welsh et al., 1972), 
are thought to be critical for the establishment of LCMV persistence (Burns and 
Buchmeier, 1993; Huang and Baltimore, 1970; Oldstone, 1998), possibly by reducing 
virus-induced cytopathology in reservoir rodents. The arenavirus matrix protein Z is a 
multifunctional protein that drives the assembly and release of standard infectious virus 
(Fehling et al., 2012; Perez et al., 2003; Strecker et al., 2003) and DI particles (Ziegler et 
al., 2016b). For many viruses, budding is controlled by one or more late domain(s) encoded 
in the matrix protein that recruit the cellular endosomal sorting complex required for 
transport (ESCRT) pathway, which drives the final membrane scission step (Votteler and 
Sundquist, 2013). The LCMV matrix protein encodes a single late domain, PPXY, which 
has been shown to be important for the formation of infectious virus-like particles (VLPs) 
(Perez et al., 2003). In the context of fully infectious virus, we recently demonstrated that 
the LCMV matrix protein uses different cellular pathways for the production of standard 
versus DI particles. In particular, DI particle formation absolutely requires LCMV’s PPXY 
late domain and the cellular ESCRT pathway while the production of standard infectious 
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particles does not (Ziegler et al., 2016b). Further, phosphorylation of the terminal tyrosine 
in the PPXY late domain may be important for regulating this late domain-driven pathway 
of DI particle formation. In the current study, we discovered an additional phosphorylation 
site in LCMV Z at serine 41 (S41). Furthermore, using site-specific mutant viruses we 
found that serine 41 plays an important regulatory role in the production of LCMV 
infectious virions and DI particles. 
 
Figure 3.1. The LCMV matrix protein Z is phosphorylated at serine 41 (S41). (a) HEK-293T cells were 
transfected with a plasmid encoding streptavidin binding peptide (SBP)-tagged LCMV strain Armstrong Z 
or an empty vector. Two days later cells and virus-like particle (VLP)-containing supernatant were lysed and 
Z-SBP was affinity purified using streptavidin-coated magnetic beads. The purified Z-SBP was subjected to 
SDS-PAGE and detected by western blotting using an anti-SBP tag antibody or Coomassie stain. The 
presumptive monomeric Z bands from cells or VLPs were excised from the Coomassie stained gels (as 
indicated by the boxes) and subjected to reduction, alkylation, and in-gel tryptic digestion prior to mass 
spectrometry analysis of extracted peptides. (b) A representative low energy collision-induced dissociation 
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tandem mass spectrum with its corresponding fragment ion table from low energy collision-induced 
dissociation of a Z-derived tryptic peptide (FDS#LVR) containing the phosphorylated S41 where # denotes 
phosphorylation. The fragment ion table lists the predicted m/z values of the singly-charged b and y ions. 
Major measured b and y ions, as well as dominant losses of phosphoric acid are labeled. Phosphoric acid loss 
is a major signature in tandem mass spectra of phosphoserine/threonine-containing peptides. (c) Cartoon of 
the LCMV Z protein depicting the G2 myristoylation site, the central zinc-binding RING domain, and the C-
terminal PPPY late domain. The S41 phosphorylation site and its flanking amino acids as well as the 
previously described Y88 phosphorylation site (Ziegler et al., 2016b) are indicated. (d) Alignment of Old and 
New World arenavirus Z protein sequences shows that S41 (bolded and underlined for LCMV strains 
Armstrong and WE) is conserved with the Old World arenaviruses Dandenong and Ippy virus. 
 
To screen for phosphorylation sites in LCMV Z, we transfected HEK-293T cells with 
a plasmid encoding the LCMV strain Armstrong Z protein fused to a C-terminal 
streptavidin binding peptide (SBP) and subsequently used magnetic streptavidin beads (as 
described in (Ziegler et al., 2016b)) to affinity purify SBP-tagged Z from the transfected 
cells as well as from VLPs that had been released into the tissue culture media. Purified Z-
SBP was separated by SDS-PAGE (Figure 3.1(a)), prepared for mass spectrometry analysis 
by in-gel tryptic digestion, and analyzed by liquid chromatography-mass spectrometry 
essentially as described (Ziegler et al., 2016b). This analysis revealed a novel serine 
phosphorylation site at S41 in Z-transfected cells (Figure 3.1(b)). S41, a site conserved in 
the Old Word arenaviruses Dandenong and Ippy (Figure 3.1(d)), is located in the central 
really interesting new gene (RING) domain of Z (Figure 3.1(c)) and is outside of any motif 




Figure 3.2. Phosphomimetic mutation of S41 significantly reduces the efficiency of infectious virus 
release and the ability of Z to form virus-like particles (VLPs). (a) Reverse genetics was used to generate 
rLCMV containing a nonphosphorylatable S41A mutation or a phosphomimetic S41D mutation. To 
determine whether infectious virus was recovered, both a standard plaque assay and an immunofocus assay 
(using an anti-nucleoprotein antibody (1.1.3)) were performed on Vero E6 cells. (b) The kinetics of infectious 
virus production were examined by growth curve analysis on Vero E6 cells (a multiplicity of infection (MOI) 
of 0.01 was used for each virus). Data represent the mean ± SEM from 3 independent experiments.  For 
statistical analysis, the data were first log-transformed then a two-way analysis of variance (ANOVA) with 
Holm-Sidak’s test for multiple comparisons was performed. (c) The area of foci obtained from the 
immunofocus assay wells shown in (A) for each rLCMV strain was measured using Image J. Data represent 
the mean ± SEM of foci from 8 wells for each virus. The Kruskal-Wallis non-parametric test with Dunn’s 
multiple comparisons test was used to compare mean values. (d) The budding activity of WT or S41-mutant 
LCMV Z proteins was measured by a VLP release assay. The LCMV Z G2A mutant, which has a budding 
defect due to its inability to be myristoylated, was included as a control (Perez et al., 2004a). The results 
shown represent the mean ± SEM from 3 independent experiments. A one-way analysis of variance with the 
Holm-Sidak’s test for multiple comparisons was used to compare the mean values. For the indicated 








































To determine the importance of the S41 residue for viral fitness, recombinant (r)LCMV 
containing a nonphosphorylatable alanine (S41A) or a phosphomimetic aspartic acid 
(S41D) substitution at position 41 were recovered using reverse genetics as previously 
described (Emonet et al., 2009b; Flatz et al., 2006; Ziegler et al., 2016b). Initially, it 
appeared that the S41D phosphomimetic mutant could not be recovered as it did not 
produce plaques in a standard plaque assay (Figure 3.2(a)). However, staining for viral 
nucleoprotein (NP) (mouse anti-LCMV NP, 1.1.3, kindly provided by M. J. Buchmeier, 
University of California, Irvine) via immunofocus assay (Battegay et al., 1991) revealed 
that the S41D mutant was recoverable despite its inability to form plaques (Figure 3.2(a)). 
Growth curve analysis revealed that the phosphomimetic S41D virus was attenuated in its 
growth kinetics while the nonphosphorylatable S41A mutant grew to similar levels as wild 
type (Figure 3.2(b)). The attenuation of the S41D mutant was also apparent in the smaller 
foci it formed, which were less than 50% of WT size (Figs. 2(a) and (c)). To determine 
whether the reduction in infectious titer of the phosphomimetic S41D virus was due to 
decreased virus budding and release, we employed a Z VLP release assay as previously 
described (Ziegler et al., 2016b). As a control, we also included the LCMV Z G2A mutant, 
which exhibits a pronounced defect in VLP formation due to its inability to be 
myristoylated at this glycine residue (Perez et al., 2004a; Strecker et al., 2006). This 
experiment demonstrated that the budding efficiency of the phosphomimetic Z-S41D was 
reduced ~60% while the budding activity of the nonphosphorylatable S41A was not 
different from WT (Figure 3.2(d)). Collectively, these findings demonstrate that the S41 
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residue possesses a previously unappreciated capacity to drive virus budding and that this 
function may be regulated by phosphorylation.  
 
Figure 3.3. The S41 phosphomotif regulates DI particle production. (a-h) Comparison of viral structural 
protein and genome content in preparations of rLCMV WT, S41A, or S41D virus. Vero E6 cells were infected 
with WT or S41-mutant rLCMV at a multiplicity of infection (MOI) of 0.0001 and clarified supernatants 
were collected 72 hours later. Equivalent FFUs of each rLCMV were then concentrated through a 20% 
sucrose cushion by ultracentrifugation. Viral protein content in these concentrated virus preparations was 
analyzed by quantitative western blotting. Representative western blots (a) as well as the quantity (mean ± 
SEM) of NP (b), GP (c), or Z (d) contained in each rLCMV virus preparation are shown. The copies of 
LCMV genomic L segment (e-f) or S-segment (g-h) were determined by quantitative RT-PCR (Haist et al., 
2015) and then normalized to the infectious titer (FFU). To enumerate copies of L segment vRNA, RT was 
performed using the RT primer 5906-, followed by QPCR using the primer probe sets located in either the L 
gene (primers L5517+ and L5645- and probe L5582-P) (e) or Z gene (primers L212+ and L276- and probe 
L251-P) (f). To determine the copies of S segment vRNA, RT was performed using the RT primer 2865-, 
followed by QPCR using the primer probe sets located in either the NP gene (primers S2275+ and S2338- 
and probe S2295+P) (g) or GPC gene (primers S929+ and S988- and probe S952+P) (h). (i-j) Measurement 
of standard infectious virus and DI particles produced by rLCMV WT, S41A, or S41D. The infectious titer 
of each of the clarified supernatants used in (a-h) was determined by focus forming assay (i) and the DI 
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particle titer was assessed by plaque interference assay (j). PIU50/mL, plaque interfering units50/mL. For (b-
j), values represent the mean ± SEM of protein (b-d), viral genome (e-h), FFU/mL (i), or DI particle titer (j) 
from 4 independent experiments and statistical analyses were performed by one-way ANOVA with Holm-
Sidak’s test for multiple comparisons for which *, p < 0.05, **, p < 0.01; ****, and p < 0.0001. (k) Model 
of S41’s impact on infectious virus and DI particle formation. WT virus containing the native S41 (Z WT) 
produces high levels of infectious and DI particles. Mutation of S41 to alanine (Z S41A) to prevent 
phosphorylation has little effect on infectious or DI particle production. Mutation of S41 to aspartic acid (Z 
S41D) to mimic the negative charge associated with phosphorylation of S41 results in decreased infectious 
virus and DI particle release. The S41D mutation disproportionately impacts DI formation over standard 
infectious virus. 
 
As the reduction in VLP release by Z-S41D (Figure 3.2(d)) did not appear to fully 
explain the greater than 10-fold reduction in virus titer observed in Figure 3.2(b), we 
probed rLCMV WT or S41 mutant virion preparations (that were generated in Vero E6 
cells infected at a multiplicity of infection (MOI) of 0.0001 and collected 72 hours after 
infection) for structural protein and/or genome deficits. To determine the composition of 
each virus particle preparation, an equal number of focus forming units (FFU) of cell-free 
rLCMV WT, S41A, or S41D viruses were concentrated through a 20% sucrose cushion by 
ultracentrifugation as described in (Ziegler et al., 2016b) and virion protein quantity was 
analyzed by quantitative western blotting (Figs. 3(a) to (d)). The S41D phosphomimetic 
virus preparation, despite containing equivalent infectious units as the WT and S41A 
preparations, had markedly reduced levels of NP, glycoprotein (GP2), and Z (Figures 
3.3(a) to (d)). Interestingly, the quantities of viral genomic S and L segment RNAs, 
measured by quantitative polymerase chain reaction (PCR) as described in (Haist et al., 
2015; Ziegler et al., 2016b), did not differ between the preparations of WT, S41A, or S41D 
viruses (Figs. 3(e) - (h)). The loss in viral structural protein content without a corresponding 
loss in infectious titer led us to hypothesize that the S41D phosphomimetic virus may be 
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defective in its ability to generate DI particles, which could explain the reduced levels of 
viral protein observed relative to infectious units. To test whether S41 can indeed act as a 
regulatory motif to control DI particle production, we next measured the infectious virus 
levels and DI particle activity of the same virus preparations  used above in Figs. 3(a) to 
(h) using the immunofocus assay and the plaque interference assay, respectively, as 
described in (Welsh and Pfau, 1972; Ziegler et al., 2016b). All three viruses had 
approximately equivalent titers of infectious virus (Figure 3.3(i)). The DI particle titer of 
the S41D phosphomimetic virus, however, was reduced greater than 10-fold compared to 
WT virus while the DI particle titer of the S41A virus was not different from WT (Figure 
3.3(j)). These results indicate that the loss of viral structural protein content observed in 
the phosphomimetic S41D virus preparation (Figs. 3(a)-(d)) was likely due to the reduced 
production of DI particles, not infectious virus particles.  
The S41 phosphomotif represents a novel regulatory site within the LCMV Z 
protein. We recently demonstrated that the PPXY late domain in LCMV Z is not absolutely 
required for the production of infectious LCMV virions (Ziegler et al., 2016b). Provided 
that the only other motif in Z with a known role in budding activity is the myristoylation 
site at the glycine at position 2 (Figs. 1(c) and 2(d)) (Perez et al., 2004a; Strecker et al., 
2006), our finding here expands the functional repertoire of motifs in LCMV Z that regulate 
the efficiency of infectious virus release. Further, we have built upon our previous findings 
regarding the PPXY late domain (Ziegler et al., 2016b) by showing that S41 also serves as 
a key regulator of DI particle formation. To our knowledge, these are the only two motifs 
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known to specifically regulate DI particle formation over standard particles for any virus 
family. While we have shown that DI particle formation requires a functional ESCRT 
pathway (Ziegler et al., 2016b), it will be important to determine whether the PPXY late 
domain and/or the S41 phosphomotif directly engage ESCRT machinery and, if so, the 
mechanistic basis for this interaction as it relates to DI particle production. Further, our 
findings support the hypothesis that phosphorylation of Z is an important mechanism by 
which the virus can adjust its rate of DI particle formation in response to the dynamic 
environment of the host cell (e.g. phosphorylation at Y88 appears to increase DI particle 
production (Ziegler et al., 2016b) whereas phosphorylation of S41 represses it (Figure 
3.3(j)). In this scenario, the S41 site could function as an important rheostat for regulating 
the potency of the PPXY-driven DI production pathway. Other arenaviruses, if they 
produce fewer DI particles than LCMV (e.g. Junin virus Candid #1) (Ziegler et al., 2016b), 
may not require a secondary regulatory motif such as S41, which could explain why the 
S41 site is only found in LCMV-like viruses and the closely related Old World arenavirus 
Ippy (Figure 3.1d). Identifying the key kinases and phosphatases that target S41 and Y88 
and determining how their activity is regulated in response to environmental stimuli will 
be important for understanding how DI particle formation is regulated during infection. It 
will also be important to determine whether phosphorylation of matrix proteins can play a 
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Junín virus (JUNV), the causative agent of Argentine hemorrhagic fever, belongs 
to the arenavirus family of rodent-borne viruses. These viruses contain a simple genome 
encoding only four proteins yet are capable of executing complex functions in their cellular 
host. The arenavirus matrix protein Z drives virus assembly and release, in addition to other 
functions, yet relatively little is known about which cellular proteins Z hijacks to 
accomplish these functions. In this study, affinity purification-mass spectrometry was used 
to unbiasedly determine the cellular proteins that JUNV Z interacts with in host cells and 
in Z-virus like particles (VLPs). Mass spectrometry was also used to determine the host 
protein content of bona fide viral particles from the Candid 1 (C#1) strain of JUNV. Several 
identified proteins were selected for functional screening which revealed that ARF1, 
ATP5B, ATP6V0D1, IMPDH2 and PRDX3 are required for JUNV infection. ATP5B, 
IMPDH2 and Rab5c were also required for infection of the Old World arenavirus, 
lymphocytic choriomeningitis virus (LCMV). Numerous endosomal sorting complex 
required for transport (ESCRT) proteins were identified in JUNV virions and VLPs. 
Inducible expression of the ESCRT accessory protein VPS4 was used to determine that 
efficient release of infectious JUNV virions requires a functional ESCRT pathway, in 
contrast to LCMV, which does not utilize ESCRT for infectious virus production. The Z-
host protein-protein interaction network mapped in this study provides a framework for 
further identification of the critical host factors required for Z protein function and 





Argentine hemorrhagic fever is a severe disease with high mortality and very 
limited treatment options that is caused by the arenavirus, Junín. The arenavirus matrix 
protein, Z, serves several roles in the virus life cycle of which most prominent is Z’s 
required role in the assembly and release of virus particles. These various functions of Z 
likely require an array of host cellular proteins but little is known about which host proteins 
Z interacts with to accomplish these functions. This study used affinity purification and 
mass spectrometry to identify protein-protein interactions between Z and its cellular host. 
Functional assays were used to screen a subset of the host proteins which revealed that 
several of the identified host factors are critical for arenavirus infection. This study 
provides deeper insight into the cellular biology of the Z protein and identifies potential 




Arenaviruses are a family of viruses carried by various species of rodents found 
throughout the world. The family is divided into two major subclasses based on the 
geographic distribution of each virus, namely the Old World and New World arenaviruses 
which represent viruses primarily from Africa or the Americas, respectively (Charrel et al., 
2008). The rodent carriers of these viruses are asymptomatic but infected lifelong and shed 
infectious virus which can result in human infection through exposure to infectious excreta 
from the infected rodents (Childs et al., 1992; Keenlyside et al., 1983; Salazar-Bravo et al., 
2002a). Several arenaviruses cause severe hemorrhagic fever disease in humans with high 
morbidity and mortality. The causative agent of Lassa hemorrhagic fever, Lassa virus 
(LASV), causes ~200,000 infections per year in western Africa (McCormick et al., 1987). 
Similar hemorrhagic fever diseases are found in the New World caused by Guanarito, 
Junín, Machupo, and Sabia viruses (Charrel and Lamballerie, 2003). Junín virus (JUNV), 
is endemic to central Argentina and causes Argentine hemorrhagic fever in humans 
(Maiztegui, 1975). The live, attenuated vaccine strain of JUNV Candid 1 (C#1) has 
demonstrated efficacy in reducing cases of Argentine hemorrhagic fever in the endemic 
region but it has not been approved for use by the United States Food and Drug 
Administration (Enria et al., 2008b). Furthermore, the only therapy with demonstrated 
efficacy against JUNV infection is immune plasma and thus there is a clear need for 
therapeutics to treat JUNV infection (Enria et al., 2008b). 
Arenaviruses have a simple, negative-sense, bi-segmented RNA genome 
comprised of two single-stranded segments with an ambisense coding strategy. The small 
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(S) segment encodes the nucleoprotein (NP) and the glycoprotein (GP) while the large (L-
segment) encodes the RNA-dependent RNA polymerase (L) and the matrix protein Z 
(Auperin et al., 1986; Clegg et al., 1991; Djavani et al., 1997; Lukashevich et al., 1997; 
Riviere et al., 1985; Salvato and Shimomaye, 1989; Singh et al., 1987). All four proteins 
are structural components of the virion. GP forms spikes on the exterior of the virion, NP 
and L together with the genome form the ribonucleoprotein (RNP) complex which is 
packaged inside virions, and Z forms a matrix layer on the interior side of the viral 
membrane (Lee and de la Torre, 2002; Neuman et al., 2005; Salvato et al., 1992a; Strecker 
et al., 2003). Arenaviruses are enveloped and enter cells through receptor-mediated 
endocytosis, undergo replication and assembly in the cytoplasm, and are released from the 
cell via budding from the plasma membrane (Urata and Yasuda, 2012). GP mediates cell 
entry by binding cell surface receptors which triggers endocytosis of the bound virus into 
the endocytic pathway (Borrow and Oldstone, 1994; Cao et al., 1998; Kunz, 2009; 
Martinez et al., 2007; Quirin et al., 2008; Spiropoulou et al., 2002). In endosomes, GP 
triggers fusion of the viral envelope with the endosomal membrane releasing viral 
ribonucleoproteins into the cytoplasm (Klewitz et al., 2007). Viral replication occurs in the 
cytoplasm where the genome is transcribed and replicated by the L polymerase but also 
requires NP (Lee et al., 2000; Lopez et al., 2001).  
In the present study, we focused on the multifunctional matrix protein Z. A small 
protein, Z is largely comprised of a central zinc-binding really interesting new gene (RING) 
domain and the Z protein of most arenaviruses contains one or two late domains within its 
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flexible C-terminal region (Djavani et al., 1997; Fehling et al., 2012). Z is responsible for 
a number of critical functions in the viral life cycle. Z regulates viral genome replication 
and transcription by antagonizing the viral L polymerase (Cornu and de la Torre, 2001; 
Jacamo et al., 2003b; Kranzusch and Whelan, 2011). Z can repress the translation of capped 
mRNAs by directly binding to and inhibiting the translation initiation factor eIF4E 
(Campbell Dwyer et al., 2000; Kentsis et al., 2001; Kranzusch and Whelan, 2011; Volpon 
et al., 2010). The Z protein of pathogenic arenaviruses can also inhibit the innate immune 
response by binding to and inhibiting retinoic acid-inducible gene 1-like proteins (Fan et 
al., 2010; Xing et al., 2015). Finally, the most prominent role of Z is to drive assembly, 
budding, and release of virions at the plasma membrane. Z coordinates the assembly of 
virus particles at sites of budding by interacting with glycoprotein and the viral 
ribonucleoprotein complex (Capul et al., 2007; Schlie et al., 2010). The release of 
arenavirus virions has traditionally been thought to be mediated by Z’s recruitment of the 
cellular endosomal sorting complex required for transport (ESCRT) through its C-terminal 
late domains, either P(S/T)AP and/or PPXY (Perez et al., 2003; Strecker et al., 2003; Urata 
et al., 2006). Accordingly, Z, in the absence of other viral proteins, can induce the 
formation of virus-like particles (VLPs) and thus is both necessary and sufficient for 
driving the budding process (Eichler et al., 2004; Perez et al., 2003; Strecker et al., 2003). 
However, our lab recently reported that defective interfering particle but not infectious 
virus particle production for the prototypic Old World arenavirus, lymphocytic 
choriomeningitis virus (LCMV), requires a functional PPXY late domain and ESCRT 
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complex (Ziegler et al., 2016b). We also reported recently that a motif outside of any 
known late domain in the LCMV Z protein contributed to both infectious virus and 
defective interfering particle production (Ziegler et al., 2016a). The New World arenavirus 
Tacaribe (TACV) lacks a functional late domain in Z while a recombinant Pichinde virus 
(PICV) with mutations to its PSAP late domain is viable but attenuated (Urata et al., 2009; 
Wang et al., 2012). This highlights the level of diversity among arenaviruses and 
emphasizes the need to better understand the molecular machinery each of the arenaviruses 
employ to accomplish their various functions. 
Viruses are dependent upon the cellular hosts they infect in order to carry out their 
life cycle. While several functions of the arenavirus Z protein are known, the specific 
molecular mechanisms and corresponding host machinery hijacked by Z to drive these 
processes is not well described. In this study, JUNV Z protein from cells or VLPs was co-
purified in complex with host protein partners then subjected to mass spectrometry-based 
protein identification in order to map the Z-host protein interactome. The host protein 
content of Z VLPs was also confirmed and additional host protein content was identified 
by immunoprecipitation of JUNV C#1 virions and mass spectrometry. Functional 
characterization of six host protein partners was carried out by RNA silencing which 
yielded several novel pro-viral factors including a component of the mitochondrial ATP 
synthase complex, ATP5B, which was required for the production JUNV as well as the 
prototypic Old World arenavirus, LCMV. This study also revealed that ESCRT complex 
proteins are enriched in Z VLPs and JUNV C#1 virions. Using cells expressing wild type 
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(WT) or dominant negative (EQ) VPS4A or VPS4B, we were able to demonstrate for the 
first time that release of infectious JUNV C#1 virions requires a functional ESCRT 
pathway, in contrast to its Old World arenavirus counterpart, LCMV. 
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Materials and Methods 
Cells, viruses and plasmids 
Human embryonic kidney cells (HEK-293T/17) (CRL-11268, American Type 
Culture Collection, Manassas, VA) (referred to as HEK293T cells in the manuscript) were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) (11965-092) supplemented 
with 10% fetal bovine serum (FBS) (16140-071), 1% penicillin-streptomycin (15140-122), 
1% MEM Non-Essential Amino Acids Solution (11140-050), 1% HEPES Buffer Solution 
(15630-130), and 1% GlutaMAX (35050-061) purchased from Invitrogen (Carlsbad, CA). 
Stably transduced T-Rex HEK293 cells expressing WT or the dominant negative EQ 
mutant of vacuolar protein sorting 4A (VPS4A) or VPS4B under a tetracycline-inducible 
promoter described in (Dalal et al., 2004; Lin et al., 2005; Taylor et al., 2007) were kindly 
provided by M. Kielian (Albert Einstein College of Medicine, Bronx) and were maintained 
in the same media as HEK293T cells but were also supplemented with 100 µg/mL Zeocin 
(R250-01, Invitrogen). African green monkey kidney cells (Vero E6) were kindly provided 
by J. L. Whitton (The Scripps Research Institute, La Jolla) and grown in DMEM 
supplemented with 10% FBS, 1% penicillin-streptomycin, and 1% HEPES Buffer 
Solution. Human lung carcinoma cells (A549) (CCL-185, American Type Culture 
Collection) were maintained in 50:50 DMEM:F12 medium (11330-032, Invitrogen) 
supplemented with 10% FBS and 1% penicillin-streptomycin. All cell lines were grown at 
37 ºC in a humidified incubator containing 5% CO2. Lymphocytic choriomeningitis virus 
(LCMV) strain Armstrong 53b was kindly provided by J. L. Whitton. Recombinant 
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(r)LCMV WT based on the Armstrong 53b strain used in VPS4 assays was generated as 
described previously (Flatz et al., 2006; Ziegler et al., 2016b). The candidate vaccine strain 
of Junín virus (JUNV), C#1, an attenuated strain derived from virulent JUNV strain XJ as 
described in (Chosewood et al., 2009; Goñi et al., 2006), was kindly provided by M. 
Buchmeier (University of California, Irvine) and R. Tesh (The University of Texas Medical 
Branch at Galveston). Working stocks of these viruses were generated and infectious titers 
were measured via plaque assay using Vero E6 cells.  
Plasmids pLCMV-Z, pLASV-Z and pJUNV-Z contain a Z gene fused to the 
streptavidin binding peptide (SBP) sequence through an 18 base pair linker at the C-
terminus. Z was amplified by PCR from existing constructs using the forward primer 
LCMVZf (5’-ACAAGTTTGTACAAAAAAGCAGGCTGATATCGCCACCATGGGTC 
AAGGCAAGTCCAGA-3’), LASVZf (5’-ACAAGTTTGTACAAAAAAGCAGGCTGA 
TATCGCCACCATGGGAAACAAGCAAGCCAAA-3’) or JUNVZf (5’-ACAAGTTTG 
TACAAAAAAGCAGGCTGATATCGCCACCATGGGCAACTGCAACGGGGCA-3’) 
which have a 5’ overhang containing AttB1 and Kozak sequences and the reverse primer 
LCMVZr (5’-ACCTCCACCTCCAGCTGCCTCTTCGTAGGGAGGTGGAGA-3’), 
LASVZr (5’-ACCTCCACCTCCAGCTGCGGGACTGTAGGGTGGGGGTCT-3’) or 
JUNVZr (5’-ACCTCCACCTCCAGCTGCTGGTGGTGGTGCTGTTGGCTC-3’) which 
have an overhang containing the linker sequence. The SBP sequence was amplified by 
PCR from pT7-FLAG-SBP-1 (Sigma-Aldrich) using the forward primer SBPf (5’- 
GCAGCTGGAGGTGGAGGTATGGACGAAAAAACCACCGGT-3’) which has a 5’ 
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overhang containing the linker sequence and reverse primer SBPr (5’-
ACCACTTTGTACAAGAAAGCTGGGTCTTACGGTTCACGCTGACCCTGCGG-3’) 
containing a 3’ overhang with stop codon preceding the AttB2 sequence.  The two products 
were fused by PCR using the appropriate Z forward primer and the SBPr primer.  Each 
cassette was subcloned using the Gateway cloning system (Invitrogen) following 
manufacturer’s instructions into a modified pCAGGS vector containing AttB sites that was 
previously described (Cornillez-Ty et al., 2009; Klaus et al.). 
Affinity Purification and Immunoprecipitation 
For Z mass spectrometry experiments and subsequent western blot validation, 5 
x105 HEK293T cells seeded in each well of two 6 well plates per condition 24 hours (hr) 
prior to transfection. Cells were transfected with 100μL DMEM containing 2μg of the SBP-
tagged JUNV Z construct or an empty vector (p0) and 8μg of 1mg/mL polyethyleneinimine 
(23966, Polysciences, INC., Warrington, PA) per well. Virus-like particles (VLPs) and 
cells were harvested 48 hr after transfection. The VLP-containing cell culture media was 
clarified by centrifugation and the cells were scraped into phosphate buffered saline (PBS) 
and pelleted by centrifugation. VLPs and cells were lysed on ice for 20 minutes using 
Triton lysis buffer (final concentration of 0.5% NP40, 1% Triton X-100 (Acros), 140mM 
NaCl, 25mM Tris HCl) with protease inhibitor cocktail (04693159001,Roche, 
Indianapolis, IN) and PhosphoStop phosphatase inhibitor cocktail (4906837001, Roche). 
SBP-tagged Z protein in complex with host proteins was purified by incubating with 
Dynabeads MyOne Streptavidin T1 beads (65602, Invitrogen) for 2 hr at 4oC on a rotating 
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platform. The protein-bound beads were washed 4 times with Triton lysis buffer then were 
eluted in Laemmli sample buffer (62.5mM Tris-HCl, 10% glycerol, 2% sodium dodecyl 
sulfate and 0.01% bromophenol blue) containing 5% 2-mercaptoethanol by heating at 
100oC for 10 minutes. 
For JUNV C#1 virion mass spectrometry experiments and subsequent western 
blot validation, 6x106 HEK293T cells were seeded in 5 T-150 tissue culture flasks per 
condition 24 hr prior to infection. Cells were infected with JUNV C#1 at a multiplicity of 
infection of 0.1 plaque forming units per cell (PFU/cell). 48 hr post infection (pi) the media 
was aspirated and the cells were washed with warmed PBS then 8 mL of Pro293 media 
(12-764Q, Lonza) supplemented with 1% penicillin-streptomycin (15140-122), 1% MEM 
Non-Essential Amino Acids Solution (11140-050), 1% HEPES Buffer Solution (15630-
130), and 1% GlutaMAX (35050-061) purchased from Invitrogen (Carlsbad, CA) was 
added to each flask. 72 hr pi cell culture media was pooled and clarified by centrifugation. 
To the virus containing media, calcium chloride was added to a final concentration of 1mM 
and 1 protease inhibitor cocktail tablet (04693159001,Roche) per 15 mL was added then 
68 µL of magnetic, protein G-conjugated beads (10004D, Invitrogen) were added to each 
tube and incubated for 15 minutes on ice. The pre-cleared supernatant was then transferred 
to a new tube and was incubated with 34 µg of mouse monoclonal glycoprotein 1 (GP1)-
specfic antibody clone QC03-BF11 (NR-2566, BEI Resources) or 34ug of mouse IgG 
antibody (MAB002, B&D Biosciences) for 2 hr, then 600 µL of protein G magnetic beads 
were added and incubated for an additional hour. The virion-bound beads were washed 4 
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times with PBS containing 0.1 % bovine serum albumin (BP1600-100, Fisher-Scientific) 
then were resuspended in 2x-concentrated Laemmli sample buffer (125mM Tris-HCl, 20% 
glycerol, 4% sodium dodecyl sulfate and 0.02% bromophenol blue). Virion protein content 
was eluted from the beads by boiling the resuspended beads at 100oC for 10 minutes with 
5% 2-mercaptoethanol or without (for western blotting with anti-GP1 antibody). 
Identification of Host Proteins by Mass Spectrometry 
Protein precipitates were separated using NuPAGE 4-12% Bis-Tris or 4-20% 
Tris-glycine gels (Invitrogen). Following electrophoresis, each gel was stained with 
coomassie (40% methanol, 20% acetic acid and 0.1% Brilliant Blue R (Sigma-Aldrich)) 
overnight then excess stain was removed with a solution of 30% methanol and 10% acetic 
acid and imaged using a Canon Canoscan 8800F scanner. Each sample lane was cut into 
16 (Z) or 12 (virion) slices which were processed with chemicals from Fisher-Scientific as 
follows. Each slice was rinsed with HPLC grade water then incubated with destain solution 
(50mM ammonium bicarbonate and 50% acetonitrile) for 30 minutes at 37oC. The destain 
solution was removed and the gel slices were dehydrated by incubating with 100% 
acetonitrile for 5 minutes twice. Samples were reduced with 25mM dithiothreitol in 50 mM 
ammonium bicarbonate for 30 minutes at 55oC then allowed to cool for 10 minutes at room 
temperature. The slices were partially dehydrated by incubating with 100% acetonitrile for 
5 minutes then were alkylated with 10 mM iodoacetamide in 50mM ammonium 
biocarbonate for 45 minutes in the dark at room temperature.  The samples were washed 
two times by incubating with destain solution for 5 minutes, dehydrating with 100% 
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acetonitrile, then rehydrating with water for 10 minutes. Gel slices were then completely 
dehydrated by incubating two times with 100% acetonitrile for 5 minutes and dried at room 
temperature. The gel slices were rehydrated with a solution of 12.5 ng/μL sequencing grade 
modified trypsin (Promega) in 50 mM ammonium bicarbonate on ice for 30 minutes then 
were digested overnight at 37oC. Peptides were extracted with a solution of 2.5% formic 
acid in 50% acetonitrile while spinning in a microcentrifuge at 13,000 rpm for 10 minutes. 
The supernatant was collected and the gel slices were dehydrated by twice incubating with 
100% acetonitrile and collecting the extract. All solvent was removed from the extracts 
using a vacuum centrifuge at 37oC. The peptides were resuspended in 2.5% acetonitrile 
and 2.5% formic acid then separated in a microcapillary column packed with 12 cm Magic 
C18, 200 Å, 5 μm material (PM5/66100/00, Michrom Bioresources, Auburn, CA) using a 
MicroAS autosampler (Thermo Scientific, Pittsburgh, PA). Peptides were eluted with a 
5−35% acetonitrile (0.15% formic acid) gradient using a Surveyor Pump Plus HPLC 
(Thermo Scientific) over 40 minutes, after a 15 minute isocratic loading at 2.5% 
acetonitrile and 0.15% formic acid. Mass spectra were acquired in an LTQ-XL linear ion 
trap mass spectrometer (Thermo Scientific) using 10 MS/MS scans following each survey 
scan over the entire run. The human IPI forward and reverse concatenated databases were 
referenced with SEQUEST software requiring tryptic peptide matches with a 2 Da mass 
tolerance to analyze the raw data. For spectral analysis, the following precursor mass 
differences were allowed: serine, threonine, and tyrosine residues (+79.96633 Da); 
methionine (+15.99492 Da) and cysteines (+57.02146 Da or 71.0371). Proteins identified 
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in the database were further filtered by excluding peptides with XCorr scores less than 2.0 
and proteins with only one unique peptide sequence identified. Proteins that were identified 
in both the Z protein or JUNV C#1 infected conditions were excluded if they were also 
identified in the empty vector or mock infected controls unless there were at least 5-fold 
more unique peptide sequences identified in the Z protein or JUNV C#1 infected 
conditions. 
SDS-PAGE and Western Blotting 
Protein samples diluted in Laemmli buffer with 5% 2-mercaptoethanol were 
subjected to polyacrylamide gel electrophoresis on NuPAGE 4-12% Bis-Tris gels with 
MES buffer. Western blotting was carried out using nitrocellulose iBlot gel transfer stacks 
(IB301001, Invitrogen) and the Invitrogen iBlot transfer apparatus. Protein transfer was 
confirmed by staining membranes with a solution containing 0.1% Ponceau S (P3504, 
Sigma-Aldrich) and 5% acetic acid which was subsequently removed by washing with 
water. Membranes were blocked for 1 hr using PBS containing 5% non-fat milk 
(fluorescent detection) or 5% non-fat milk, 0.05% IGEPAL CA-630 (198596, MP 
Biomedicals, Solon, OH) in PBS (chemiluminescent detection). Primary antibodies were 
diluted in PBS containing 5% non-fat milk and 0.2% Tween 20 (Fisher-Scientific) 
(fluorescent detection) or in 5% non-fat milk, 0.05% IGEPAL CA-630, and 3% fetal 
bovine serum (chemiluminescent detection) and were incubated overnight at room 
temperature. The membranes were washed 5 times for 5 minutes with western wash 
solution (0.05% IGEPAL CA-630 (198596, MP Biomedicals, Solon, OH) in PBS) then 
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incubated with secondary antibodies diluted in PBS containing 5% milk, 0.2% Tween 20 
(BP337, Fisher-Scientific) and 0.02% sodium dodecyl sulfate for 1 hr at room temperature 
(fluorescent detection) or diluted in 5% non-fat milk, 0.05% IGEPAL CA-630, and 3% 
fetal bovine serum (chemiluminescent detection) and incubated for 2 hr. The membranes 
were then washed 5 times for 5 minutes with western wash buffer. For fluorescent 
detection, the membranes were washed one time for 5 minutes with PBS then imaged using 
a Licor Odyssey CLx imaging system. For fluorescent detection of actin, LCMV or JUNV 
NP, and green fluorescent protein (GFP)-tagged VPS4A and VPS4B, the iBind Flex 
western device (SLF2000, Thermo Scientific) and the corresponding iBind fluorescent 
detection solution (SLF2019, Thermo Scientific) was used. For chemiluminescent 
detection, membranes were developed using chemiluminescent substrate (SuperSignal 
West Pico (34080) or Femto (34096), Thermo Scientific) and detected with film. 
The following primary antibodies (at the indicated concentrations) were used for 
western blotting: mouse anti-β-actin (A5441, Sigma-Aldrich) (1:2,500) rabbit anti-actin 
(A2066; Sigma-Aldrich) (1:2,500), mouse anti-ADP ribosylation factor 1 (ARF1) (MA4-
060, Thermo Scientific) (1:1,000), mouse anti-ATP5B (sc-166443, Santa Cruz 
Biotechnology, Dallas, TX) (1:100), anti-ATP6V0D1 (sc-818877, Santa Cruz 
Biotechnology) (1:500), mouse anti-green fluorescent protein (GFP) (632380, Clontech, 
Mountain View, CA) (1:1,000), rabbit anti-inosine monophosphate dehydrogenase 2 
(IMPDH2) (ab131158, Abcam, Cambridge, MA), rabbit anti-LCMV nucleoprotein (2165) 
(1:5,000), mouse anti-JUNV glycoprotein 1 (NR-2564, BEI Resources, Manassas, VA) 
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(1:250), mouse anti-JUNV nucleoprotein (NR-2582, BEI Resources) (1:200), rabbit anti-
JUNV Z protein (1:1,000), mouse anti-peroxiredoxin 3 (PRDX3) (LF-MA0044, 
AbFrontier, Seoul, Korea) (1:1,000), mouse anti-Rab5c (sc-365667, Santa Cruz 
Biotechnology) (1:500), and anti-streptavidin binding peptide (SBP) (MAB10764; EMD 
Millipore, Billerica, MA) (1:10,000). LCMV nucleoprotein antibody, 2165, was 
generously provided by M. J. Buchmeier (University of California, Irvine). The following 
secondary antibodies (at the indicated concentrations) were used for western blotting: goat 
anti-mouse IRDye 680LT (926–68020, LI-COR) (1,20,000), goat anti-rabbit IRDye 
800CW (926–32211) (1:20,000), goat anti-mouse horse radish peroxidase (HRP) (71045, 
EMD Millipore) (1,5,000), goat anti-mouse IgG Fcγ-specific HRP (115-035-164, Jackson 
Immunoresearch Laboratories, West Grove, PA) (1:50,000), goat anti-mouse light chain-
specific HRP (AP200P, EMD Millipore), and goat anti-rabbit HRP (111-035-045, Jackson 
Immunoresearch Laboratories). 
RNA Interference Virus Challenges 
For RNA interference experiments, 1.2uL of RNAiMax (13778075, Life 
Technologies) and a 10 nM final concentration of Silencer Select silencing (si)RNA 
(4390824, Life Technologies) targeting ARF1 (s1551), ATP5B (s1774), ATP6V0D1 
(s17395), IMPDH2 (s7416), PRDX3 (s21509), or Rab5c (s11710) or a non-targeting 
control siRNA (4390843) in OptiMEM (31985070, Thermo Fisher Scientific) was added 
to each well of a 12 well plate and then combined with 40,000 A549 cells per well in 
normal growth media. 48 hr after reverse transfection, the cells were infected with JUNV 
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C#1 at a multiplicity of infection (MOI) of 0.1 PFU/cell or with LCMV Arm at an MOI of 
0.001 PFU/cell. One hour later, the virus inoculum was removed and fresh media was 
added. 48 hr after infection, the virus-containing supernatant and the cells were collected. 
Viral titers were determined by standard plaque assay and values with each independent 
experiment were normalized to the sum of all the values within each experiment 
(normalization by summation), then each value was normalized to the mean of the WT 
values and the mean of the WT was set to 100 % as described in (Degasperi et al., 2014). 
Host protein knockdown as well as viral nucleoprotein and cellular actin levels were 
determine by western blotting. 
Virus Challenges in VPS4A- and VPS4B- Transduced Cells 
VPS4A or VPS4B WT or dominant negative (EQ) T-rex HEK293 cells were used 
to assess the dependency of JUNV C#1 on the ESCRT pathway for infectious virus release. 
For these experiments, 2.5 x 105 cells were seeded in poly D-lysine-treated 6-well plates 
then were infected 24 hr later with JUNV C#1 at an MOI of 0.1 PFU/cell or with LCMV 
Arm at an MOI of 0.001 PFU/cell. 48 hr after infection when all cells were productively 
infected, expression of transduced VPS4A or VPS4B was induced with 1 µg/mL 
tetracycline or medium only as a control. 5 hr later, the cells were washed with PBS then 
fresh media containing 1 µg/mL tetracycline or medium alone was added. 15 hr later the 
cells and virus-containing supernatants were collected. Infectious virus titers were 
determined via plaque assay and expression of exogenous GFP-tagged VPS4A or VPS4B 




GraphPad Prism software was used to perform a one-way ANOVA with Holm-
Sidak’s test for multiple comparisons to analyze the viral titers in the siRNA challenge 
experiment in Figures 4.4C and D as well as the VPS4A and VPS4B challenges in Figures 




Affinity Purification-Mass Spectrometry Identification of Z-Host Protein-Protein 
Interactions and Cellular Proteins in JUNV C#1 Virions.  
 
Figure 4.1. Identification of Z-host protein-protein interactions and cellular proteins in JUNV C#1 
virions. (A) Flowchart of experimental strategy for mass spectrometry-based identification of host protein 
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partners of JUNV Z and host proteins in virions. (B and C) Coomassie stained SDS-PAGE gels of Z co-
purified with its host protein partners or immunoprecipitated JUNV C#1 virions were subjected to mass 
spectrometry-based proteomic analysis. (B) SBP-tagged Z and co-purifying host proteins were purified from 
transfected HEK293T cells or virus-like particles (VLPs) produced from transfected cells. An empty vector-
transfected condition was used as a control. (C) JUNV C#1 virions produced in HEK293T cells and 
immunoprecipitated with an antibody specific to the surface glycoprotein (GP1). Control conditions included 
both immunoprecipitation of virus-containing supernatants with a non-specific mouse IgG antibody and 
uninfected (mock) supernatants with the GP1 antibody. The molecular weight in kDa and viral proteins are 
indicated. Each gel is representative of two independent experiments. (D) Venn diagram indicating the 
number of host proteins identified in JUNV C#1 virions, interacting with Z in cells or in VLPs as well as 
those proteins conserved across the different conditions. The represented proteins include those that were 
identified in both replicate experiments and do not include proteins found in control conditions according to 
the criteria described in the Material and Methods. 
 
To identify host protein binding partners of the JUNV Z protein, HEK293T cells 
were transfected with a streptavidin binding peptide (SBP)-tagged Z protein, which was 
then affinity purified with streptavidin beads from whole cell lysates and from clarified Z 
VLP-containing cell culture media (Figure 4.1A). The protein samples containing Z and 
its co-purifying host binding partners were first separated by gel electrophoresis then 
analyzed by liquid chromatography-mass spectrometry (Figure 4.1B). Cells transfected 
with empty vector were used as a control to eliminate any proteins that bound non-
specifically to the streptavidin beads (Figure 4.1B). From two replicate experiments, a total 
of 163 host proteins were identified from cell lysates of which 70 proteins (43%) were 
conserved between the two replicate experiments. A total of 517 host proteins were 
identified in Z VLPs of which 161 (31%) were found in both replicate experiments.  
To identify the host protein content in bona fide JUNV C#1 virions, a surface 
glycoprotein-specific antibody (GP1) was used to immunoprecipitate virions which were 
subjected to protein gel electrophoresis and in-gel tryptic digestion, followed by mass 
spectrometry analysis (Figure 4.1A). Two different control conditions were used to 
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eliminate non-specifically binding host proteins: an uninfected (mock) condition 
immunoprecipatated with the same GP1 antibody as well as an infected condition where a 
non-specific immunoglobulin control antibody was used (Figure 4.1C). A total of 179 host 
proteins were identified in JUNV virions and 113 (63%) were conserved across two 
replicate experiments. Overall, there was a relatively high degree of overlap in host protein 
content between Z VLPs and JUNV virions (64% of proteins found in Z VLPs were also 
found in virions) (Figure 4.1D). However, the host protein content of Z VLPs and JUNV 
C#1 virions was largely different than intracellular Z’s host protein partners (Figure 4.1D). 
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Host Protein Partners of Z.  
 
Ribosomal Proteins (41.2) 
RPL10A, RPL11, RPL12, RPL13, RPL13A, 
RPL13P12, RPL18, RPL18A, RPL19, RPL21, 
RPL21P16, RPL21P19, RPL23, RPL28, RPL3, 
RPL30, RPL36, RPL38, RPL4, RPL5, RPL6, 
RPL7, RPL7A, RPL7P32, RPL8, RPL9, RPLP0,
RPLP1, RPLP2, RPS10, RPS11, RPS14, 
RPS15A, RPS16, RPS17, RPS18, RPS19, RPS2,
RPS21, RPS24, RPS27, RPS3, RPS3A, RPS4X, 
RPS5, RPS6, RPS8, RPS9 
Nucleotide Binding/Chaperone/Stress 
Response (15.4) 
ABCE1, ACTBL2, CCT2, CCT3, CCT4, 
CCT5, CCT6A, CKB, HSP90AB1, HSPA1A, 
HSPA1B, HSPA1L, HSPA4, HSPA5, HSPA8, 
HYOU1, LARS, MYO1D, TCP1 
ESCRT Complex (12.5) 
CHMP2A, CHMP2B, CHMP4B, 
CHMP5, MVB125A, MVB125B, 
VPS25, VPS28, VPS37B 
ATP Binding (11.3) 
ACTBL2, ASCC3, CCT3, CCT6A, 
DDX3X, DDX6, DYNC1H1, EIF4A1, 
G3BP1, MOV10, PRIC285, SNORA67 
Microtubule Cytoskeleton (8.6) 
TBCA, TCP1, TUBA4A, TUBB2C 
Ras Superfamily (7.7) 
ARF1, ARF6, EEF2, EHD1, NRAS, RAB13, 
RAB1A, RAB2A, RAB35, RAB5B, RAB5C, 
RAB7A, RAB8A, RALB, RAP1B, RRAS2 
Histone Proteins (5.5) 
H2AFV, HIST1H1C, HIST1H4A, HIST1H4B, 
HIST1H4C, HIST1H4D, HIST1H4E, 
HIST1H4F, HIST1H4H, HIST1H4I, HIST1H4J,
HIST1H4K, HIST1H4L, HIST2H2BE, 
HIST2H4A, HIST2H4B, HIST4H4 
Plasma Membrane-Associated Cytoskeletal 
Proteins (5.5) 
CTNNA1, EZR, FERMT2, MSN, RDX, TLN1
Axonogenesis (1.9) 
CTNNA1, EZR, FERMT2, MSN, RDX, TLN1
Transmembrane Glycoproteins (1.8) 
ALCAM, BSG, CD99, CXADR, EFNB2, 
IGSF3, IGSF8, MFAP3, PTGFRN 
Ribosomal Proteins (20.2) 
HEATR1, RPL10A, RPL11, RPL13A, RPL18, 
RPL3, RPL4, RPL6, RPL7, RPLP0, RPS2, 
RPS3A, RPS4X, RPS6, RPS8, RPS9, RPSAP12
Nucleotide Binding/Chaperone/Stress 
Response (19.3) 
ACTA2, ACTBL2, CCT2, CCT3, CCT4, 
CCT5, CCT6A, CCT7, CCT8, CKB, DDX3X, 
HSP90AA1, HSP90AA2, HSP90AB1, 
HSPA1A, HSPA1B, HSPA8, HSPA9, LARS, 
MARS, MCM7, RUVBL2, TCP1 
Translation Factors (13.7) 
EEF1A1, EEF1A2, EEF2, EFTUD2, TUFM 
tRNA Synthetase (10.9) 
AARS, EPRS, GARS, LARS, MARS 
Microtubule Cytoskeleton (9.2) 
TCP1, TUBA1C, TUBA4A, TUBB, 
TUBB1, TUBB2C 
Proteasomal Process (8.9) 
CDK1, PSMC3, PSMC5, PSMC6, 
PSMD10, PSMD12, PSMD2, PSMD6, 
PSMD7, PSMD8, RPS27A, UBB, UBC 
mRNA Processing (8.7) 
EFTUD2, HNRNPK, HNRNPM, HNRNPU, 
PCBP1, PCBP2, SFRS1 
Ras Superfamily (6.6) 
ARF1, RAB10, RAB1A, RAB7A 
Nuclear Import/Export (5.5) 
IPO4, IPO5, IPO7, KPNA2, KPNB1, XPO1 
 
 
Mitochondrial Membrane (9.3) 
CHCHD3, IMMT, MTCH2, PHB, PHB2, 
SLC25A6, STOML2, TIMM50, TOMM40, 
VDAC1, VDAC2, VDAC3 
Nuclear Import/Export (6.4) 
CSE1L, IPO5, IPO7, KPNB1, NUP205, 
TNPO1, XPO1, XPO5, XPOT 
Nucleotide Binding/Chaperone (4.5) 
ATAD3A, CCT4, CCT5, 
CCT6A, CLPB, HYOU1 
ATPase/ATP Synthase (3.4) 





Table 4.1. Major protein classes represented in Z protein and virion interactome. Generated using NIH 
DAVID Gene Functional Classification analysis using the medium stringency setting. The gene functional 
classification tool in DAVID version 6.7 was used to categorize all protein identified in JUNV C#1 virions 
or as binding partners of intracellular JUNV Z or JUNV Z in virus-like particles. A description of the gene 
functional class and the DAVID enrichment score are listed. 
 
A total of 416 host proteins were identified as binding partners of Z in host cells 
or in VLPs, as components of virions or were found in more than one of these conditions. 
DAVID version 6.7 functional gene classification tool (Huang et al., 2008, 2009) was used 
to categorize functionally related proteins that were over-represented in each of these 
conditions (Table 4.1). Ribosomal proteins were the most highly represented protein class 
in both virions and Z VLPs. This finding was not unexpected, as arenaviruses are named 
for the Latin word, arenosus, meaning “sandy,” for the electron dense granules observed 
in virions presumed to be ribosomes (Rowe et al., 1970). The next most highly represented 
protein class included nucleotide binding proteins and chaperone proteins (Table 4.1). 
Several of these proteins interacted with Z in cells and VLPs and were found in virions 
which may indicate that Z recruits these proteins into virions. Additionally, several nuclear 
import or export factors were over represented in VLPs as well as cells, which raises 
questions about whether Z executes any functions in the nucleus. Both the ESCRT complex 
and the Ras superfamily, both involved in intracellular vesicular trafficking, were enriched 
in virions as well (Table 4.1). It should be noted that the ESCRT complex proteins 
CHMP1A and TSG101 as well as the ESCRT accessory protein, PDCD6IP (also known 
as ALIX), were identified in this study (Figure 4.2 and Table 4.S1) despite not being 
included in the ESCRT complex protein class generated by DAVID. Additionally, 
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intracellular Z interacted with several ATP synthases and ATPases as well as several 
mitochondrial membrane proteins (Table 4.1). Finally, nearly the entire human 
peroxiredoxin family was represented in this study, primarily in Z VLPs (Figure 4.2 and 
Table 4.S1), despite not being identified using the medium stringency settings in the 




Figure 4.2. JUNV Z-host and JUNV C#1 virion host protein interactome network. Virus-host protein 
interaction network generated using Cytoscape 3.3.0 software. All host proteins identified in both replicate 
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experiments for each condition are represented by rectangles and lines indicate host protein interactions with 
each viral condition (circular nodes). Host proteins selected for further analysis in this study are highlighted 
in yellow. 
 
Confirmation of select host protein partners. 
 
Table 4.2. Host proteins selected for further analysis. Six host proteins identified in different 
representative conditions or multiple conditions were selected for western blot confirmation and functional 
studies. The official gene symbol, Entrez gene ID, gene description and mass spectrometry condition(s) 
identified in are indicated. Additionally, whether each protein was identified as a component of virions from 
other virus families in other proteomics studies as well as whether each host protein was a required factor for 
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Figure 4.3. Western blot confirmation of select JUNV-host protein partners. (A) Plasmids expressing 
SBP-tagged Z protein of representative Old World arenaviruses, lymphocyctic choriomeningitis virus 
(LCMV) and Lassa virus (LASV), and JUNV were transfected into HEK293T cells and two days later cells 
as well as VLPs produced from transfected cells were lysed and Z and its host protein partners were co-
purified with streptavidin beads. The proteins were separated by SDS-PAGE and the indicated host proteins 
and Z were detected by western blot using antibodies specific to each host protein or an antibody to Z’s SBP 
affinity tag. (B) JUNV C#1 virions produced in HEK293T cells were immunoprecipitated using a GP1-
specific antibody then subjected to SDS-PAGE followed by western blot detection of the host protein ARF1 
as well viral GP1, nucleoprotein and Z protein using protein specific antibodies. All proteins were detected 
with horse radish peroxidase-conjugated secondary antibodies and chemiluminenscent-based detection with 
standard film. All western blots are representative of at least 2 independent experiments. 
 
A subset of these host protein partners were selected for further characterization 
(Table 4.2). To confirm these interactions with the Z protein of JUNV and see if the 
interactions extended to the Old World arenaviruses, LCMV or LASV, western blot 
analysis of individually affinity purified Z proteins in complex with host proteins was 
performed using host protein-specific antibodies (Figure 4.3A). Western blot detection 
largely recapitulated the mass spectrometry based detection, but afforded greater sensitivity 
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for certain proteins. ATP5B and IMPDH2, which were only detected in VLPs by mass 
spectrometry, also interacted with intracellular Z of all three representative arenaviruses 
(Figure 4.3A). Mass spectrometry, despite its ability to identify proteins in a high 
throughput manner, may fail to consistently detect proteins in complex samples. For 
example, a total of 15 Rab family proteins were identified as JUNV Z protein partners or 
in JUNV C#1 virions in at least one replicate mass spectrometry experiment (Table 4.S1), 
yet only three of the Rab proteins (Rab1a, Rab7a, and Rab10) met the most stringent cutoff 
for Z protein partners. Additionally, Rab5c, which was only detected in JUNV C#1 virions 
by mass spectrometry, also interacted with LASV and JUNV intracellular Z as well as Z 
in VLPs for all three viruses. Thus, some of the host proteins identified in only one or two 
of the conditions may not actually be exclusive to that condition. However, interaction of 
JUNV Z (or LASV or LCMV Z) with ATP6V0D1 was not detectable in VLPs despite 
interacting particularly strongly with LASV and LCMV Z in cells (Figure 4.3A). An 
interaction of PRDX3 with intracellular Z was similarly undetectable for all three viruses 
despite a strong interaction with JUNV Z in VLPs (Figure 4.3A). Finally, ARF1 was 
confirmed as a component of JUNV C#1 virions by western blotting (Figure 4.3B). 
Confirmation of additional host protein content in JUNV C#1 virions from the selected 
panel by western blotting was obscured by signal from the heavy and light chain of the 
antibody used to immunoprecipitate virions. Largely, these data suggest that the Z protein 
of disparate arenaviruses engage a common core of host machinery to accomplish certain 
functions in addition to host factors engaged by specific viral Z proteins. 
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Screening for functional importance of select host proteins.  
 
Figure 4.4. Functional siRNA screen of select JUNV-host protein partners. (A-D) A functional screen 
using silencing (si)RNAs was performed with JUNV C#1 virus as well as the prototypic Old World 
arenavirus, LCMV. Human lung carcinoma (A549) cells were reversed transfected with siRNAs then two 
days later infected with JUNV C#1 or LCMV Armstrong 53B (Arm) and two days later cells and the virus-
containing media were collected. (A) Cell lysates were probed for JUNV C#1 or LCMV Arm nucleoprotein 
(NP) and cellular actin by western blotting using fluorescent detection. (B) Silencing of protein expression 
was confirmed by western blot using lysates from cells transfected with gene specific siRNA (siTARGET) 
or a non-targeting siRNA (siNEG). (C) JUNV C#1 or (D) LCMV Arm infectious titers were measured by 
standard plaque assay are shown as a percentage of the titer of the non-targeting control siRNA condition. 
Western blots are representative of 3 independent experiments and infectious titers represent the mean ± 
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SEM of 3 independent experiments. Mean values were compared with a one-way ANOVA with Holm-
Sidak’s test for multiple comparisons where *p < 0.05 and ***p < 0.001 for (C-D). 
 
In order determine whether any of the proteins identified in the mass spectrometry 
study were functionally required for infectious Junín virus production, silencing (si)RNAs 
were used to knockdown expression of the selected host proteins. Silencing of the selected 
genes did not significantly decrease cellular actin levels indicating that cellular growth and 
overall health were not impacted (Figure 4.4A). Silencing of each gene was confirmed by 
western blotting (Figure 4.4B). Protein expression levels of IMPDH2, PRDX3 and Rab5c 
were below the limit of detection with gene-specific siRNA (siTARGET) (Fig 4B). 
Expression of ARF1, ATP5B and ATP6V0D1 were substantially reduced with gene-
specific siRNA, but low levels of each were detected (Figure 4.4B). 
Protein selection downstream of the mass spectrometry study was partly informed 
by a literature search for host proteins required for the propagation of other viruses. 
However, mapping of the Z proteome first was an effective means of prioritizing targets 
for functional screening. Using this approach, 5 of the 6 selected Z protein partners had a 
statistically significant impact on JUNV production. Infectious titers of JUNV were 
decreased by greater than 80% with loss of ATP5B and IMPDH2 expression (P < 0.001; 
Figure 4.4C). Viral nucleoprotein (NP) expression was also substantially decreased in 
infected cells transfected with ATP5B or IMPDH2 siRNAs which indicates that spread of 
JUNV throughout the culture was impacted, expression of the NP in infected cells was 
reduced or a combination of the two (Figure 4.4A). JUNV C#1 infectious titers were also 
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reduced ~50% with loss of ARF1, ATP6V0D1 and PRDX3 expression (p < 0.05; Figure 
4.4C). Loss of Rab5c, however, had no impact on Junín virus production (Figure 4.4C).  
This study was also extended to include the Old World arenavirus, LCMV, to 
allow identification of host factors utilized across the arenavirus family which could serve 
as potential broad spectrum antiviral targets. Levels of infectious LCMV were reduced to 
similar levels as observed for JUNV with loss of ATP5B and IMPDH2 (21% and 27%, 
respectively) (p < 0.001; Figure 4.4D). Infectious titers of LCMV in cells transfected with 
ARF1 or ATP6V0D1 siRNAs were not reduced to statistically significant levels (p value 
0.13 and 0.11, respectively). Interestingly, there was specificity among the selected host 
proteins. Knockdown of PRDX3, which reduced JUNV titers ~50 %, had no impact on 
LCMV (Figures 4.4C and D) and Rab5c silencing did not impact Junín virus production, 
but LCMV titers were reduced 63 % (p < 0.001; Figure 4.4D). As several Rab family 
proteins were identified in JUNV Z VLPs and/or JUNV C#1 virions it will be important to 
understand the broader role this protein family plays in the arenavirus life cycle. 
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Testing for ESCRT complex dependency.  
 
Figure 4.5. Efficient release of infectious JUNV virus particles requires the ESCRT pathway. (A-B) 
HEK293 T-Rex cells stably expressing tetracycline-induced, GFP-tagged WT or DN mutant (EQ) vacuolar 
protein sorting 4A or 4B (VPS4A or VPS4B) were infected with (A) JUNV C#1 at an multiplicity of infection 
(MOI) of 0.1 PFU/cell or (B) rLCMV WT at an MOI of 0.001 PFU/cell. 48 hr post-infection (pi) the cells 
were treated with tetracycline to induce expression of VPS4A/B WT or DN. 5 hr after induction (53 hr pi) 
the cells were washed and fresh tetracycline-containing media was added. The supernatants and cells were 
collected 68 hr pi and virus titers were determined via plaque assay and an anti-GFP antibody was used to 
measure GFP-tagged VPS4A/B expression, anti- (A) JUNV NP or (B) LCMV NP antibodies were used to 
measure global viral protein expression and actin was probed for as a loading control. Western blots are 
representative of 3 independent experiments and infectious titers represent the mean ± SEM of 3 independent 
experiments. Mean values were compared with a one-way ANOVA with Holm-Sidak’s test for multiple 
comparisons. (A-B), n.s. (not significant), **p < 0.01. 
 
In total, 14 ESCRT complex or ESCRT-associated proteins were identified in at 
least one experimental condition in Z VLPs or JUNV C#1 virions (Figure 4.2, Table 4.1 
and Table 4.S1). The overall contribution of the ESCRT for New World arenavirus 
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production has not been previously assessed in the context of infection. In order to test the 
dependency of JUNV infectious virus production on the ESCRT pathway, cell lines stably 
transduced with WT or dominant negative (EQ) versions of the ESCRT accessory protein 
VPS4A or VPS4B were infected with JUNV or as a control, LCMV. In order to avoid 
measuring an impact of ESCRT inhibition on viral entry, expression of VPS4 was induced 
at a point when all of the cells in the culture were productively infected. This resulted in 
an 82 % decrease in JUNV infectious virus production in the VPS4A EQ cells (p value 
0.009) and an 80 % decrease in VPS4B EQ cells (p value 0.006) (Figure 4.5A). Release of 
infectious LCMV virions was not affected by VPS4A EQ or VPS4B EQ expression (p 
value 0.98 and 0.98, respectively) in alignment with previous results (Figure 4.5B) (Ziegler 




This study has for the first time comprehensively mapped the host protein network 
engaged by the JUNV matrix protein Z as well as the host proteins that Z or other JUNV 
proteins recruit into virus particles. As relatively few virus-host protein interactions have 
been identified for the JUNV Z protein or other arenavirus Z proteins, identification of 
these interactions is a critical first step in understanding the molecular networks employed 
by Z to carry out its various functions. While the initial proteomics screen focused on 
JUNV, these findings were also extended to the Old World arenavirus Z proteins of LCMV 
and LASV for select proteins. The Z-host protein-protein interactions were largely 
conserved across the disparate arenavirus Z proteins and this conservation in protein 
complexes was reflected in the overall impact on virus production assessed by siRNA 
screening for ATP5B and IMPDH2 (Figures 4.4C and D). The finding that IMPDH2, 
which catalyzes the rate limiting step in guanine nucleotide biosynthesis, was required for 
efficient JUNV and LCMV production fits with previous studies that demonstrated that 
depletion of the intracellular GTP pool by mycophenolic acid (MPA) or 5-ethynyl-1-β-D-
ribofuranosylimidazole-4-carboxamide (EICAR) treatment inhibits arenavirus production 
(Linero et al., 2012). Conversely, knockdown of PRDX3 and Rab5c had differential effects 
on JUNV versus LCMV production (Figures 4.4C and D) despite similar binding affinities 
(Figure 4.3A) which highlights the fact that these viruses utilize host machinery in both 
conserved and distinct ways. While the mechanism by which the PRDX3 contributes to the 
production of JUNV, some of the other proteins selected in this study have more obvious 
potential contributions to the arenavirus lifecycle. 
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ATP6V0D1 is a component of the vacuolar ATPase complex that is responsible 
for the acidification of endosomes and is an important factor in the life cycle of several 
RNA viruses (Table 4.2) (Forgac, 2007; Hao et al., 2008; Karlas et al., 2010; Konig et al., 
2010; Krishnan et al., 2008; Le Sommer et al., 2012; Panda et al., 2011; Sessions et al., 
2009). ATP6V0D1 knockdown resulted in a 46 % reduction in JUNV titer (p value 0.017) 
(Figure 4.4C) but only a 29 % reduction in LCMV titer (p value 0.11) (Figure 4.4D). While 
the reduction in LCMV titer was not statistically significant, ATP6V0D1 has been 
implicated in LCMV production previously (Panda et al., 2011). These data are also 
supported by other studies which showed that arenavirus entry is sensitive to bafilomycin 
treatment, which targets the vacuolar ATPase complex (Castilla et al., 2001; Cosset et al., 
2009; Forgac, 2007). While it is clear that inhibiting the vacuolar ATPase complex impacts 
viral entry for disparate viruses, whether there is a functional role for interaction of 
intracellular Z with ATP6V0D1 remains unclear. Additionally, ATP6V0D1 was not 
detected in Z VLPs or virions which suggests that the interaction with Z could be important 
for a step in the life cycle prior to assembly and budding. 
Several vesicular trafficking proteins including members of the Ras superfamily 
were enriched in Z VLPs and/or JUNV virions (Table 4.1). Representative proteins from 
this superfamily, ARF1 and Rab5c, were selected for functional siRNA screening (Fig 4C 
and D). While there was a significant reduction in JUNV titer with ARF1 depletion, LCMV 
titers were not reduced to the same extent (Fig 4C and D). ARF1, however, was identified 
as a required host factor for LCMV in a larger scale siRNA screen and thus ARF1 may be 
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broadly important for arenavirus infection (Panda et al., 2011). The mechanism for ARF1’s 
impact on arenavirus production is unknown but several possibilities exist. As a regulator 
of intracellular traffic, ARF1 is required for human immunodeficiency virus 1 (HIV-1) Gag 
trafficking to the plasma membrane and ARF1 disruption results in decreased HIV-1 
assembly and release (Joshi et al.). Thus, ARF1 could be important for trafficking of Z 
and/or other viral proteins to sites of virus assembly. ARF1 is also an important factor in 
the secretory pathway and regulates cargo release from the ER-Golgi intermediate 
compartment (ERGIC) (Donaldson and Jackson, 2011). Our lab has recently shown that a 
key component of the ERGIC, ERGIC-53 (LMAN1), is a component of JUNV virions and 
is a critical regulator of the infectivity of those virions (Klaus et al.). This raises the 
possibility that trafficking of ERGIC-53 into virions may be disrupted by ARF1 depletion. 
Additionally, trafficking of the mature viral glycoprotein into nascent virions could also be 
disrupted by ARF1 depletion as arenavirus glycoproteins undergo processing in the 
endoplasmic reticulum and Golgi apparatus (Lenz et al., 2001; Wright et al., 1990). Future 
work needs to investigate the mechanism by which ARF1 and the other ARF family 
proteins identified in this study contribute to arenavirus infection. 
A preponderance of Rab family proteins were identified in Z VLPs and JUNV 
virions. Rab family GTPases are key mediators of intracellular vesicular trafficking and 
are exploited by a wide variety of viruses (Alenquer and Amorim, 2015; Bruce et al., 2012; 
Stenmark, 2009). In the case of arenaviruses, Rab5 has been implicated in JUNV and 
LASV entry, while Rab7 is required for efficient JUNV but not LASV entry (JM et al., 
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2008; Martinez et al., 2009). The presence of Rab proteins in virions, however, suggests 
some of these Rab proteins may have a role in late steps of the virus life cycle (i.e. assembly 
and budding). Accordingly, Rab11 has been implicated in the assembly and budding of 
several viruses including influenza A virus (Bruce et al., 2010; Bruce et al., 2012). While 
the work here revealed that LCMV, but not JUNV infection, depended on Rab5c, the over-
representation of this family of proteins suggests a functional role and that disparate 
arenaviruses may engage this host machinery in distinct ways. Finally, as the Z protein is 
a key mediator of virus assembly (Fehling et al., 2012), the interactions of Z with key Rab 
proteins may be critical for delivery of cargo into virions. 
The Z matrix protein is required for budding and release of virus particles at the 
plasma membrane, a process thought to be driven largely by recruitment of ESCRT 
complexes (Perez et al., 2003; Strecker et al., 2003; Urata et al., 2006). In this study, we 
identified representative proteins in Z VLPs and JUNV C#1 virions of ESCRT-I 
(MVB12A/B, TSG101, VPS28 and VPS37B/C), ESCRT-II (VPS25), ESCRT-III 
(CHMP1A, CHMP2A/B, CHMP4, and CHMP5) and ESCRT accessory proteins (VPS4B 
and PDCD6IP (ALIX)) but not ESCRT-0 (Figure 4.2, Table 4.1 and Table 4.S1) (Schmidt 
and Teis). This fits the model whereby the PTAP-containing JUNV Z protein recruits 
ESCRT-I by direct binding to TSG101 which then recruits ESCRT-II, ESCRT–III, and 
finally VPS4A/B to drive virus release (Votteler and Sundquist, 2013). Accordingly, 
ESCRT proteins, including the ESCRT-I proteins TSG101 and VPS28, have been 
identified in virions of other viruses containing the P(T/S)AP late domain including Ebola 
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virus and HIV-1 presumably because these proteins are present at the final stages of virus 
release (Cantin et al., 2005; Spurgers et al., 2010). Finally, the ATPase VPS4, which is 
required for ESCRT complex disassembly, was found in JUNV virions previously in 
addition to in this study (Lu et al., 2014; Votteler and Sundquist, 2013). 
The ESCRT complex is presumed to function in arenavirus release, yet evidence 
for this model is limited primarily to VLP assays. Knockdown of the ESCRT-I protein 
TSG101 results in decreased VLP production for LCMV and LASV (Perez et al., 2003; 
Strecker et al., 2003). Perturbation of the ESCRT accessory protein VPS4 reduces VLP 
production for Tacaribe and LASV but not Lujo virus (Urata et al., 2006; Urata et al., 2016; 
Urata et al., 2009). Finally, our lab has recently shown that LCMV utilizes the ESCRT 
complex specifically for defective interfering particle production but not release of 
infectious virus (Ziegler et al., 2016b). This indicates that VLP assays, while useful, may 
not always faithfully recapitulate all the facets of infection. Accordingly, we assessed the 
dependency of JUNV C#1 release on the ESCRT complex using VPS4-expressing cell 
lines. Importantly, expression of either WT or dominant-negative (EQ) VPS4A/B was 
induced once all of the cells were productively infected in order to eliminate the potential 
impact ESCRT inhibition could have on virus entry, as Old World arenaviruses utilize the 
ESCRT complex during viral entry (Pasqual et al., 2011). Efficient release of JUNV C#1 
infectious virions did require a functional ESCRT pathway (Figure 4.5A) while release of 
infectious LCMV virions did not in concordance with our previous results (Figure 4.5B) 
(Ziegler et al., 2016b). The requirement of ESCRT for JUNV C#1 is also supported by 
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recent work which demonstrated that an inhibitor of the P(T/S)AP-TSG101 interaction 
reduced infectious JUNV production (Lu et al., 2014). Interestingly, the data presented 
here showed that depletion of ATP5B, which can function as an ATPase and can be plasma 
membrane localized, resulted in significantly reduced JUNV and LCMV titers (Figure 4.4C 
and D) (Gorai et al., 2012; Jonckheere et al., 2012). As the ATPase activity of ATP5B was 
recently shown to be an important factor in influenza A virus release and HIV-1 cell-to-
cell transfer, our findings here raise the possibility that the energetics of arenavirus release 
could also involve ATP5B (Gorai et al., 2012; Yavlovich et al., 2012). The precise role and 
overall impact of each ESCRT protein identified in this study on arenavirus release as well 
as the mechanism by which ATP5B contributes to virus production remains to be 
determined and is the subject of future study.   
In conclusion, we have provided a detailed map of the JUNV Z protein-host 
interactome for the first time, identified several critical host factors for JUNV infection. 
While the mechanism by which these host proteins function in the virus life cycle is not 
yet clear, this work represents a crucial step in understanding the protein networks 
employed by arenaviruses to drive the virus life cycle. Future studies will begin to address 
the mechanisms by which these host proteins contribute to Z protein functions. This study 
also highlights the important role the ESCRT pathway has in driving the efficient 
production of infectious JUNV virions. Finally, the insights provided by this work will also 
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A2M 2 alpha-2-macroglobulin IPI00478003 x
AARS 16 alanyl-tRNA synthetase IPI00027442 x x x
AARS2 57505 alanyl-tRNA synthetase like IPI00394788 x
ABCD3 5825








ATP-binding cassette, sub-family F (GCN20), 
member 1
IPI00013495.1 x
ACACA 31 acetyl-Coenzyme A carboxylase alpha IPI00011569 x
ACAD9 28976




acyl-Coenzyme A dehydrogenase, C-4 to C-12 
straight chain
IPI00005040 x x
ACLY 47 ATP citrate lyase IPI00021290 x x x x
ACTA2 59 actin, alpha 2, smooth muscle, aorta IPI00008603 x x x
ACTB 60 actin, beta IPI00021439 x x x x x
ACTBL2 345651 similar to RIKEN cDNA 4732495G21 gene IPI00003269 x x x x x
ACTN1 87 actinin, alpha 1 IPI00013508.5 x
ACTN4 81 actinin, alpha 4 IPI00013808.1 x x
ACYP1 97 acylphosphatase 1, erythrocyte (common) type IPI00221117.3 x
ADAM10 102 ADAM metallopeptidase domain 10 IPI00013897.1 x x
AFP 174 alpha-fetoprotein IPI00022443 x x
AGK 55750 multiple substrate lipid kinase IPI00019353 x
AGPS 8540 alkylglycerone phosphate synthase IPI00010349 x x
AGRN 375790 agrin IPI00374563.3 x x
AHCY 191 S-adenosylhomocysteine hydrolase IPI00012007 x x x
AIFM1 9131
programmed cell death 8 (apoptosis-inducing 
factor)
IPI00000690.1 x x
AIMP2 7965 JTV1 gene IPI00011916 x
AIP 9049 aryl hydrocarbon receptor interacting protein IPI00010460 x
AK1 203 adenylate kinase 1 IPI00018342 x
AK2 204 adenylate kinase 2 IPI00172460 x x x
ALCAM 214 activated leukocyte cell adhesion molecule IPI00015102.2 x x
ALDH18A1 5832 aldehyde dehydrogenase 18 family, member A1 IPI00008982 x x x
ALDH1B1 219 aldehyde dehydrogenase 1 family, member B1 IPI00103467 x x x x
ALDH2 217
aldehyde dehydrogenase 2 family 
(mitochondrial)
IPI00006663 x
ALDOA 226 aldolase A, fructose-bisphosphate IPI00465439.5 x x
ALG1 56052
asparagine-linked glycosylation 1 homolog 
(yeast, beta-1,4-mannosyltransferase)
IPI00549761 x
AMOT 154796 angiomotin IPI00163085 x x



















ANXA2P2 304 IPI00334627 x
ANXA5 308 annexin A5 IPI00329801 x x x
ANXA6 309 annexin A6 IPI00002459.4 x x
AP1B1 162
adaptor-related protein complex 1, beta 1 
subunit
IPI00328257 x x
APOB 338 apolipoprotein B (including Ag(x) antigen) IPI00022229 x x
APOE 348 apolipoprotein E IPI00021842 x x
APRT 353 adenine phosphoribosyltransferase IPI00218693 x x
ARF1 375 ADP-ribosylation factor 1 IPI00215914 x x x x
ARF4 378 ADP-ribosylation factor 4 IPI00215918 x x
ARF6 382 ADP-ribosylation factor 6 IPI00215920.8 x x
ARHGDIA 396 Rho GDP dissociation inhibitor (GDI) alpha IPI00003815.3 x x
ARPC3 10094




activating signal cointegrator 1 complex subunit 
3
IPI00430472 x x x
ATAD3A 55210 ATPase family, AAA domain containing 3A IPI00295992 x x x






ATPase, Na+/K+ transporting, alpha 1 
polypeptide
IPI00006482.1 x x x x
ATP1A2 477
















ATP synthase, H+ transporting, mitochondrial 
F1 complex, alpha subunit 1, cardiac muscle
IPI00440493 x x x
ATP5B 506
ATP synthase, H+ transporting, mitochondrial 
F1 complex, beta polypeptide
IPI00303476 x x x x
ATP5C1 509
ATP synthase, H+ transporting, mitochondrial 
F1 complex, gamma polypeptide 1
IPI00395769 x
ATP5O 539
ATP synthase, H+ transporting, mitochondrial 




ATPase, H+ transporting, lysosomal accessory 
protein 2
IPI00168884.3 x x
ATP6V0A1 535 IPI00743576 x
ATP6V0D1 9114




ATPase, H+ transporting, lysosomal 70kDa, 
V1 subunit A
IPI00007682 x




























ATPase, H+ transporting, lysosomal 31kDa, 
V1 subunit E1
IPI00003856 x
ATR 545 ataxia telangiectasia and Rad3 related IPI00412298 x
ATXN10 25814 ataxin 10 IPI00001636 x x
AURKB 9212 aurora kinase B IPI00176642 x x x
BAG2 9532 BCL2-associated athanogene 2 IPI00000643 x x x
BAG5 9529 BCL2-associated athanogene 5 IPI00007731.1 x
BANF1 8815 barrier to autointegration factor 1 IPI00026087 x x
BAT3 7917 HLA-B associated transcript 3 IPI00465128 x x
BCL2L12 83596 BCL2-like 12 (proline rich) IPI00019835 x
BCOR 54880 BCL6 co-repressor IPI00100291.1 x x
BIRC2 329 baculoviral IAP repeat-containing 2 IPI00013418 x
BSG 682 basigin (Ok blood group) IPI00019906.1 x x
BTF3 689 basic transcription factor 3 IPI00221035.4 x
BTF3L4 91408 basic transcription factor 3-like 4 IPI00412792.2 x
BZW1 9689 basic leucine zipper and W2 domains 1 IPI00180128.4 x
C11orf59 55004 hypothetical protein FLJ20625 IPI00016670 x
C14orf166 51637 chromosome 14 open reading frame 166 IPI00006980 x x
C1orf57 84284 chromosome 1 open reading frame 57 IPI00031570 x
C1orf58 148362 chromosome 1 open reading frame 58 IPI00065500.3 x x
C1QBP 708
complement component 1, q subcomponent 
binding protein
IPI00014230 x x
C22orf28 51493 hypothetical protein HSPC117 IPI00550689 x x
C3 718 IPI00783987 x x
C7orf20 51608 chromosome 7 open reading frame 20 IPI00419575 x
C8orf62 137133 phosphoserine aminotransferase 1 pseudogene IPI00001734.3 x
CA2 760 carbonic anhydrase II IPI00218414.5 x x
CACYBP 27101 calcyclin binding protein IPI00395627 x x
CAD 790
carbamoyl-phosphate synthetase 2, aspartate 
transcarbamylase, and dihydroorotase
IPI00301263 x x x
CALM1 801 IPI00075248 x x
CALM2 805 calmodulin 2 (phosphorylase kinase, delta) IPI00075248 x x
CALM3 808 IPI00075248 x x
CAMK2D 817
calcium/calmodulin-dependent protein kinase 
(CaM kinase) II delta
IPI00172636 x
CAND1 55832 cullin-associated and neddylation-dissociated 1 IPI00100160 x x
CAND2 23066 IPI00374208 x x
CANX 821 calnexin IPI00020984 x
CAPZA1 829
capping protein (actin filament) muscle Z-line, 
alpha 1
IPI00005969.3 x x
CBR1 873 carbonyl reductase 1 IPI00295386.7 x
CBS 875 cystathionine-beta-synthase IPI00219352.4 x



















CCDC124 115098 coiled-coil domain containing 124 IPI00060627.2 x x
CCDC72 51372 coiled-coil domain containing 72 IPI00006378.3 x
CCT2 10576 chaperonin containing TCP1, subunit 2 (beta) IPI00297779 x x x x
CCT3 7203
chaperonin containing TCP1, subunit 3 
(gamma)
IPI00290770 x x x x x
CCT4 10575 chaperonin containing TCP1, subunit 4 (delta) IPI00302927 x x x x x x
CCT5 22948
chaperonin containing TCP1, subunit 5 
(epsilon)
IPI00010720 x x x x x x
CCT6A 908
chaperonin containing TCP1, subunit 6A (zeta 
1)
IPI00027626 x x x x x x
CCT7 10574 chaperonin containing TCP1, subunit 7 (eta) IPI00018465 x x x x
CCT8 10694 chaperonin containing TCP1, subunit 8 (theta) IPI00302925 x x x x
CD2AP 23607 CD2-associated protein IPI00412771.1 x x
CD81 975 CD81 molecule IPI00000190.1 x
CD9 928 CD9 molecule IPI00215997.5 x x
CD99 4267 CD99 molecule IPI00253036.5 x x
CD99L2 83692 CD99 molecule-like 2 IPI00152488.1 x
CDC42SE2 56990 CDC42 small effector 2 IPI00024973.1 x
CDK1 983 cell division cycle 2, G1 to S and G2 to M IPI00026689 x x x x
CDK4 1019 cyclin-dependent kinase 4 IPI00007811 x
CECR5 27440
cat eye syndrome chromosome region, 
candidate 5
IPI00011511 x
CEP55 55165 centrosomal protein 55kDa IPI00101532 x x x




IPI00015833 x x x
CHMP1A 5119 chromatin modifying protein 1A IPI00382452.1 x x
CHMP2A 27243 chromatin modifying protein 2A IPI00004416.1 x x
CHMP2B 25978 chromatin modifying protein 2B IPI00550181.2 x x
CHMP4B 128866 chromatin modifying protein 4B IPI00025974 x x x x
CHMP5 51510 chromatin modifying protein 5 IPI00100796.4 x x
CKAP5 9793 cytoskeleton associated protein 5 IPI00028275 x x x
CKB 1152 creatine kinase, brain IPI00022977 x x x x
CKMT1A 548596 IPI00658109.1 x
CKMT1B 1159 creatine kinase, mitochondrial 1B IPI00658109.1 x
CLIC1 1192 chloride intracellular channel 1 IPI00010896 x x x
CLPB 81570




ClpX caseinolytic peptidase X homolog (E. 
coli)
IPI00008728 x
CLTC 1213 clathrin, heavy polypeptide (Hc) IPI00024067 x x
CLTCL1 8218 clathrin, heavy polypeptide-like 1 IPI00022881 x x
CNOT1 23019 CCR4-NOT transcription complex, subunit 1 IPI00166010 x x x
CNP 1267 2',3'-cyclic nucleotide 3' phosphodiesterase IPI00220993 x x
COL18A1 80781 collagen, type XVIII, alpha 1 IPI00022822.5 x x
COL6A1 1291 collagen, type VI, alpha 1 IPI00291136 x x
COPA 1314 coatomer protein complex, subunit alpha IPI00295857 x



















COPB1 1315 coatomer protein complex, subunit beta IPI00295851 x
CPNE1 8904 copine I IPI00018452 x
CPNE3 8895 copine III IPI00024403 x x
CPNE8 144402 copine VIII IPI00334276 x
CPOX 1371 coproporphyrinogen oxidase IPI00093057.6 x x
CSDA 8531 cold shock domain protein A IPI00031801.4 x x
CSDE1 7812 cold shock domain containing E1, RNA-binding IPI00470891.2 x
CSE1L 1434 CSE1 chromosome segregation 1-like (yeast) IPI00022744 x x x x
CSK 1445 c-src tyrosine kinase IPI00013212 x
CSNK2A1 1457 casein kinase 2, alpha 1 polypeptide IPI00016613 x x x
CSNK2A2 1459 casein kinase 2, alpha prime polypeptide IPI00020602 x x
CSPG4 1464 chondroitin sulfate proteoglycan 4 IPI00019157.2 x
CSTB 1476 cystatin B (stefin B) IPI00021828.1 x x
CTNNA1 1495




catenin (cadherin-associated protein), beta 1, 
88kDa
IPI00017292.1 x
CTNND1 1500 catenin (cadherin-associated protein), delta 1 IPI00182469 x x
CXADR 1525 coxsackie virus and adenovirus receptor IPI00019146.6 x x
CYB5R3 1727 cytochrome b5 reductase 3 IPI00328415 x
CYC1 1537 cytochrome c-1 IPI00029264 x
DAP3 7818 death associated protein 3 IPI00018120 x
DARS 1615 aspartyl-tRNA synthetase IPI00216951 x
DARS2 55157 aspartyl-tRNA synthetase 2 (mitochondrial) IPI00100460 x
DBT 1629 dihydrolipoamide branched chain transacylase IPI00003944 x
DCAF7 10238 WD repeat domain 68 IPI00006754 x
DCTN1 1639 dynactin 1 (p150, glued homolog, Drosophila) IPI00029485 x
DCTN2 10540 dynactin 2 (p50) IPI00220503 x
DDX1 1653 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 IPI00293655.3 x
DDX20 11218




DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, 
X-linked
IPI00215637 x x x x
DDX5 1655 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 IPI00017617 x x
DDX6 1656 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 IPI00030320.4 x x
DECR1 1666 2,4-dienoyl CoA reductase 1, mitochondrial IPI00003482.1 x x
DHX15 1665 DEAH (Asp-Glu-Ala-His) box polypeptide 15 IPI00396435 x
DHX30 22907 DEAH (Asp-Glu-Ala-His) box polypeptide 30 IPI00411733 x
DHX9 1660 IPI00844578 x x x
DLAT 1737
dihydrolipoamide S-acetyltransferase (E2 
component of pyruvate dehydrogenase 
complex)
IPI00021338 x




















DnaJ (Hsp40) homolog, subfamily A, member 
1
IPI00012535 x x x x x
DNAJA2 10294
DnaJ (Hsp40) homolog, subfamily A, member 
2
IPI00032406 x x x x x
DNAJB1 3337 DnaJ (Hsp40) homolog, subfamily B, member 1 IPI00015947 x
DNAJC7 7266 DnaJ (Hsp40) homolog, subfamily C, member 7 IPI00329629 x x x
DNM2 1785 dynamin 2 IPI00033022 x x x
DOCK11 139818 dedicator of cytokinesis 11 IPI00411452.3 x
DRG1 4733
developmentally regulated GTP binding protein 
1
IPI00031836 x
DSG2 1829 desmoglein 2 IPI00028931 x x x
DSP 1832 desmoplakin IPI00013933 x
DTYMK 1841 deoxythymidylate kinase (thymidylate kinase) IPI00013862 x
DYNC1H1 1778 dynein, cytoplasmic 1, heavy chain 1 IPI00456969 x x x x
DYNC1I2 1781 dynein, cytoplasmic 1, intermediate chain 2 IPI00216348 x x
DYNC1LI1 51143








signaling intermediate in Toll pathway, 
evolutionarily conserved
IPI00063188 x
EDC3 80153 LSM16 homolog (EDC3, S. cerevisiae) IPI00018009 x
EDC4 23644 autoantigen IPI00376317 x x
EDF1 8721 endothelial differentiation-related factor 1 IPI00006362.1 x
EDIL3 10085 EGF-like repeats and discoidin I-like domains 3 IPI00306046.1 x
EEF1A1 1915 chemokine (C-C motif) receptor 5 IPI00025447 x x x x
EEF1A2 1917




eukaryotic translation elongation factor 1 delta 
(guanine nucleotide exchange protein)
IPI00023048 x
EEF1G 1937
eukaryotic translation elongation factor 1 
gamma
IPI00000875 x x x x x
EEF2 1938 eukaryotic translation elongation factor 2 IPI00186290 x x x x
EFNB1 1947 ephrin-B1 IPI00024307.1 x x x x
EFNB2 1948 ephrin-B2 IPI00005126.1 x x
EFNB3 1949 ephrin-B3 IPI00019501.1 x x
EFTUD2 9343
elongation factor Tu GTP binding domain 
containing 2
IPI00003519 x x
EHD1 10938 EH-domain containing 1 IPI00017184 x x x
EHD4 30844 EH-domain containing 4 IPI00005578 x x x
EIF1 10209 eukaryotic translation initiation factor 1 IPI00015077.1 x x
EIF1AY 9086
eukaryotic translation initiation factor 1A, Y-
linked
IPI00023004.7 x x




















eukaryotic translation initiation factor 2, 
subunit 1 alpha, 35kDa
IPI00219678.3 x x
EIF2S2 8894
eukaryotic translation initiation factor 2, 
subunit 2 beta, 38kDa
IPI00021728.3 x
EIF3A 8661
eukaryotic translation initiation factor 3, 
subunit 10 theta, 150/170kDa
IPI00029012 x x
EIF3B 8662








eukaryotic translation initiation factor 3, 
subunit 5 epsilon, 47kDa
IPI00654777 x x
EIF3I 8668












eukaryotic translation initiation factor 4A, 
isoform 1
IPI00025491 x x x x
EIF4A3 9775
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
48
IPI00009328 x x
EIF4B 1975 eukaryotic translation initiation factor 4B IPI00012079.3 x
EIF4G1 1981
eukaryotic translation initiation factor 4 gamma, 
1
IPI00220365 x
EIF5 1983 eukaryotic translation initiation factor 5 IPI00022648 x
EIF5A2 56648 eukaryotic translation initiation factor 5A2 IPI00006935.3 x
EIF5B 9669 eukaryotic translation initiation factor 5B IPI00299254 x
EIF6 3692 integrin beta 4 binding protein IPI00010105 x
ELAVL1 1994
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 1 (Hu antigen R)
IPI00301936 x
EMD 2010 emerin (Emery-Dreifuss muscular dystrophy) IPI00032003 x x
ENO1 2023 enolase 1, (alpha) IPI00465248 x x
EPHA2 1969 EPH receptor A2 IPI00021267 x
EPHA4 2043 EPH receptor A4 IPI00008318.1 x
EPHB4 2050 EPH receptor B4 IPI00186826 x x x
EPRS 2058 glutamyl-prolyl-tRNA synthetase IPI00013452 x x x
ERLIN1 10613 SPFH domain family, member 1 IPI00007940 x x
ERLIN2 11160 SPFH domain family, member 2 IPI00026942 x x
ESYT1 23344





polypeptide (glutaric aciduria II)
IPI00010810 x x
ETFB 2109 electron-transfer-flavoprotein, beta polypeptide IPI00004902 x x
EXOC2 55770 IPI00783559 x
EXOC4 60412 exocyst complex component 4 IPI00059279 x



















EZR 7430 ezrin IPI00746388.3 x x
FAF2 23197 UBX domain containing 8 IPI00172656 x
FAM125A 93343 family with sequence similarity 125, member A IPI00744702.2 x x
FAM125B 89853 family with sequence similarity 125, member B IPI00022918.6 x x
FAM49B 51571 family with sequence similarity 49, member B IPI00303318.2 x x
FANCA 2175 Fanconi anemia, complementation group A IPI00006170 x
FANCD2 2177 Fanconi anemia, complementation group D2 IPI00075081 x
FANCI 55215 KIAA1794 IPI00019447 x x
FARSA 2193
phenylalanine-tRNA synthetase-like, alpha 
subunit
IPI00031820 x
FARSB 10056 phenylalanyl-tRNA synthetase, beta subunit IPI00300074.3 x
FASN 2194 fatty acid synthase IPI00026781 x x x x
FBLN1 2192 fibulin 1 IPI00218803 x x
FERMT2 10979 fermitin family homolog 2 (Drosophila) IPI00000856.7 x x
FKBP3 2287 FK506 binding protein 3, 25kDa IPI00024157.1 x x
FLAD1 80308
Fad1, flavin adenine dinucleotide synthetase, 
homolog (yeast)
IPI00220299 x
FLNA 2316 filamin A, alpha (actin binding protein 280) IPI00302592 x x x
FLNB 2317 filamin B, beta (actin binding protein 278) IPI00289334 x
FLOT1 10211 flotillin 1 IPI00027438 x x
FLOT2 2319 IPI00789008 x x
FMNL2 114793 formin-like 2 IPI00044748.6 x
FN1 2335 fibronectin 1 IPI00022418.1 x x
FTSJ1 24140 FtsJ homolog 1 (E. coli) IPI00004308 x
FYN 2534 FYN oncogene related to SRC, FGR, YES IPI00166845 x
G3BP1 10146




GTPase activating protein (SH3 domain) 
binding protein 2
IPI00009057.2 x
GALK1 2584 galactokinase 1 IPI00019383 x x
GANAB 23193 glucosidase, alpha; neutral AB IPI00011454 x
GAPDH 2597 glyceraldehyde-3-phosphate dehydrogenase IPI00219018 x x x






GBF1 8729 golgi-specific brefeldin A resistance factor 1 IPI00021954 x
GCN1L1 10985
GCN1 general control of amino-acid synthesis 1-
like 1 (yeast)
IPI00001159 x x x x x
GDI1 2664 GDP dissociation inhibitor 1 IPI00010154.3 x x
GDI2 2665 GDP dissociation inhibitor 2 IPI00031461.2 x x



















GEMIN4 50628 gem (nuclear organelle) associated protein 4 IPI00027717 x x
GFM1 85476 G elongation factor, mitochondrial 1 IPI00154473 x
GFPT1 2673 glutamine-fructose-6-phosphate transaminase 1 IPI00217952 x
GIGYF2 26058 trinucleotide repeat containing 15 IPI00647635 x
GIPC1 10755
GIPC PDZ domain containing family, member 
1
IPI00024705 x
GK 2710 glycerol kinase IPI00027424.3 x x
GLO1 2739 glyoxalase I IPI00220766.5 x x
GLOD4 51031 glyoxalase domain containing 4 IPI00007102.3 x
GLRX3 10539 thioredoxin-like 2 IPI00008552 x
GNA13 10672
guanine nucleotide binding protein (G protein), 
alpha 13
IPI00290928 x x x x
GNAI2 2771
guanine nucleotide binding protein (G protein), 
alpha inhibiting activity polypeptide 2
IPI00217906 x x
GNAI3 2773
guanine nucleotide binding protein (G protein), 
alpha inhibiting activity polypeptide 3
IPI00220578 x x
GNAS 2778 GNAS complex locus IPI00095891 x x
GNB2 2783
guanine nucleotide binding protein (G protein), 
beta polypeptide 2
IPI00003348 x x x x x
GNB2L1 10399
guanine nucleotide binding protein (G protein), 
beta polypeptide 2-like 1
IPI00641950 x x x x
GNL3 26354
guanine nucleotide binding protein-like 3 
(nucleolar)
IPI00003886 x
GOLGA7 51125 golgin A7 IPI00480022.1 x
GOLGB1 2804
golgi autoantigen, golgin subfamily b, 
macrogolgin (with transmembrane signal), 1
IPI00004671 x
GPC1 2817 glypican 1 IPI00015688.1 x x
GPC3 2719 glypican 3 IPI00019907.1 x x
GPC4 2239 glypican 4 IPI00232571.1 x
GPC6 10082 glypican 6 IPI00001755.1 x
GPI 2821 glucose phosphate isomerase IPI00027497.5 x
GRB2 2885 growth factor receptor-bound protein 2 IPI00021327.3 x
GRID1 2894 glutamate receptor, ionotropic, delta 1 IPI00374337.1 x
GRSF1 2926 G-rich RNA sequence binding factor 1 IPI00478657 x
GSN 2934 gelsolin (amyloidosis, Finnish type) IPI00026314 x x
GSTM3 2947 glutathione S-transferase M3 (brain) IPI00246975 x
GSTP1 2950 glutathione S-transferase pi IPI00219757 x x x
H2AFV 94239 H2A histone family, member V IPI00018278 x x x




Coenzyme A hydratase (trifunctional protein), 
alpha subunit
IPI00031522 x






















Coenzyme A hydratase (trifunctional protein), 
beta subunit
IPI00022793 x x x x
HAX1 10456 HCLS1 associated protein X-1 IPI00010440 x
HBA1 3039 hemoglobin, zeta IPI00410714 x x
HBA2 3040 IPI00410714 x x
HBS1L 10767 HBS1-like (S. cerevisiae) IPI00009070.1 x
HDAC2 3066 histone deacetylase 2 IPI00289601.1 x
HDLBP 3069
high density lipoprotein binding protein 
(vigilin)
IPI00022228 x
HEATR1 55127 HEAT repeat containing 1 IPI00024279 x x x x
HEATR2 54919 hypothetical protein FLJ20397 IPI00242630 x x x
HEATR3 55027 hypothetical protein FLJ20718 IPI00100984 x
HEATR6 63897 amplified in breast cancer 1 IPI00464999 x
HERC2 8924 hect domain and RLD 2 IPI00005826.1 x
HIST1H1C 3006 histone 1, H1c IPI00217465 x x x x
HIST1H2AA221613 histone 1, H2aa IPI00045109 x
HIST1H4A 8359 histone cluster 1, H4a IPI00453473.6 x x
HIST1H4B 8366 histone cluster 1, H4b IPI00453473.6 x x
HIST1H4C 8364 histone cluster 1, H4c IPI00453473.6 x x
HIST1H4D 8360 histone cluster 1, H4d IPI00453473.6 x x
HIST1H4E 8367 histone cluster 1, H4e IPI00453473.6 x x
HIST1H4F 8361 histone cluster 1, H4f IPI00453473.6 x x
HIST1H4H 8365 histone cluster 1, H4h IPI00453473.6 x x
HIST1H4I 8294 histone cluster 1, H4i IPI00453473.6 x x
HIST1H4J 8363 histone cluster 1, H4j IPI00453473.6 x x
HIST1H4K 8362 histone cluster 1, H4k IPI00453473.6 x x
HIST1H4L 8368 histone cluster 1, H4l IPI00453473.6 x x
HIST2H2BE 8349 histone 2, H2be IPI00003935 x x x x
HIST2H3A 333932 histone H3/o IPI00171611 x
HIST2H3C 126961 IPI00171611 x
HIST2H3D 653604 IPI00171611 x
HIST2H4A 8370 histone cluster 2, H4a IPI00453473.6 x x
HIST2H4B 554313 histone cluster 2, H4b IPI00453473.6 x x
HIST4H4 121504 histone cluster 4, H4 IPI00453473.6 x x
HNRNPA2B 3181 heterogeneous nuclear ribonucleoprotein A2/B1 IPI00386854 x
HNRNPC 3183




heterogeneous nuclear ribonucleoprotein C-like 
1
IPI00027569 x
HNRNPF 3185 heterogeneous nuclear ribonucleoprotein F IPI00003881 x
HNRNPH3 3189
heterogeneous nuclear ribonucleoprotein H3 
(2H9)
IPI00013877 x
HNRNPK 3190 heterogeneous nuclear ribonucleoprotein K IPI00216049 x x x
HNRNPM 4670 heterogeneous nuclear ribonucleoprotein M IPI00171903 x x



















HNRNPR 10236 heterogeneous nuclear ribonucleoprotein R IPI00012074.3 x x
HNRNPU 3192
heterogeneous nuclear ribonucleoprotein U 
(scaffold attachment factor A)
IPI00479217 x x x
HPRT1 3251
hypoxanthine phosphoribosyltransferase 1 
(Lesch-Nyhan syndrome)
IPI00218493 x x x
HRSP12 10247 heat-responsive protein 12 IPI00005038.1 x
HSD17B10 3028
hydroxyacyl-Coenzyme A dehydrogenase, 
type II
IPI00017726 x x
HSD17B12 51144 hydroxysteroid (17-beta) dehydrogenase 12 IPI00007676 x x x
HSD17B4 3295 hydroxysteroid (17-beta) dehydrogenase 4 IPI00019912 x x
HSDL2 84263 hydroxysteroid dehydrogenase like 2 IPI00031107 x
HSP90AA1 3320
heat shock protein 90kDa alpha (cytosolic), 
class A member 1
IPI00382470 x x x
HSP90AA2 3324 IPI00031523 x x x
HSP90AB1 3326
heat shock protein 90kDa alpha (cytosolic), 
class B member 1
IPI00414676 x x x x x x
HSP90B1 7184




stress 70 protein chaperone, microsome-
associated, 60kDa
IPI00299299 x
HSPA14 51182 heat shock 70kDa protein 14 IPI00292499 x
HSPA1A 3303 heat shock 70kDa protein 1A IPI00304925 x x x x
HSPA1B 3304 IPI00304925 x x x x
HSPA1L 3305 heat shock 70kDa protein 7 (HSP70B) IPI00301277 x x x x
HSPA4 3308 heat shock 70kDa protein 4 IPI00002966.2 x x
HSPA5 3309
heat shock 70kDa protein 5 (glucose-regulated 
protein, 78kDa)
IPI00003362 x x x x
HSPA8 3312 heat shock 70kDa protein 8 IPI00003865 x x x x
HSPA9 3313 heat shock 70kDa protein 9B (mortalin-2) IPI00007765 x x x
HSPD1 3329 IPI00784154 x x x
HSPG2 3339 heparan sulfate proteoglycan 2 IPI00024284.5 x x
HSPH1 10808 heat shock 105kDa/110kDa protein 1 IPI00218993 x x x
HYOU1 10525 hypoxia up-regulated 1 IPI00000877 x x x x
HYPK 25764 - IPI00335001.2 x
IARS 3376 isoleucine-tRNA synthetase IPI00514082 x x
IARS2 55699 isoleucine-tRNA synthetase 2, mitochondrial IPI00017283 x
IDE 3416 insulin-degrading enzyme IPI00220373 x x
IDH2 3418
isocitrate dehydrogenase 2 (NADP+), 
mitochondrial
IPI00011107 x
IDH3A 3419 isocitrate dehydrogenase 3 (NAD+) alpha IPI00030702 x x
IDH3B 3420 isocitrate dehydrogenase 3 (NAD+) beta IPI00304417 x
IGF2BP1 10642
insulin-like growth factor 2 mRNA binding 
protein 1
IPI00008557 x x x
IGF2BP2 10644




insulin-like growth factor 2 mRNA binding 
protein 3
IPI00658000.2 x x



















IGSF3 3321 immunoglobulin superfamily, member 3 IPI00016890.4 x x
IGSF8 93185 immunoglobulin superfamily, member 8 IPI00056478.1 x x
ILF2 3608 interleukin enhancer binding factor 2, 45kDa IPI00005198 x
ILK 3611 integrin-linked kinase IPI00013219 x
ILK 3611 IPI00302927 x x x x
ILK-2 55522 integrin-linked kinase-2 IPI00302927.6 x x
IMMT 10989
inner membrane protein, mitochondrial 
(mitofilin)
IPI00009960 x x x
IMPDH2 3615




internexin neuronal intermediate filament 
protein, alpha
IPI00001453 x
INSR 3643 insulin receptor IPI00025803 x
IPO13 9670 importin 13 IPI00005651 x
IPO4 79711 importin 4 IPI00156374 x x x
IPO5 3843 IPI00793443 x x x x
IPO7 10527 importin 7 IPI00007402 x x x x
IPO8 10526 importin 8 IPI00007401 x x
IPO9 55705 importin 9 IPI00185146 x x
IQGAP1 8826
IQ motif containing GTPase activating protein 
1
IPI00009342 x x x
IQGAP3 128239
IQ motif containing GTPase activating protein 
3
IPI00328905 x
IRS4 8471 insulin receptor substrate 4 IPI00020729 x x x x x
ITGA6 3655 integrin, alpha 6 IPI00010697.2 x
ITGB1 3688
integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12)
IPI00217561.2 x x
ITIH2 3698 inter-alpha (globulin) inhibitor H2 IPI00305461 x x
ITIH3 3699 inter-alpha (globulin) inhibitor H3 IPI00028413 x x
JUP 3728 junction plakoglobin IPI00554711 x x x
KCTD12 115207
potassium channel tetramerisation domain 
containing 12
IPI00060715.1 x
KIAA0174 9798 KIAA0174 IPI00024660.1 x x
KIAA0368 23392 IPI00157790 x
KIAA0406 9675 KIAA0406 gene product IPI00011702 x
KIAA0664 23277 KIAA0664 IPI00024425 x
KIAA1524 57650 KIAA1524 IPI00154283 x x x
KIF23 9493 kinesin family member 23 IPI00291579 x
KIF5B 3799 kinesin family member 5B IPI00012837 x
KLHL20 27252 kelch-like 20 (Drosophila) IPI00032338.5 x
KPNA1 3836 karyopherin alpha 1 (importin alpha 5) IPI00303292 x
KPNA2 3838
karyopherin alpha 2 (RAG cohort 1, importin 
alpha 1)
IPI00002214 x x x x
KPNB1 3837 karyopherin (importin) beta 1 IPI00001639 x x x x x x
LACTB 114294 lactamase, beta IPI00294186 x
LAMA5 3911 laminin, alpha 5 IPI00783665.4 x



















LAMB1 3912 laminin, beta 1 IPI00013976.3 x
LAMB2 3913 laminin, beta 2 (laminin S) IPI00296922.4 x
LAMC1 3915 laminin, gamma 1 (formerly LAMB2) IPI00298281.4 x x
LAP3 51056 leucine aminopeptidase 3 IPI00419237 x
LARS 51520 leucyl-tRNA synthetase IPI00103994 x x x x x
LDHA 3939 lactate dehydrogenase A IPI00217966 x x
LDHB 3945 lactate dehydrogenase B IPI00219217 x x x
LGALS3BP 3959
lectin, galactoside-binding, soluble, 3 binding 
protein
IPI00023673.1 x x
LMNB1 4001 lamin B1 IPI00217975 x
LOC284889 284889 hypothetical protein LOC284889 IPI00293276.1 x
LOC389842 389842 IPI00399212 x x
LOC442497 442497 hypothetical protein LOC442497 IPI00027493.1 x x
LONP1 9361 protease, serine, 15 IPI00005158 x x
LPHN2 23266 latrophilin 2 IPI00017562 x x
LRBA 987
LPS-responsive vesicle trafficking, beach and 
anchor containing
IPI00002255 x
LRPPRC 10128 IPI00783271 x x
LRRC47 57470 leucine rich repeat containing 47 IPI00170935 x
LRRC57 255252 leucine rich repeat containing 57 IPI00470576.4 x
LRRC59 55379 leucine rich repeat containing 59 IPI00396321.1 x
LYN 4067
v-yes-1 Yamaguchi sarcoma viral related 
oncogene homolog
IPI00298625 x
MAP2K1 5604 mitogen-activated protein kinase kinase 1 IPI00219604 x
MAP2K2 5605 mitogen-activated protein kinase kinase 2 IPI00003783 x
MAPK14 1432 mitogen-activated protein kinase 14 IPI00002857 x
MAPRE2 10982









65108 MARCKS-like 1 IPI00641181.5 x
MARS 4141 methionine-tRNA synthetase IPI00008240 x x
MATR3 9782 matrin 3 IPI00017297 x
MCAM 4162 melanoma cell adhesion molecule IPI00016334.2 x
MCCC2 64087 IPI00784044 x
MCM4 4173




MCM7 minichromosome maintenance deficient 
7 (S. cerevisiae)
IPI00219740 x x
MCTS1 28985 malignant T cell amplified sequence 1 IPI00179026.2 x
MDH2 4191 malate dehydrogenase 2, NAD (mitochondrial) IPI00291006 x x
MDN1 23195 MDN1, midasin homolog (yeast) IPI00167941 x
MFAP3 4238 microfibrillar-associated protein 3 IPI00022791.1 x x
MFGE8 4240 milk fat globule-EGF factor 8 protein IPI00002236.3 x x
MIF 4282
macrophage migration inhibitory factor 
(glycosylation-inhibiting factor)
IPI00293276.1 x



















MYO1D 4642 myosin ID IPI00329719.1 x x
NAA15 80155












nascent polypeptide-associated complex alpha 
subunit
IPI00023748.3 x x





NCAPG 64151 chromosome condensation protein G IPI00106495 x
NCDN 23154 neurochondrin IPI00549543 x x
NCKIPSD 51517 NCK interacting protein with SH3 domain IPI00009319 x
NCL 4691 nucleolin IPI00183526 x x
NCS1 23413 neuronal calcium sensor 1 IPI00219110.7 x
NDUFA9 4704




NADH dehydrogenase (ubiquinone) Fe-S 




NADH dehydrogenase (ubiquinone) Fe-S 
protein 3, 30kDa (NADH-coenzyme Q 
reductase)
IPI00025796 x x
NEO1 4756 neogenin homolog 1 (chicken) IPI00023814 x
NME1 4830




non-metastatic cells 2, protein (NM23B) 
expressed in
IPI00026260.1 x
NONO 4841 non-POU domain containing, octamer-binding IPI00304596 x
NOP56 10528
nucleolar protein 5A (56kDa with KKE/D 
repeat)
IPI00411937 x
NOTCH2 4853 Notch homolog 2 (Drosophila) IPI00297655 x x x
NPEPPS 9520 aminopeptidase puromycin sensitive IPI00026216.4 x x
NPM1 4869 anaplastic lymphoma kinase (Ki-1) IPI00220740 x x
NRAS 4893
neuroblastoma RAS viral (v-ras) oncogene 
homolog
IPI00000005 x x x
NSF 4905 N-ethylmaleimide-sensitive factor IPI00006451 x
NT5DC2 64943 5'-nucleotidase domain containing 2 IPI00009662 x
NUDC 10726
nuclear distribution gene C homolog (A. 
nidulans)
IPI00550746.4 x
NUP133 55746 nucleoporin 133kDa IPI00291200 x
NUP153 9972 nucleoporin 153kDa IPI00292059 x
NUP160 23279 IPI00748807 x
NUP205 23165 IPI00783781 x x x
OAT 4942 ornithine aminotransferase (gyrate atrophy) IPI00022334 x























OLA1 29789 Obg-like ATPase 1 IPI00216105.1 x x
OPA1 4976 optic atrophy 1 (autosomal dominant) IPI00006721 x
OXSR1 9943 oxidative-stress responsive 1 IPI00010080 x
P4HB 5034
procollagen-proline, 2-oxoglutarate 4-
dioxygenase (proline 4-hydroxylase), beta 
polypeptide
IPI00010796 x x
PA2G4 5036 proliferation-associated 2G4, 38kDa IPI00299000 x x x
PABPC1 26986 poly(A) binding protein, cytoplasmic 1 IPI00008524 x x x
PABPC4 8761
poly(A) binding protein, cytoplasmic 4 
(inducible form)
IPI00012726.4 x x
PABPC4L 132430 poly(A) binding protein, cytoplasmic 4-like IPI00885166.1 x x
PACSIN2 11252











IPI00217223 x x x
PARK7 11315




poly (ADP-ribose) polymerase family, member 
1
IPI00449049 x x x
PCBP1 5093 poly(rC) binding protein 1 IPI00016610 x x x
PCBP2 5094 poly(rC) binding protein 2 IPI00012066 x x x x
PCNA 5111 proliferating cell nuclear antigen IPI00021700 x x
PDAP1 11333 PDGFA associated protein 1 IPI00013297.1 x
PDCD10 11235 programmed cell death 10 IPI00298558.2 x
PDCD5 9141 programmed cell death 5 IPI00023640.3 x x
PDCD6 10016 programmed cell death 6 IPI00025277.5 x
PDCD6IP 10015 programmed cell death 6 interacting protein IPI00246058 x x x x
PDHA1 5160 pyruvate dehydrogenase (lipoamide) alpha 1 IPI00306301 x x
PDHB 5162 pyruvate dehydrogenase (lipoamide) beta IPI00003925 x x
PDIA6 10130 protein disulfide isomerase family A, member 6 IPI00299571 x
PEBP1 5037 phosphatidylethanolamine binding protein 1 IPI00219446.5 x x
PEF1 553115 penta-EF-hand domain containing 1 IPI00018235 x
PELP1 27043 proline, glutamic acid and leucine rich protein 1 IPI00006702 x
PFDN2 5202 prefoldin subunit 2 IPI00006052.3 x
PFDN6 10471 prefoldin subunit 6 IPI00005657.1 x
PFN1 5216 profilin 1 IPI00216691 x x
PGAM2 5224 phosphoglycerate mutase 2 (muscle) IPI00218570.6 x x
PGAM5 192111 phosphoglycerate mutase family member 5 IPI00063242 x
PGD 5226 phosphogluconate dehydrogenase IPI00219525 x x x
PGK1 5230 phosphoglycerate kinase 1 IPI00169383.3 x x



















PHB 5245 prohibitin IPI00017334.1 x x x
PHB2 11331 prohibitin 2 IPI00027252.6 x x
PHGDH 26227 phosphoglycerate dehydrogenase IPI00011200 x x x x x
PI4KA 5297















PITRM1 10531 pitrilysin metallopeptidase 1 IPI00219613 x
PKM2 5315 pyruvate kinase, muscle IPI00220644 x x x x x
PLS3 5358 plastin 3 IPI00216694.3 x x
PNP 4860 purine nucleoside phosphorylase IPI00017672.4 x
POLDIP2 26073
polymerase (DNA-directed), delta interacting 
protein 2
IPI00165506 x
POLR1C 9533 polymerase (RNA) I polypeptide C, 30kDa IPI00005179 x
POLR2B 5431




polymerase (RNA) II (DNA directed) 
polypeptide C, 33kDa
IPI00018288 x
PPIA 5478 peptidylprolyl isomerase A (cyclophilin A) IPI00419585 x x x
PPP1CC 5501








protein phosphatase 2 (formerly 2A), 
regulatory subunit A (PR 65), alpha isoform
IPI00168184 x x x
PPP2R1B 5519
protein phosphatase 2 (formerly 2A), 
regulatory subunit A (PR 65), beta isoform
IPI00294178 x
PRDX1 5052 peroxiredoxin 1 IPI00000874 x x x x
PRDX2 7001 peroxiredoxin 2 IPI00027350 x x x
PRDX3 10935 peroxiredoxin 3 IPI00024919 x x
PRDX4 10549 peroxiredoxin 4 IPI00011937.1 x x
PRDX5 25824 peroxiredoxin 5 IPI00024915 x
PRDX6 9588 peroxiredoxin 6 IPI00220301 x x x
PREP 5550 prolyl endopeptidase IPI00008164 x
PRIC285 85441




protein kinase, DNA-activated, catalytic 
polypeptide
IPI00296337 x x x x x
PRPF8 10594




proteasome (prosome, macropain) subunit, 
alpha type, 4
IPI00299155 x




























proteasome (prosome, macropain) 26S subunit, 
ATPase, 3
IPI00018398 x x x
PSMC4 5704
























proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 12
IPI00185374 x x x
PSMD13 5719
























proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 7 (Mov34 homolog)
IPI00019927 x x x
PSMD8 5714




proteasome (prosome, macropain) activator 
subunit 3 (PA28 gamma; Ki)
IPI00030243 x
PTBP1 5725 polypyrimidine tract binding protein 1 IPI00179964 x
PTGFRN 5738 prostaglandin F2 receptor negative regulator IPI00022048.8 x x
PTK7 5754 PTK7 protein tyrosine kinase 7 IPI00168813 x
PTP4A1 7803




protein tyrosine phosphatase-like A domain 
containing 1
IPI00008998 x
PTPRF 5792 protein tyrosine phosphatase, receptor type, F IPI00107831 x x



















PURA 5813 purine-rich element binding protein A IPI00023591.1 x x
PVR 5817 poliovirus receptor IPI00219425.3 x x
PYCR2 29920
pyrroline-5-carboxylate reductase family, 
member 2
IPI00335061 x x x
RAB10 10890 RAB10, member RAS oncogene family IPI00016513 x x x
RAB11B 9230 RAB11B, member RAS oncogene family IPI00020436 x x x
RAB13 5872 RAB13, member RAS oncogene family IPI00016373.3 x x
RAB14 51552 RAB14, member RAS oncogene family IPI00291928 x x
RAB1A 5861 RAB1A, member RAS oncogene family IPI00005719 x x x x x
RAB1B 81876 RAB1B, member RAS oncogene family IPI00008964.3 x
RAB2A 5862 RAB2A, member RAS oncogene family IPI00031169.1 x x
RAB35 11021 RAB35, member RAS oncogene family IPI00300096 x x x
RAB5A 5868 RAB5A, member RAS oncogene family IPI00023510.1 x
RAB5B 5869 RAB5B, member RAS oncogene family IPI00017344.3 x x
RAB5C 5878 RAB5C, member RAS oncogene family IPI00016339 x x x
RAB7A 7879 RAB7, member RAS oncogene family IPI00016342 x x x x x
RAB8A 4218 RAB8A, member RAS oncogene family IPI00028481.1 x x
RAB8B 51762 RAB8B, member RAS oncogene family IPI00024282.1 x
RAB9A 9367 RAB9A, member RAS oncogene family IPI00016372 x
RAC1 5879
ras-related C3 botulinum toxin substrate 1 (rho 
family, small GTP binding protein Rac1)
IPI00010271.3 x x
RAD50 10111 RAD50 homolog (S. cerevisiae) IPI00107531 x
RALB 5899
v-ral simian leukemia viral oncogene homolog B 
(ras related; GTP binding protein)
IPI00004397.2 x x
RAN 5901 RAN, member RAS oncogene family IPI00643041 x x
RANBP6 26953 RAN binding protein 6 IPI00514622 x
RANP1 221547
RAN, member RAS oncogene family 
pseudogene 1
IPI00643041.3 x
RAP1A 5906 RAP1A, member of RAS oncogene family IPI00019345.1 x
RAP1B 5908 RAP1B, member of RAS oncogene family IPI00015148 x x x
RAP2C 57826 RAP2C, member of RAS oncogene family IPI00009607 x x
RARS 5917 arginyl-tRNA synthetase IPI00004860 x x
RBBP4 5928 retinoblastoma binding protein 4 IPI00328319 x x
RCN2 5955
reticulocalbin 2, EF-hand calcium binding 
domain
IPI00029628.1 x x
RCTPI1 729708 TPI1 pseudogene IPI00465028.7 x
RDX 5962 radixin IPI00017367.6 x x
RFC2 5982 replication factor C (activator 1) 2, 40kDa IPI00017412 x
RFC3 5983 replication factor C (activator 1) 3, 38kDa IPI00031521 x
RFC4 5984 replication factor C (activator 1) 4, 37kDa IPI00017381 x
RFC5 5985 replication factor C (activator 1) 5, 36.5kDa IPI00031514 x
RG9MTD1 54931
RNA (guanine-9-) methyltransferase domain 
containing 1
IPI00099996 x
RHEB 6009 Ras homolog enriched in brain IPI00016669.1 x
RHOA 387 ras homolog gene family, member A IPI00478231.2 x
RHOG 391 ras homolog gene family, member G (rho G) IPI00017342.1 x
RNF160 26046 IPI00783835 x



















RNF213 57674 ring finger protein 213 IPI00642126.3 x
RNF214 257160 IPI00742996 x
RNH1 6050 ribonuclease/angiogenin inhibitor 1 IPI00550069 x
RPL10A 4736 ribosomal protein L10a IPI00412579 x x x x
RPL10L 140801 ribosomal protein L10-like IPI00064765.3 x
RPL10P16 284393 ribosomal protein L10 pseudogene 16 IPI00374260.4 x
RPL11 6135 ribosomal protein L11 IPI00376798 x x x x
RPL12 6136 ribosomal protein L12 IPI00024933.3 x x
RPL13 6137 ribosomal protein L13 IPI00465361.4 x x
RPL13A 23521 ribosomal protein L13a IPI00304612 x x x x
RPL13P12 388344 IPI00397611 x x x
RPL15 6138 ribosomal protein L15 IPI00470528.5 x
RPL18 6141 ribosomal protein L18 IPI00215719 x x x x x
RPL18A 6142 ribosomal protein L18a IPI00026202.1 x x
RPL19 6143 ribosomal protein L19 IPI00025329.1 x x
RPL21 6144 ribosomal protein L21 IPI00247583.5 x x
RPL21P16 729402 ribosomal protein L21 pseudogene 16 IPI00247583.5 x x
RPL21P19 641293 ribosomal protein L21 pseudogene 19 IPI00247583.5 x x
RPL23 9349 ribosomal protein L23 IPI00010153.5 x x
RPL24 6152 ribosomal protein L24 IPI00306332 x
RPL26L1 51121 ribosomal protein L26-like 1 IPI00007144 x x
RPL27 6155 ribosomal protein L27 IPI00219155.5 x
RPL28 6158 ribosomal protein L28 IPI00182533.5 x x
RPL3 6122 ribosomal protein L3 IPI00550021 x x x x
RPL30 6156 ribosomal protein L30 IPI00219156.7 x x
RPL31 6160 ribosomal protein L31 IPI00026302.3 x
RPL34 6164 ribosomal protein L34 IPI00219160.3 x
RPL35 11224 ribosomal protein L35 IPI00412607 x x
RPL35A 6165 ribosomal protein L35a IPI00029731.8 x
RPL36 25873 ribosomal protein L36 IPI00216237.5 x x
RPL38 6169 ribosomal protein L38 IPI00215790 x x x
RPL4 6124 ribosomal protein L4 IPI00003918 x x x x
RPL5 6125 ribosomal protein L5 IPI00000494 x x x
RPL6 6128 ribosomal protein L6 IPI00329389 x x x x
RPL7 6129 ribosomal protein L7 IPI00030179 x x x x x
RPL7A 6130 ribosomal protein L7a IPI00299573 x x x
RPL7P32 1E+08 ribosomal protein L7 pseudogene 32 IPI00030179.3 x x
RPL8 6132 ribosomal protein L8 IPI00012772 x x x
RPL9 6133 ribosomal protein L9 IPI00031691.1 x x
RPLP0 6175 ribosomal protein, large, P0 IPI00008530 x x x x
RPLP1 6176 ribosomal protein, large, P1 IPI00008527.3 x x
RPLP2 6181 ribosomal protein, large, P2 IPI00008529.1 x x
RPN1 6184 ribophorin I IPI00025874 x x
RPS10 6204 ribosomal protein S10 IPI00008438.1 x x
RPS11 6205 ribosomal protein S11 IPI00025091 x x x
RPS12 6206 ribosomal protein S12 IPI00013917.3 x
RPS14 6208 ribosomal protein S14 IPI00026271 x x x
RPS15 6209 ribosomal protein S15 IPI00479058.2 x



















RPS15A 6210 ribosomal protein S15a IPI00221091.9 x x
RPS16 6217 ribosomal protein S16 IPI00221092 x x x
RPS17 6218 ribosomal protein S17 IPI00221093.7 x x
RPS18 6222 ribosomal protein S18 IPI00013296 x x x
RPS19 6223 ribosomal protein S19 IPI00215780.5 x x
RPS2 6187 ribosomal protein S2 IPI00013485 x x x x
RPS20 6224 ribosomal protein S20 IPI00012493.1 x
RPS21 6227 ribosomal protein S21 IPI00017448.1 x x
RPS23 6228 ribosomal protein S23 IPI00218606.7 x
RPS24 6229 ribosomal protein S24 IPI00029750 x x x
RPS27 6232 ribosomal protein S27 IPI00397358.4 x x
RPS27A 6233 ribosomal protein S27a IPI00179330 x x x x x
RPS28 6234 ribosomal protein S28 IPI00719622.1 x
RPS3 6188 ribosomal protein S3 IPI00011253 x x x x
RPS3A 6189 ribosomal protein S3A IPI00419880 x x x x
RPS4X 6191 ribosomal protein S4, X-linked IPI00217030 x x x x
RPS5 6193 ribosomal protein S5 IPI00008433.4 x x
RPS6 6194 ribosomal protein S6 IPI00021840 x x x x
RPS7 6201 ribosomal protein S7 IPI00013415.1 x
RPS7P4 149224 ribosomal protein S7 pseudogene 4 IPI00008293.4 x
RPS8 6202 ribosomal protein S8 IPI00216587 x x x x
RPS9 6203 ribosomal protein S9 IPI00221088 x x x x
RPSAP12 387867 IPI00398958 x x x
RRAS2 22800 related RAS viral (r-ras) oncogene homolog 2 IPI00012512 x x x
RRM1 6240 ribonucleotide reductase M1 polypeptide IPI00013871 x
RSL1D1 26156 ribosomal L1 domain containing 1 IPI00008708 x
RSU1 6251 Ras suppressor protein 1 IPI00017256 x
RUVBL1 8607 RuvB-like 1 (E. coli) IPI00021187 x x x x x
RUVBL2 10856 RuvB-like 2 (E. coli) IPI00009104 x x x x x
SAMM50 25813
sorting and assembly machinery component 50 
homolog (S. cerevisiae)
IPI00412713 x
SAPS3 55291 SAPS domain family, member 3 IPI00019540 x
SARM1 23098 sterile alpha and TIR motif containing 1 IPI00007919 x
SBDS 51119 Shwachman-Bodian-Diamond syndrome IPI00427330.3 x
SCRIB 23513 scribbled homolog (Drosophila) IPI00410666 x x
SDCBP 6386 syndecan binding protein (syntenin) IPI00299086 x x x
SDK2 54549 sidekick homolog 2 (chicken) IPI00384376.3 x
SDR39U1 56948 chromosome 14 open reading frame 124 IPI00643286 x
SEC16A 9919 IPI00031242 x
SERBP1 26135 SERPINE1 mRNA binding protein 1 IPI00410693.3 x x
SERPINA7 6906
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 7
IPI00292946 x x
SERPINC1 462




serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived factor), 
member 1
IPI00006114 x x




















splicing factor, arginine/serine-rich 1 (splicing 
factor 2, alternate splicing factor)
IPI00215884 x x
SH3BGRL 6451
SH3 domain binding glutamic acid-rich protein 
like
IPI00025318.1 x x
SH3GL1 6455 SH3-domain GRB2-like 1 IPI00019169.3 x x
SH3GL3 6457 SH3-domain GRB2-like 3 IPI00019172.3 x x
SH3GLB1 51100 SH3-domain GRB2-like endophilin B1 IPI00006558 x
SH3KBP1 30011 SH3-domain kinase binding protein 1 IPI00294962.4 x
SHMT2 6472
serine hydroxymethyltransferase 2 
(mitochondrial)
IPI00002520 x
SIRT7 51547 pyrroline-5-carboxylate reductase 1 IPI00260769 x
SLC12A2 6558





solute carrier family 16 (monocarboxylic acid 
transporters), member 1
IPI00024650 x x x
SLC1A5 6510
solute carrier family 1 (neutral amino acid 
transporter), member 5
IPI00019472 x x x
SLC25A1 6576
solute carrier family 25 (mitochondrial carrier; 
citrate transporter), member 1
IPI00294159.3 x
SLC25A10 1468
solute carrier family 25 (mitochondrial carrier; 
dicarboxylate transporter), member 10
IPI00015920 x
SLC25A11 8402
solute carrier family 25 (mitochondrial carrier; 
oxoglutarate carrier), member 11
IPI00219729 x
SLC25A12 8604
solute carrier family 25 (mitochondrial carrier, 
Aralar), member 12
IPI00386271 x
SLC25A13 10165 solute carrier family 25, member 13 (citrin) IPI00007084.3 x x
SLC25A22 79751




solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 3
IPI00022202.3 x
SLC25A4 291
solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 4
IPI00022891 x
SLC25A40 55972 mitochondrial carrier family protein IPI00290827 x
SLC25A6 293
solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 4
IPI00291467.7 x x
SLC29A1 2030




solute carrier family 3 (activators of dibasic and 
neutral amino acid transport), member 2
IPI00027493 x x x
SLC7A1 6541
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1
IPI00027728.1 x
SLC7A5 8140
solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 5
IPI00008986.1 x x
SLIT2 9353 slit homolog 2 (Drosophila) IPI00006288 x
SLITRK5 26050 SLIT and NTRK-like family, member 5 IPI00016679 x x x




















SWI/SNF related, matrix associated, actin 








SMC2 structural maintenance of chromosomes 
2-like 1 (yeast)
IPI00007927 x x
SMC3 9126 chondroitin sulfate proteoglycan 6 (bamacan) IPI00219420 x
SMC4 10051
SMC4 structural maintenance of chromosomes 
4-like 1 (yeast)
IPI00328298 x
SNAP29 9342 synaptosomal-associated protein, 29kDa IPI00032831.4 x
SND1 27044 staphylococcal nuclease domain containing 1 IPI00140420 x x x
SNORA67 26781 small nucleolar RNA, H/ACA box 67 IPI00025491.1 x x
SNRNP200 23020




small nuclear ribonucleoprotein D2 polypeptide 
16.5kDa
IPI00017963.1 x
SNRPE 6635 small nuclear ribonucleoprotein polypeptide E IPI00029266.1 x
SNRPG 6637 small nuclear ribonucleoprotein polypeptide G IPI00016572.1 x
SPC24 147841




serine palmitoyltransferase, long chain base 
subunit 1
IPI00005745.1 x
SRM 6723 spermidine synthase IPI00292020 x
SRP68 6730 signal recognition particle 68kDa IPI00102936.3 x
SRSF10 10772 FUS interacting protein (serine/arginine-rich) 1 IPI00009071 x
SSB 6741 Sjogren syndrome antigen B (autoantigen La) IPI00009032 x
SSR4 6748
signal sequence receptor, delta (translocon-
associated protein delta)
IPI00019385.3 x
SSRP1 6749 structure specific recognition protein 1 IPI00005154.1 x
ST13 6767
suppression of tumorigenicity 13 (colon 
carcinoma) (Hsp70 interacting protein)
IPI00032826.1 x x
STIP1 10963 stress-induced-phosphoprotein 1 IPI00013894.1 x x
STK24 8428
serine/threonine kinase 24 (STE20 homolog, 
yeast)
IPI00002212 x
STMN1 3925 stathmin 1 IPI00479997.4 x
STOML2 30968 stomatin (EPB72)-like 2 IPI00334190 x x x
STRAP 11171
serine/threonine kinase receptor associated 
protein
IPI00294536.2 x
STX12 23673 syntaxin 12 IPI00329332 x
STX16 8675 syntaxin 16 IPI00023149 x
STX4 6810 syntaxin 4 IPI00029730.1 x
STXBP3 6814 syntaxin binding protein 3 IPI00297626 x
SUCLA2 8803
succinate-CoA ligase, ADP-forming, beta 
subunit
IPI00217232 x
























synaptotagmin binding, cytoplasmic RNA 
interacting protein
IPI00018140.3 x x
TACO1 51204 coiled-coil domain containing 44 IPI00019903 x
TAGLN2 8407 transgelin 2 IPI00550363 x x x
TAOK1 57551 TAO kinase 1 IPI00002232 x
TARBP1 6894 Tar (HIV-1) RNA binding protein 1 IPI00298447 x
TARS 6897 threonyl-tRNA synthetase IPI00329633.5 x
TBC1D15 64786 TBC1 domain family, member 15 IPI00154645 x
TBC1D4 9882 TBC1 domain family, member 4 IPI00220901 x
TBCA 6902 tubulin folding cofactor A IPI00217236.4 x x
TBCD 6904 tubulin-specific chaperone d IPI00030774 x
TBCE 6905 tubulin-specific chaperone e IPI00018402 x
TCP1 6950 t-complex 1 IPI00290566 x x x x
TELO2 9894 KIAA0683 gene product IPI00016868 x x
TFAM 7019 transcription factor A, mitochondrial IPI00020928 x
TFRC 7037 transferrin receptor (p90, CD71) IPI00022462 x x x
THADA 63892 thyroid adenoma associated IPI00412647 x x
THBS1 7057 thrombospondin 1 IPI00296099 x x
TIMM13 26517








translocase of inner mitochondrial membrane 50 
homolog (yeast)
IPI00418497.1 x x
TLN1 7094 talin 1 IPI00298994 x x x
TLN2 83660 talin 2 IPI00219299.4 x
TMEM189-
UBE2V1
387522 TMEM189-UBE2V1 readthrough IPI00019599.1 x
TMEM33 55161 transmembrane protein 33 IPI00299084.1 x
TMEM43 79188 transmembrane protein 43 IPI00301280 x
TNC 3371 tenascin C IPI00031008.1 x
TNIP1 10318 TNFAIP3 interacting protein 1 IPI00216616 x
TNIP2 79155 TNFAIP3 interacting protein 2 IPI00168953 x
TNPO1 3842 transportin 1 IPI00024364 x x x
TNPO3 23534 transportin 3 IPI00395694 x x x x
TOMM40 10452
translocase of outer mitochondrial membrane 40 
homolog (yeast)
IPI00014053.3 x x
TOP2B 7155 topoisomerase (DNA) II beta 180kDa IPI00027280 x
TPD52L2 7165 tumor protein D52-like 2 IPI00221178.1 x
TPI1 7167 triosephosphate isomerase 1 IPI00465028.7 x
TPT1 7178 tumor protein, translationally-controlled 1 IPI00009943 x x x
TRAP1 10131 TNF receptor-associated protein 1 IPI00030275 x
TRIM28 10155 tripartite motif-containing 28 IPI00438229 x
TRIP13 9319 thyroid hormone receptor interactor 13 IPI00003505 x
TSFM 10102 Ts translation elongation factor, mitochondrial IPI00021016 x



















TSG101 7251 tumor susceptibility gene 101 IPI00018434 x x x x x
TST 7263 thiosulfate sulfurtransferase (rhodanese) IPI00216293 x
TTC19 54902 tetratricopeptide repeat domain 19 IPI00170855 x
TTLL12 23170 tubulin tyrosine ligase-like family, member 12 IPI00029048 x
TUBA1C 84790 tubulin, alpha 6 IPI00166768 x x x
TUBA4A 7277 tubulin, alpha 1 (testis specific) IPI00007750 x x x x
TUBB 203068 tubulin, beta IPI00011654 x x x x
TUBB1 81027 tubulin, beta 1 IPI00006510 x x x
TUBB2A 7280 tubulin, beta 2A IPI00013475 x x
TUBB2C 10383 tubulin, beta 2C IPI00007752 x x x x
TUBB3 10381 tubulin, beta 3 IPI00013683 x
TUBB6 84617 tubulin, beta 6 IPI00641706 x
TUBG1 7283 tubulin, gamma 1 IPI00295081 x
TUFM 7284 Tu translation elongation factor, mitochondrial IPI00027107 x x x
TXN 7295 thioredoxin IPI00216298 x x x
TYMS 7298 thymidylate synthetase IPI00103732 x
UACA 55075




ubiquitin-activating enzyme E1 (A1S9T and 
BN75 temperature sensitivity complementing)
IPI00645078 x x x x
UBA6 55236 ubiquitin-activating enzyme E1-like 2 IPI00023647 x
UBAP2L 9898 ubiquitin associated protein 2-like IPI00029019.6 x
UBB 7314 IPI00179330 x x x x x
UBC 7316 IPI00179330 x x x x x
UBE2L3 7332 ubiquitin-conjugating enzyme E2L 3 IPI00021347.1 x
UBE2N 7334
ubiquitin-conjugating enzyme E2N (UBC13 
homolog, yeast)
IPI00003949.1 x
UBE2V1 7335 ubiquitin-conjugating enzyme E2 variant 1 IPI00019599.1 x
UBP1 7342 upstream binding protein 1 (LBP-1a) IPI00005018 x
UCHL1 7345




uridine monophosphate synthetase (orotate 
phosphoribosyl transferase and orotidine-5'-
decarboxylase)
IPI00003923 x
UNC45A 55898 unc-45 homolog A (C. elegans) IPI00072534 x
UPF1 5976




ubiquinol-cytochrome c reductase core protein 
II
IPI00305383 x
USP5 8078 ubiquitin specific peptidase 5 (isopeptidase T) IPI00024664 x
USP9X 8239 ubiquitin specific peptidase 9, X-linked IPI00003964 x x
UTRN 7402 utrophin (homologous to dystrophin) IPI00009329 x
VAC14 55697 Vac14 homolog (S. cerevisiae) IPI00025160 x
VAMP3 9341
vesicle-associated membrane protein 3 
(cellubrevin)
IPI00549343.3 x x
VARS 7407 valyl-tRNA synthetase IPI00000873 x



















VCP 7415 valosin-containing protein IPI00022774 x x x
VDAC1 7416 voltage-dependent anion channel 1 IPI00216308.5 x x
VDAC2 7417 voltage-dependent anion channel 2 IPI00024145 x x x x
VDAC3 7419 voltage-dependent anion channel 3 IPI00031804 x x x x
VIM 7431 vimentin IPI00418471 x x x
VPS13C 54832 vacuolar protein sorting 13C (yeast) IPI00412216.2 x
VPS25 84313
vacuolar protein sorting 25 homolog (S. 
cerevisiae)
IPI00031655.1 x x
VPS28 51160 vacuolar protein sorting 28 (yeast) IPI00007155 x x x
VPS35 55737 vacuolar protein sorting 35 (yeast) IPI00018931 x x
VPS37B 79720 vacuolar protein sorting 37B (yeast) IPI00002926 x x x
VPS37C 55048 vacuolar protein sorting 37C (yeast) IPI00401773 x x
VPS4B 9525
vacuolar protein sorting 4 homolog B (S. 
cerevisiae)
IPI00182728.2 x x
WDR43 23160 IPI00055954 x
WDR6 11180 WD repeat domain 6 IPI00013953 x x x
WDR77 79084 WD repeat domain 77 IPI00012202 x
WIBG 84305 within bgcn homolog (Drosophila) IPI00305092.7 x
XPO1 7514 exportin 1 (CRM1 homolog, yeast) IPI00298961 x x x x x
XPO4 64328 exportin 4 IPI00028357 x
XPO5 57510 exportin 5 IPI00640703 x x x
XPO6 23214 exportin 6 IPI00465296 x x
XPO7 23039 exportin 7 IPI00302458 x
XPOT 11260
exportin, tRNA (nuclear export receptor for 
tRNAs)
IPI00306290 x x x
XRCC5 7520
X-ray repair complementing defective repair in 




X-ray repair complementing defective repair in 
Chinese hamster cells 6
IPI00644712.4 x
YARS 8565 tyrosyl-tRNA synthetase IPI00007074 x x x
YARS2 51067 tyrosyl-tRNA synthetase 2 (mitochondrial) IPI00165092 x
YBX1 4904 Y box binding protein 1 IPI00031812.3 x x
YES1 7525
v-yes-1 Yamaguchi sarcoma viral oncogene 
homolog 1
IPI00013981 x x x x
YKT6 10652 YKT6 v-SNARE homolog (S. cerevisiae) IPI00008569.1 x
YME1L1 10730 YME1-like 1 (S. cerevisiae) IPI00045946 x
YTHDF1 54915 YTH domain family, member 1 IPI00221345.1 x
YTHDF2 51441 YTH domain family, member 2 IPI00306043.1 x x
YWHAB 7529
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta 
polypeptide
IPI00216318 x x x
YWHAE 7531
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, epsilon 
polypeptide
IPI00000816 x x x x x x
































monooxygenase activation protein, theta 
polypeptide
IPI00018146 x x x
YWHAZ 7534
tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide
IPI00021263 x x x x
ZC3HAV1 56829 zinc finger CCCH-type, antiviral 1 IPI00332936 x x x
ZCCHC3 85364 zinc finger, CCHC domain containing 3 IPI00011550.1 x x
ZNF609 23060 zinc finger protein 609 IPI00307591.5 x
ZW10 9183
ZW10, kinetochore associated, homolog 
(Drosophila)
IPI00011631 x x









CHAPTER 5: SUMMARY OF FINDINGS AND FUTURE DIRECTIONS 
The work presented here has unveiled a new paradigm in arenavirus biology and 
rekindles an interest in defective interfering particles both in terms of therapeutic 
implications as well as understanding arenavirus infections in their natural rodent 
reservoirs. This work also demonstrates the importance of understanding the interactions 
of viral proteins with their cellular hosts. There are a number of key questions that these 
studies have raised and will be logical extensions of this work. 
Defective interfering particles are generally thought to be virus particles containing 
genomic deletions. The deletions in DI genomes are often fairly large, which is thought to 
confer a replicative advantage over longer, standard genomes (Huang and Baltimore, 1970; 
Lazzarini et al., 1981). The replicative advantage of truncated genomes in DI particles is 
thought to be the basis for DI particle-mediated interference (Huang and Baltimore, 1970). 
In the case of arenaviruses, however, a genetic basis for DI particles has yet to be 
confirmed. Meyer and Southern identified short truncations in the untranslated regions of 
LCMV genome segments which permitted genome replication but not transcription (Meyer 
and Southern, 1997). The truncated genomes were identified in both acute and persistent 
stages of LCMV infection (Meyer and Southern, 1997). They predicted that during the 
establishment of persistent infection, the ratio of intact to terminally truncated genomes 
would decrease resulting in decreased viral protein expression due to the inability of the 
truncated genomes to be transcribed (Meyer and Southern, 1997). While this alternate 
model of DI particle interference is plausible, it is yet unclear whether these truncated 
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genomes are packaged into DI particles and whether they can actually interfere with 
standard virus. Accordingly, modern sequencing technologies need to be employed to deep 
sequence the population of LCMV genomes in order to identify any additional deleted 
genomes that could be the basis for the DI phenotype. Fortunately, the PPXY late domain-
mutant viruses generated in this work represent the first strains of LCMV known to produce 
very low levels of DI particles and could be used to purify viral RNA from a virtually DI 
particle-free population.  
An additional shortcoming of previous work on arenavirus DI particles was the 
inability to actually test the impact of any identified mutations in the viral genome using a 
complete virus system. However, there now exists reverse genetics systems for several 
arenaviruses which permit genetic manipulation of the viral genome and recovery of 
recombinant viruses (Albariño et al., 2009; Albariño et al., 2011; Bergeron et al., 2012; 
Flatz et al., 2006; Lan et al., 2009; Pinschewer et al., 2003; Sanchez and De la Torre, 2006). 
In order to determine whether arenavirus DI particle interference is genome mediated, it 
will be important to use the LCMV reverse genetics system to test impact of the deletions 
identified in the untranslated regions by Meyer and Southern and any additional alternate 
genomes identified by deep sequencing. It is possible that some of the disrupted viral 
genomes may prevent recovery of an infectious arenavirus (which may in itself be 
indicative of a defective genome). In that case, the constructs used in the reverse genetics 
system to express the L or S genome segments, which are expressed under control of the 
cellular RNA polymerase I promoter (Flatz et al., 2006), could be expressed in cells that 
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are also infected with wild type LCMV. A decrease in the production of infectious LCMV 
following transfection of the defective genomes would indicate the ability of the genomes 
to interfere.  
While the dogmatic view maintains that DI particle interference occurs through a 
genetic mechanism, the work presented in Chapter 2 may suggest an alternate, protein 
based mechanism. In particular, this work showed that DI particles are likely enriched in 
Z protein (Figure 2.3) and that DI particle release is regulated by the Z protein (Figure 2.5). 
Early studies on the composition of arenavirus DI particles concluded that the viral protein 
and genome composition were virtually indistinguishable from infectious virus particles 
(Welsh and Buchmeier, 1979). However, the arenavirus Z protein was not discovered until 
almost a decade after most of the work on arenavirus DI particles had ceased (Iapalucci et 
al., 1989; Salvato and Shimomaye, 1989). Curiously, the arenavirus Z protein inhibits viral 
genome replication and transcription through direct inhibition of the viral L polymerase in 
a dose dependent manner (Cornu and de la Torre, 2001, 2002; Jacamo et al., 2003a; 
Kranzusch and Whelan, 2011; Lopez et al., 2001). This inhibition of the polymerase by Z 
is correlated with the genetic relatedness of the Z and L proteins; the Old World arenavirus 
LCMV Z protein does not inhibit the polymerase of the New World arenavirus, Machupo, 
but the more closely related JUNV Z does (Kranzusch and Whelan, 2011). Also, 
overexpression of the LCMV Z protein renders cells refractory to LCMV but not vesicular 
stomatitis virus infection (Cornu and de la Torre, 2001). Such homologous interference is 
a hallmark of DI particles, though, it has been presumed to occur through a genome 
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mediated mechanism. Additionally, the amount of Z protein contained in a virus particle 
may provide a high enough concentration to inhibit the L polymerase (Kranzusch and 
Whelan, 2011). Therefore, arenavirus DI particle-mediated interference may at least in part 
occur through a mechanism by which the high levels of Z protein in DI particles interfere 
with both the replication and transcription of the viral genome. In order to determine 
whether particle-derived Z protein is sufficient to interfere with infectious virus, the LCMV 
Z protein in combination with the glycoprotein could be expressed via plasmid in cells in 
order to produce virus like particles (VLPs) that are capable of entering cells. These VLPs 
could then be added to cells and subsequently infected with LCMV. The level of 
interference could be assessed both by measurement of viral nucleoprotein levels in the 
cells as well as by measuring infectious virus titers by plaque assay. It would also be 
interesting to determine whether these VLPs could inhibit LCMV plaque formation. While 
it is clear that Z is an important regulator of arenavirus infections, it is difficult to imagine, 
however, that the Z protein’s inhibition of the viral polymerase could alone mediate the 
very potent interference observed with DI particles. During a normal infection, the Z 
protein concentration in cells must increase from the levels prior to transcription and 
translation of the viral genome and mRNAs in order to produce new virions. Thus if Z’s 
repression of the polymerase was too potent, the production of progeny virions would fail 
to occur.  
Another interesting consideration with regard to LCMV DI particles, is that our 
work here was done with an LCMV strain, Armstrong 53b, which was isolated from an 
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infected patient in the first half of the 20th, century (Armstrong and Lillie, 1934; Cesar et 
al., 2010). This strain has been passaged in many different ways, so it begs the question of 
whether the sequence of the reverse genetics system that we used here (Armstrong 53b) is 
representative of strains of LCMV found in the wild or of disease-causing clinical isolates. 
A study that looked at a variety of LCMV strains, including both clinical isolates as well 
as mouse-derived strains revealed up to 28% nucleotide sequence divergence across the 
different LCMV strains (Delgado et al., 2008a). For the Z protein, this resulted in up to 
18% sequence divergence at the amino acid level (Cesar et al., 2010). However, key motifs 
in Z including the G2 myristoylation site, the RING domain, the PPXY late domain, and 
the S41 phosphorylation site identified in this study were all highly conserved (Cesar et al., 
2010). In addition, a key requirement for the functionality of arenavirus reverse genetics 
systems is having intact 5’ and 3’ untranslated regions (Flatz et al., 2006). Meyer and 
Southern found that populations of arenavirus genomes contain significant diversity in their 
untranslated regions (Meyer and Southern, 1994). These deletions were found both in 
genomic sense viral RNA as well as the anti-genomic RNA, indicating that at least some 
of the terminally deleted genomes can be used as a template by the viral polymerase, but 
are likely not transcription-competent (Meyer and Southern, 1994, 1997). Thus, it seems 
likely that the Armstrong 53b reverse genetics system here is representative of a standard, 
infectious virus particle and does not differ significantly from other LCMV strains with 
regard to key identified regions of the Z protein. 
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Since early studies on arenavirus DI particles in the 1970’s, it has been 
hypothesized that DI particles are critical for maintaining persistent infections in their 
natural rodent hosts. One major obstacle to substantiating this has been the fact that 
arenaviruses naturally produce DI particles during the course of infection and thus are 
always producing a mixture of standard and DI particles. The late domain mutant viruses 
used in this work represent the first strains of LCMV that produce undetectable levels of 
DI particles. As the titers of standard virus reach the same levels as that of WT LCMV, it 
also expected that they would likely grow well in vivo. Thus, the late domain mutant strains 
of LCMV could be used in an in vivo model of Mus musculus infection to assess the overall 
requirement of DI particles in their natural hosts and to determine whether the DI particles 
mediate the protective effect that they are suspected to have. 
The work presented in Chapter 2 demonstrates that the PPXY late domain in LCMV 
Z is a key regulator of DI particle production. We also provided evidence that the New 
World arenavirus, JUNV, which does not contain a PPXY late domain, produces drastically 
less DI particles than LCMV (Figure 2.S4). It is possible, therefore, that addition of a PPXY 
late domain to viral matrix proteins that do not contain a PPXY motif may increase the 
production of DI particles for that virus. It is also possible that adding additional PPXY 
late domains to PPXY-containing viral matrix proteins may serve to enhance DI particle 
production beyond normal levels. As discussed in chapter 1.3, DI particles have been 
shown to elicit protection against standard virus (Barrett and Dimmock, 1986; Dimmock 
and Kennedy, 1978; Doyle and Holland, 1973; Help and Coto, 1980; Holland and Doyle, 
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1973; Spandidos and Graham, 1976; Welsh et al., 1977; Welsh and Oldstone, 1977). 
Consequently, enhancing the ability of a virus to produce this protective class of particles 
may serve as a broad spectrum attenuation strategy which could be used to generate live-
attenuated vaccines. Additionally, the data in Chapter 4 suggest that host-mediated 
phosphorylation of LCMV Z’s PPXY late domain may serve as a positive regulator of DI 
particle production. Therefore, we hypothesize that blocking phosphorylation of the PPXY 
domain through small molecule inhibition of host kinases would decrease DI particle 
release resulting in decreased DI particle-mediated interference and ultimately would 
permit infectious virus to replicate less inhibited. Such a strategy could be used to more 
efficiently produce virus particles for an inactivated vaccine. 
The initial finding which lead to the discovery that the PPXY late domain is 
required for DI particle formation was that Y88 in LCMV Z was phosphorylated. In chapter 
2 we were able to demonstrate that LCMV is reversible phosphorylated at Y88 and that the 
phosphomimetic Y88E rLCMV produced more DI particles than the Y88F or Y88A 
rLCMV, though this increase did not meet statistical significance. This suggests that the 
host cell may be able to dynamically regulate the production of DI particles through 
phosphorylation of Y88 in LCMV Z using host kinases. A major advance in this area would 
be the identification of the host kinase(s) responsible for phosphorylation of Y88. While 
kinase prediction algorithms fail to predict a kinase for this tyrosine, particularly due to its 
location near the C-terminus of the protein, there exists some evidence that may help 
narrow the search for the kinase. The PPXY motif in Ebola VP40 is phosphorylated by c-
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Abl1 kinase (García et al., 2012) and the host proteins IFITM3 and β-dystroglycan are 
phosphorylated on their PPXY motifs by the Src family tyrosine kinases, Fyn and Src, 
respectively (Chesarino et al., 2014; Sotgia et al., 2001). As we can readily detect Y88 
phosphorylation in LCMV Z by western blotting and there are several available chemical 
inhibitors of these kinases (Garcia et al., 2012; Golas et al., 2003), it should be relatively 
straightforward to identify the kinase. As some of the potential kinase inhibitors are FDA-
approved drugs, it is possible that they could also be tools used for in vivo LCMV infection. 
As the data with the phosphomimetic rLCMV Y88E suggests that phosphorylation 
positively regulates DI particle production, we would predict that treatment with the 
appropriate kinase inhibitor would decrease DI particle release which would provide an 
additional means of studying LCMV infection in a relatively DI particle-free environment.  
A key open question for PPXY late domain containing viruses is how these late 
domains recruit the cellular ESCRT pathway. PPXY motifs are known to bind the WW-
domains found in Nedd4 family E3 ubiquitin ligases (Chen and Sudol, 1995; Ingham et al., 
2005; Ingham et al., 2004; Staub et al., 1996). Accordingly, recruitment of enzymatically 
active Nedd4 family ubiquitin ligases has been shown to be required for ESCRT 
recruitment in a number of viruses including filoviruses and retroviruses (Blot et al., 2004; 
Han et al., 2016; Martin-Serrano et al., 2005; Sakurai et al., 2004; Segura-Morales et al., 
2005; Urata and Yasuda, 2010; Vana et al., 2004; Yasuda et al., 2003). These ligases may 
be required for the addition of a ubiquitin group to the viral PPXY-containing protein as 
has been shown for filovirus VP40, VSV M and some retroviral Gag proteins (Blot et al., 
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2004; Han et al., 2016; Harty et al., 2001; Harty et al., 2000; Strack et al., 2000; Vana et 
al., 2004). Addition of a ubiquitin molecule to the viral protein could permit direct ESCRT 
linkage via the ubiquitin binding domains found in many of the ESCRT-0, -I and -II 
proteins (Shields et al., 2009). This potential model of ESCRT complex recruitment could 
be analogous to multivesicular body formation where ubiquitinated integral membrane 
proteins are recognized by the ESCRT-0 proteins which ultimately results in the 
recruitment of the ESCRT-III scission machinery (Hurley, 2008). An alternative model of 
ESCRT recruitment by PPXY-containing viral proteins has also been proposed in which 
the arrestin-related trafficking (ART) proteins may serve as a direct or indirect link to the 
ESCRT-III scission machinery for PPXY motifs (Rauch and Martin-Serrano, 2011). 
For the arenaviruses, it has been shown that LASV Z can bind Nedd4 and Nedd4 
drives VLP release (Fehling et al., 2012; Han et al., 2014). It will be important to determine 
which Nedd4 family ligases bind to LCMV Z’s PPXY late domain, whether the Nedd4 
ligases directly ubiquitinate the LCMV Z protein and whether ubiquitin conjugation is 
ultimately required for ESCRT recruitment to sites of Z-mediated budding and for DI 
particle release. To facilitate these future studies, mapping the Z-host protein interactome 
for the Old World arenaviruses, LCMV and LASV, as we have done for JUNV Z in this 
work, may permit identification of proteins that interact with LCMV Z including Nedd4 
family ligases, ESCRT proteins, tyrosine kinases, and SH2 domain-containing proteins. 
Such studies may help to provide clues to the molecular link between the PPXY late 
domain and the late-acting ESCRT scission machinery. Finally, determining whether 
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phosphorylation of the PPXY late domain regulates Nedd4 ligase binding and subsequent 
ESCRT pathway recruitment will help to build a more complete picture of host cell-
mediated regulation of DI particle release. Such regulation of PPXY motifs has been 
demonstrated for the cellular proteins IFITM3 and β-dytroglycan (Chesarino et al., 2015; 
Sotgia et al., 2001). 
The ESCRT pathway represents the only known cellular machinery capable of 
mediating membrane scission for membrane extrusion away from the cytoplasm 
(Schoneberg et al., 2017). Accordingly, many enveloped viruses depend on the ESCRT 
pathway for efficient virus release (Votteler and Sundquist, 2013). However, there are 
several examples of enveloped viruses that do not depend on ESCRT including Semliki 
Forest virus, influenza A virus, respiratory syncytial virus, and Andes virus (Bruce et al., 
2010; Bruce et al., 2009; Rowe et al., 2008; Taylor et al., 2007; Utley et al., 2008). The 
data presented in Chapter 2 demonstrate that the production of infectious LCMV virions is 
not dependent on the Z protein’s PPXY late domain or the cellular ESCRT pathway which 
raises the question of how infectious virus particles are released from cells. The PPXY late 
domain represents the only canonical late domain in LCMV Z. The only other site within 
LCMV Z that is known to impact virus release is the glycine residue at position 2, which 
is myristoylated and regulates membrane association of Z (Perez et al., 2004a; Strecker et 
al., 2006). In Chapter 3, we present data suggesting that a novel motif in LCMV Z, S41, 
that does not appear to resemble motifs found in other viruses required for release, is 
important for both infectious and DI particle release. A phosphomimetic substitution at S41 
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decreased both infectious and DI particle release, indicating that the host cell may be 
regulating the ability of this motif to mediate virus release. However, it remains to be 
determined whether S41 requires interaction with specific host machinery in order to drive 
virion release and what the identity of that machinery is. Semliki Forest virus appears to 
be capable of driving membrane budding and fission through the action of its external 
glycoprotein and thus it is possible that release of infectious virus particles could happen 
without any cellular machinery (Votteler and Sundquist, 2013).  
Various host machinery may be recruited by the Z protein in order to facilitate 
infectious virus release. In chapter 4, we identified several host proteins that may impact 
arenavirus release. The ATPase, ATP5B, was required for infection of both JUNV and 
LCMV. This protein co-purified with JUNV, LCMV and LASV Z from both transfected 
cells and in VLP-derived Z. This protein, ATP5B, has been shown to be required for the 
release of influenza A virus VLPs at the plasma membrane (Gorai et al., 2012). 
Accordingly, ATP5B is found in Z VLPs which suggests that it may be required at late 
steps in the virus life cycle. Additional studies are needed to determine the precise step in 
the virus life cycle in which ATP5B functions, but the evidence points to a possible role in 
virus release. An abundance of Rab family proteins were also identified in JUNV C#1 
virions which may similarly suggest a role in late steps of arenavirus release. One of these 
proteins, Rab5c was shown to be required during LCMV infection in Chapter 4, but it is 
unclear the specific viral function Rab5c depletion impacts. (Bruce et al., 2010; Bruce et 
al., 2012). Rab family proteins are important regulators of intracellular vesicular trafficking 
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and Rab11 in particular has been shown to impact the budding and release of ESCRT-
independent viruses including the bunyavirus, Andes virus (Bruce et al., 2012; Vale-Costa 
and Amorim, 2016). Whether Rab proteins contribute to arenavirus assembly and release 
beyond trafficking of viral components to sites of assembly remains to be determined. In 
summary, this study has provided the groundwork for the identification of factors 
potentially involved in the ESCRT-independent budding of LCMV.  
Finally, in Chapter 4, a long list of JUNV Z host protein partners were identified. 
We were able to demonstrate the functional importance of several of the proteins in JUNV 
and LCMV infection. The siRNA studies did not, however, reveal the mechanism by which 
the various proteins contribute to the arenavirus life cycle. One of the identified proteins, 
ARF1, is particularly interesting as this protein regulates cargo release from the ER-Golgi 
intermediate compartment (ERGIC) and the Botten lab has recently shown that ERGIC-53 
is a key regulator of infectivity of JUNV virus particles (Donaldson and Jackson, 2011; 
Klaus et al., 2013). It would be enlightening to determine whether ARF1 depletion results 
in a failure of ERGIC-53 or the JUNV glycoprotein to traffic through the secretory pathway 
resulting in a loss of infectivity of released virions. There are also many other proteins 
which were identified as Z protein partners for which the functional relevance has not been 
determined. A comprehensive functional screen of the identified Z protein partners would 
be a valuable next step that may allow identification of essential host proteins which could 
be therapeutically targeted in order to treat arenavirus infections.  
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A large scale silencing (si)RNA screen targeting Z protein partners would be one 
effective approach for identifying functionally important targets. Such screening has been 
done on a genome-wide level for several viruses including HIV (Brass et al., 2008; König 
et al., 2008; Zhou et al., 2008), influenza virus (Brass et al., 2009; Karlas et al., 2010; Konig 
et al., 2010; Shapira et al., 2009), dengue virus (Sessions et al., 2009), hepatitis C virus (Li 
et al., 2009b; Tai et al., 2009), West Nile virus (Krishnan et al., 2008), and vesicular 
stomatitis virus (Lee et al., 2014; Panda et al., 2011). The 2011 study on VSV (Panda et 
al., 2011), also conducted a functional siRNA screen targeting 72 of the host proteins 
required for VSV. Several of the targeted proteins that were required for LCMV infection 
in that study including ARF1, COPA, COPB1, EIF3A, HNRNPK, HSPA9, NOP56, and 
RAB5C were also identified as JUNV Z protein partners in this work (see Table 4.S1). 
Building on this data with a broader scope RNAi screen for arenaviruses including all of 
the identified Z protein partners or potentially a genome-wide screen would provide a 
powerful combination of functional data and the virus-host protein interaction network. 
Such a study would aid future work focusing on the functional roles of the Z protein’s host 
partners and would help in the rational design of therapeutics that impinge on the molecular 
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